

---

**CURRICULUM VITAE**  
**PAUL M. PALEVSKY, M.D.**

**OFFICE ADDRESS:**  
Room 7E123 (111F-U)  
VA Pittsburgh Healthcare System  
University Drive Division  
4100 Aliquippa Street  
Pittsburgh, PA 15240

**HOME ADDRESS:**  
109 Bell Farm Estates  
Sewickley, PA 15143

(412) 360-3932  
Fax: (412) 360-6130  
E-mail: [palevsky@pitt.edu](mailto:palevsky@pitt.edu)  
[paul.palevsky@va.gov](mailto:paul.palevsky@va.gov)

**DATE OF BIRTH:** December 29, 1957  
**PLACE OF BIRTH:** New York, New York  
**CITIZENSHIP:** USA  
**MARITAL STATUS:** Married: Sharon R. Roseman, M.D.  
Children: Hilary Ilana Palevsky, Ph.D. (1987)  
Jason Michael Palevsky (1990)

---

**EDUCATION and TRAINING**

***UNDERGRADUATE and GRADUATE EDUCATION:***

1975-1981	Honors Program in Medical Education	B.S., 1979
	Northwestern University	M.D., 1981
	Evanston and Chicago, Illinois	

***POSTGRADUATE TRAINING:***

1981-1984	Intern and Resident in Internal Medicine Hospital of the University of Pennsylvania Philadelphia, Pennsylvania	Program Director: L. Earley, M.D.
1984-1988	Fellow in Nephrology University of Pennsylvania School of Medicine Philadelphia, Pennsylvania	Program Director: Z. Agus, M.D.

**APPOINTMENTS and POSITIONS**

***ACADEMIC:***

1988-1989	University of Pennsylvania School of Medicine Philadelphia, Pennsylvania	Research Associate in Medicine
1989-1995	University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania	Assistant Professor of Medicine



2021-present	VHA Kidney Medicine Program US Department of Veterans Affairs	Deputy Executive Director
--------------	--	------------------------------

---

**CERTIFICATION and LICENSURE**

***SPECIALTY CERTIFICATION:***

1984	American Board of Internal Medicine (Certificate #095377)
1986	American Board of Internal Medicine, Nephrology (Certificate #95377)

***MEDICAL LICENSURE:***

1982	Pennsylvania	MD 027399-E
------	--------------	-------------

---

**MEMBERSHIPS IN PROFESSIONAL AND SCIENTIFIC SOCIETIES**

American College of Physicians (Member, 1986; Fellow, 1992)	1986
International Society of Nephrology	1986
American Society of Nephrology (Member, 1988; Fellow, 2004)	1988
American Heart Association (Council on the Kidney in CVD)	1989
National Kidney Foundation (Member, 1990; Fellow 2011)	1990
Renal Physicians Association	1993
American Federation for Medical Research	1994
American College of Chest Physicians (Fellow)	1996
Allegheny County Medical Society	2001
Pennsylvania Medical Society	2001
American Medical Association	2001

---

**AWARDS, HONORS, AND MEMBERSHIPS IN HONORARY SOCIETIES**

New York State Regents Scholar	1975
National Merit Scholar	1975
Leslie B. Arey Award, Northwestern University	1978
Frederick K. Rawson Award, Northwestern University	1979
B.S. in Medicine with Highest Distinction	1979
George A. Dennis Award, Northwestern University	1980
Alpha Omega Alpha	1980
M.D. with Highest Distinction	1981
Veterans Administration Career Development Award	1986
ASAIO Fellowship Travel Award	1992
Fellow, American College of Physicians	1992
Fellow, American College of Chest Physicians	1996
Medical Director, VA Clinical Program of Excellence in Dialysis	1997
Medical Director, VA Clinical Program of Excellence in Dialysis	1999
Chairman's Award (Bronze), Pittsburgh Federal Executive Board	2000
Medical Director, VA Clinical Program of Excellence in Dialysis	2001
Fellow, American Society of Nephrology	2004

Gift of Life Award, National Kidney Foundation of the Alleghenies	2007
Gold Award of Excellence-Outstanding Contribution to Science (Medical), Pittsburgh Federal Executive Board	2009
Fellow, National Kidney Foundation	2011
Educational Ambassador, International Society of Nephrology	2013
Hayes Davis Service Award, The Renal Network	2013
Best Doctors in America	2016, 2018, 2020
J. Michael Lazarus Distinguished Award, National Kidney Foundation	2017
ESRD Patient Safety Award, Renal Physicians Association	2018
Department of Medicine Distinguished Speaker Series, University of Wisconsin-Madison	2018
International Vicenza Award, International Renal Research Institute of Vicenza, Italy	2018
Conferral of Tenure, University of Pittsburgh	2019
Charles Austin Lecture, Baylor University Medical Center	2019
Raymond Rault Faculty Teaching Award, Renal-Electrolyte Division University of Pittsburgh	2019
Leadership Award, Department of Veterans Affairs Specialty Care Program	2022
Reviewer of the Year, Clinical Journal of the American Society of Nephrology	2022
Fellow, International Society of Nephrology	2023
W. Kline Bolton Distinguished Lectureship, University of Virginia	2023
Reviewer of the Year, Journal of the American Society of Nephrology	2023

---

## PUBLICATIONS

### ***LINK TO MY BIBLIOGRAPHY in NCBI:***

<https://www.ncbi.nlm.nih.gov/myncbi/paul.palevsky.1/bibliography/public/>

### ***REFEREED ARTICLES:***

1. Douglas PS, Carmichael KA, **Palevsky PM**. Extreme hypercalcemia and electrocardiographic changes. *American Journal of Cardiology* 1984; 54:674-675. ([PMID:6475795](#))
2. **Palevsky PM**, McEntee CM, Cantwell R, Cox M, Hudson AP. Characterization of the *Bufo marinus* mitochondrial genome. *Nucleic Acids Research* 1988; 16:1622. ([PMCID: PMC336344](#))
3. Szerlip H, **Palevsky P**, Cox M, Blazer-Yost B. Relationship of the aldosterone-induced protein, GP70, to the conductive Na<sup>+</sup> channel. *Journal of the American Society of Nephrology* 1991; 2:1108-1114. ([PMID: 1663799](#))
4. Relton S, Greenberg A, **Palevsky PM**. Dialysate and blood flow dependence of diffusive solute clearance during CVVHD. *ASAIO Journal* 1992; 38:M691-M696. ([PMID: 1457951](#))
5. **Palevsky PM**, Rendulic D, Diven WF. Maltose induced hyponatremia. *Annals of Internal Medicine* 1993; 118:526-528. ([PMID: 8442623](#))

6. Banalagay E, Perlmutter JA, **Palevsky P**. Central venous hemodialysis catheter related superior vena cava syndrome. *Clinical Nephrology* 1993; 40:59-60. ([PMID: 8358876](#))
7. **Palevsky P**, Burr R, Moreland L, Tokiwa Y, Greenberg A. Failure of low molecular weight dextran to prevent clotting during continuous renal replacement therapy. *ASAIO Journal* 1995; 41:847-849. ([PMID: 8589465](#))
8. **Palevsky PM**, Bhagrath R, Greenberg A. Hyponatremia in hospitalized patients. *Annals of Internal Medicine* 1996; 124:197-203. ([PMID: 8533994](#))
9. Rokaw MD, Benos DJ, **Palevsky PM**, Cunningham SA, West ME, Johnson JP. Regulation of a sodium channel associated G-protein by aldosterone. *Journal of Biological Chemistry* 1996; 271:4491-4496. ([PMID: 8626803](#))
10. Rokaw MD, West ME, **Palevsky PM**, Johnson JP. FK506 and rapamycin but not cyclosporin inhibit aldosterone-stimulated sodium transport in A6 cells. *American Journal of Physiology* 1996; 271:C194-C202. ([PMID: 8760046](#))
11. Acker CG, Johnson JP, **Palevsky PM**, Greenberg A. Hyperkalemia in hospitalized patients: Etiology, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. *Archives of Internal Medicine* 1998; 158:917-924. ([PMID: 9570179](#))
12. Joy MS, Matzke GR, Frye RF, **Palevsky PM** Determinants of vancomycin clearance by CVVH and CVVHD. *American Journal of Kidney Diseases* 1998; 31:1019-1027. ([PMID: 9631848](#))
13. Fried LF, **Palevsky PM**, Johnston JR. Duodenal obstruction in polycystic kidney disease. *American Journal of Nephrology* 1998; 18:318-320. ([PMID: 9653836](#))
14. Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, Vaamonde CA for the Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients [**Palevsky PM**]. Subcutaneous compared with intravenous erythropoietin in patients receiving hemodialysis. *New England Journal of Medicine* 1998; 339:578-583. ([PMID:9718376](#))
15. Kellum JA, Johnson JP, Kramer D, **Palevsky P**, Brady JJ, Pinsky M. Diffusive versus convective therapy: Effects on mediators of inflammation in patients with severe systemic inflammatory response syndrome. *Critical Care Medicine* 1998; 26:1995-2000. ([PMID: 9875910](#))
16. Prasad GVR, **Palevsky PM**, Burr R, Lesko JM, Gupta B, Greenberg A. Factors affecting system clotting in continuous renal replacement therapy: Results of a randomized, controlled trial. *Clinical Nephrology*. 2000; 53:55-60. ([PMID: 10661483](#))
17. Matzke GR, Frye RF, Joy MS, **Palevsky PM**. Determinants of ceftazidime clearance by CVVH and CVVHD *Antimicrobial Agents and Chemotherapy* 2000; 44:1639-1644. ([PMCID: PMC89925](#))
18. Matzke GR, Frye RF, Joy MS, **Palevsky PM**. Determinants of ceftriaxone clearance by CVVH and CVVHD. *Pharmacotherapy* 2000; 20:635-643. ([PMID: 10853618](#))

19. **Palevsky PM**, Washington MS, Rohay JM, Stevenson JA, Dyer N, Lockett R, Perry S. Barriers to the delivery of adequate hemodialysis in ESRD Network 4. *Advances in Renal Replacement Therapy* 2000; 7 (suppl 1):S11-S20. ([PMID: 11053582](#))
20. **Palevsky PM**, Washington MS, Stevenson JA, Rohay JM, Dyer N, Lockett R, Perry S. Improving compliance with the dialysis prescription as a strategy to increase the delivered dose of hemodialysis: An ESRD Network 4 quality improvement project. *Advances in Renal Replacement Therapy* 2000; 7 (suppl 1):S21-S30. ([PMID: 11053583](#))
21. Nolin TD, Colaizzi IV, **Palevsky PM**, Matzke GR, Frye RF. Rapid microtiter plate assay for determination of inulin in human plasma and dialysate. *Journal of Pharmaceutical and Biomedical Analysis* 2002; 28:209-215. ([PMID: 11929663](#))
22. Kellum JA, Mehta RL, Angus DC, **Palevsky PM**, Ronco C for the ADQI Workgroup. The First International Consensus Conference on Continuous Renal Replacement Therapy. *Kidney International* 2002; 62:1855-1863. ([PMID: 12371989](#))
23. Venkataraman V, Kellum J, **Palevsky P**. Dosing patterns for continuous renal replacement therapy at a large academic medical center in the United States. *Journal of Critical Care* 2002; 17:246-250. ([PMID: 12501152](#))
24. Kaufman JS, O'Connor TZ, Zhang JH, Cronin RE, Fiore LD, Ganz MB, Goldfarb DS, Peduzzi PN for the Veterans Affairs Cooperative Study Group on Hemodialysis Access Graft Thrombosis [**Palevsky PM**]. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. *Journal of the American Society of Nephrology* 2003; 14:2313-2321. ([PMID:12937308](#))
25. Zgibor JC, Stevenson JA, Rohay JM, Perry SB, Dyer NJ, Freed B, **Palevsky PM**. Tracking and improving influenza immunization rates in a high risk Medicare beneficiary population. *Journal of Healthcare Quality* 2003; 25(6):17-24. ([PMID: 14671852](#))
26. Diamond LH, Klinger AS, Goldman RS, **Palevsky PM**. Quality improvement projects: How do we protect patients' rights? *American Journal of Medical Quality* 2004; 19:25-27. ([PMID: 14977022](#))
27. Weisbord SD, Bruns FJ, Saul MI, **Palevsky PM**. Provider use of preventive strategies for radiocontrast nephropathy in high-risk patients. *Nephron Clinical Practice* 2004; 96:C56-62. ([PMID: 14988599](#))
28. Bellomo R, Ronco C, Kellum JA, Mehta RL, **Palevsky PM** and the ADQI Workgroup. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. *Critical Care* 2004; 8:R204-R212. ([PMCID: PMC522841](#))
29. Weisbord SD, Ramkumar M, LaPibus SA, McBride DJ, **Palevsky PM**. Functional renal artery obstruction following percutaneous kidney biopsy. *Nephrology Dialysis and Transplantation* 2005 20:1274-1275. ([PMID: 15840676](#))
30. **Palevsky PM**, O'Connor T, Zhang JH, Star RA, Smith MW for the VA/NIH Acute Renal Failure Trial Network. Design of the VA/NIH Acute Renal Failure Trial Network (ATN) study:

Intensive versus conventional renal support in acute renal failure. *Clinical Trials* 2005; 2:423-435. ([PMCID: PMC1351394](#))

31. Aslam N, Pesacreta M, Bastacky SL, McHale T, Huston A, **Palevsky PM**, Weisbord SD. Light chain-associated Fanconi syndrome with nephrotic range proteinuria. April 2006. *American Journal of Kidney Diseases* 2006; 47: A57 and e43-e45. ([PMID: 16570366](#))

32. Chertow GM, **Palevsky PM**, Greene T. Studying the prevention of acute kidney injury: Lessons from an 18<sup>th</sup> century mathematician. *Clinical Journal of the American Society of Nephrology* 2006; 1: 1124-1127. ([PMID: 17699335](#))

33. Weisbord SD, Chen H, Stone RA, Kip KE, Fine MJ, Saul MI, **Palevsky PM**. Associations of increases in serum creatinine with mortality and length of hospital stay following coronary angiography. *Journal of the American Society of Nephrology* 2006; 17:2871-2877. ([PMID: 16928802](#))

34. Weisbord SD, Bernardini J, Mor MK, Hartwig KC, Nicoletta PJ, **Palevsky PM**, Piraino B. The effect of coronary angiography on residual renal function in peritoneal dialysis patients. *Clinical Cardiology* 2006; 29:494-497. ([PMID: 17133846](#))

35. Overberger P, Pesacreta M, **Palevsky PM** for the VA/NIH Acute Renal Failure Trial Network. Management of renal replacement therapy in acute kidney injury: A survey of practitioner prescribing practices. *Clinical Journal of the American Society of Nephrology* 2007; 2:623-630. ([PMCID: PMC2325917](#))

36. Weisbord SD, Fried LF, Mor MK, Resnick AL, Unruh ML, **Palevsky PM**, Levenson DJ, Cooksey SH, Fine MJ, Kimmel PL, Arnold RM. Renal Provider recognition of symptoms in patients on maintenance hemodialysis. *Clinical Journal of the American Society of Nephrology* 2007; 2:960-967. ([PMID: 17702730](#))

37. Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, Gaziano JM, for the Veterans Affairs Site Investigators [**Palevsky PM**]. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: A randomized controlled trial. *Journal of the American Medical Association* 2007; 298:1163-1170. ([PMID: 17848650](#))

38. Weisbord SD, Fried LF, Mor MK, Resnick AL, Kimmel PL, **Palevsky PM**, Fine FJ. Associations of race and ethnicity with anemia management among patients initiating renal replacement therapy. *Journal of the National Medical Association* 2007; 99:1218-1226. ([PMCID: PMC2574315](#))

39. Carreon M, Fried LF, **Palevsky PM**, Kimmel PL, Arnold RM, Weisbord SD. Clinical correlates and treatment of bone/joint pain and difficulty with sexual arousal in patients on maintenance hemodialysis. *Hemodialysis International* 2008; 12:268-274. ([PMID: 18394062](#))

40. Weisbord SD, Hartwig KC, Sonel AF, Fine MJ, **Palevsky PM**. The incidence of clinically significant contrast-induced nephropathy following non-emergent coronary angiography. *Catheterization and Cardiovascular Interventions* 2008; 71:879-885. ([PMID: 18412255](#))

41. Weisbord SD, Mor MK, Resnick AL, Hartwig KC, Sonel AF, Fine MJ, **Palevsky PM**. Prevention, incidence, and outcomes of contrast-induced nephropathy. *Archives of Internal Medicine* 2008; 168:1325-1332. ([PMID: 18574090](#))
42. Crowley ST, Chertow GM, Vitale J, O'Connor T, Zhang J, Schein RMH, Choudhury D, Finkel K, Vijayan A, Paganini E, **Palevsky PM** for the VA/NIH Acute Renal Failure Trial Network Study Group. Lessons for successful study enrollment from the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. *Clinical Journal of the American Society of Nephrology* 2008; 3:955-961. ([PMCID: PMC2440269](#))
43. **Palevsky PM**, Zhang JH, O'Connor TZ, Chertow GM, Crowley ST, Choudhury D, Finkel K, Kellum JA, Paganini E, Schein RMH, Smith MW, Swanson KM, Thompson BT, Vijayan A, Watnick S, Star RA, Peduzzi P for the VA/NIH Acute Renal Failure Trial Network. Intensity of renal support critically ill patients with acute kidney injury. *New England Journal of Medicine* 2008; 359:7-20. ([PMCID: PMC2750132](#))
44. Weisbord SD, Mor MK, Resnick AL, Hartwig KC, **Palevsky P**, Fine MJ. Incidence and outcomes of contrast-induced AKI following computed tomography. *Clinical Journal of the American Society of Nephrology* 2008; 3:1274-1281. ([PMCID: PMC2518784](#))
45. Weisbord SD, Bossola M, Fried LF, Giungi, S, Tazza L, **Palevsky PM**, Arnold RM, Luciani G, Kimmel PL. Cultural comparison of symptoms in patients on maintenance hemodialysis. *Hemodialysis International* 2008; 12:434-440. ([PMID: 19090866](#))
46. Fried LF, Duckworth W, Zhang JH, O'Connor T, Brophy M, Emanuele N, Huang GD, McCullough PA, **Palevsky PM**, Seliger S, Warren SR, Peduzzi P for the VA NEPHRON-D Investigators. Design of combination angiotensin receptor blockade and angiotensin converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). *Clinical Journal of the American Society of Nephrology* 2009; 4:361-368. ([PMCID: PMC2637584](#))
47. Weisbord SD, Mor MK, Kim S, Hartwig KC, Sonel AF, **Palevsky P**, Fine MJ. Factors associated with the use of preventive care for contrast-induced acute kidney injury. *Journal of General Internal Medicine* 2009; 24:289-298. ([PMCID: PMC2642579](#))
48. Jamison RL, Shih M-C, Humphries DE, Guarino PD, Kaufman JS, Goldfarb DS, Warren SR, Gaziano JM, Lavori P on behalf of the Veterans Affairs Site Investigators [**Palevsky PM**]. Effect of the *MTHFR* C677T and A1298C polymorphisms on survival in patients with advanced CKD and ESRD: A prospective study. *American Journal of Kidney Diseases* 2009; 53:779-789. ([PMID: 19272686](#))
49. **Palevsky PM**, O'Connor TZ, Chertow GM, Crowley ST, Zhang JH, Kellum JA for the VA/NIH Acute Renal Failure Trial Network. Intensity of renal replacement therapy in acute kidney injury: Prospective from within the Acute Renal Failure Trial Network Study. *Critical Care* 2009; 13:310. ([PMCID: PMC2750132](#))
50. Jasuja D, Mor MK, Hartwig KC, **Palevsky PM**, Fine MJ, Weisbord SD. Provider knowledge of contrast-induced acute kidney injury. *American Journal of the Medical Sciences*. 2009; 338: 280-286. ([PMID: 19641454](#))



51. Jun M, Heerspink HJ, Ninomiya T, Gallagher M, Bellomo R, Myburgh J, Finfer S, **Palevsky PM**, Kellum J, Perkovic V, Cass A. Intensities of renal replacement therapy in acute kidney injury: a systematic review and meta-analysis. *Clinical Journal of the American Society of Nephrology* 2010; 5: 956-963. ([PMCID: PMC2879310](#))
52. Johansen KL, Smith MW, Unruh ML, Siroka AM, O'Connor TZ, **Palevsky PM** for the VA/NIH Acute Renal Failure Trial Network. Predictors of health utility among 60-day survivors of acute kidney injury in the VA/NIH Acute Renal Failure Trial Network Study. *Clinical Journal of the American Society of Nephrology* 2010; 5:1366-1372. ([PMCID: PMC2924409](#))
53. Weisbord SD, Shields AM, Mor MK, Sevick MA, Homer M, Peternel J, Porter P, Rollman BL, **Palevsky PM**, Arnold RM, Fine MJ. Methodology of a Randomized Clinical Trial of Symptom Management Strategies in Patients Receiving Chronic Hemodialysis: The SMILE Study. *Contemporary Clinical Trials* 2010; 31:491-497 ([PMID: 20601163](#)).
54. Green JA, Mor MK, Shields AM, Sevick MA, **Palevsky PM**, Fine MJ, Arnold RM, Weisbord SD. Prevalence and Demographic and Clinical Associations of Health Literacy in Patients on Maintenance Hemodialysis. *Clinical Journal of the American Society of Nephrology* 2011; 6:1354-1360. ([PMCID: PMC3109932](#))
55. Srisawat N, Wen X, Lee MJ, Kong L, Elder M, Carter M, Unruh M, Finkel K, Vijayan A, Ramkumar M, Paganini E, Singbartl K, **Palevsky PM**, Kellum JA for the BioMaRK Investigators. Urinary biomarkers predict renal recovery in critically ill patients with renal support. *Clinical Journal of the American Society of Nephrology* 2011; 6:1815-1823. ([PMCID: PMC3156420](#))
56. Demirjian S, Chertow GM, Zhang JH, O'Connor TZ, Vitale J, Paganini EP, **Palevsky PM** for the VA/NIH Acute Renal Failure Trial Network. Clinical risk model to predict mortality in critically ill adults with acute kidney injury. *Clinical Journal of the American Society of Nephrology* 2011; 6: 2114-2120. ([PMCID: PMC3359007](#)).
57. Green JA, Mor MK, Shields AM, Sevick MA, **Palevsky PM**, Fine MJ, Arnold RM, Weisbord SD. Renal provider perceptions and practice patterns regarding the management of pain, sexual dysfunction, and depression in hemodialysis patients. *Journal of Palliative Medicine* 2012; 15: 163-167 ([PMID: 22339326](#)).
58. Joyce VR, Smith MW, Johansen KL, Unruh ML, Siroka AM, O'Connor TZ, **Palevsky PM** for the VA/NIH Acute Renal Failure Trial Network. Health-related quality of life as a predictor of mortality among survivors of acute kidney injury. *Clinical Journal of the American Society of Nephrology* 2012; 7: 1063-1070 ([PMCID: PMC3386668](#)).
59. Chandra D, Stamm JA, **Palevsky PM**, Leader JK, Fuhrman CR, Zhang Y, Bon J, Duncan SR, Branch RA, Weissfeld J, Gur D, Gladwin MT, Sciruba FC. The relationship between pulmonary emphysema and kidney function in smokers. *Chest* 2012; 142: 655-662. ([PMCID: PMC3435137](#))
60. Weisbord SD, Mor MK, Green JA, Sevick MA, Shields AM, Zhao X, Rollman BL, **Palevsky PM**, Arnold RM, Fine MJ. Comparison of symptom management strategies for pain, erectile dysfunction, and depression in patients receiving chronic hemodialysis: A cluster randomized effectiveness trial. *Clinical Journal of the American Society of Nephrology* 2013; 8: 90-99 ([PMCID: PMC3531656](#)).

61. Green JA, Mor MK, Shields AM, Sevick MA, Arnold RM, **Palevsky PM**, Fine MJ, Weisbord SD. Associations of Health Literacy with Dialysis Adherence and Health Resource Utilization in Patients Receiving Chronic Hemodialysis. *American Journal of Kidney Disease* 2013; 62:73-80 ([PMID 23352380](#)).
62. Hill M, Mor MK, Travis L, Ward T, **Palevsky PM**, Ramkumar M, Weisbord SD. Renal function following fistulography in patients with advanced chronic kidney disease. *Renal Failure* 2013; 35: 791-795 ([PMID: 23713575](#)).
63. Weisbord SD, Gallagher M, Kaufman J, Cass A, Parikh CR, Chertow GM, Shunk KA, McCullough PA, Fine MJ, Mor MK, Lew RA, Huang GD, Conner TA, Brophy MT, Lee J, Soliva S, **Palevsky PM**. Prevention of contrast-induced acute kidney injury: A review of published trials and the design of the Prevention of Serious Adverse Events Following Angiography (PRESERVE) trial. *Clinical Journal of the American Society of Nephrology* 2013; 8:1618-1631. ([PMCID: PMC3805082](#))
64. Zhang JH, **Palevsky PM**, Chertow GM, Hartigan J, O'Connor TZ, Guarino P, Zhou B. Piecewise analysis of patient survival after onset of acute kidney injury. *Clinical Journal of the American Society of Nephrology* 2013; 8:1679-1684. ([PMCID: PMC3789347](#))
65. Afshinnia F, Belanger K, **Palevsky P**, Young E. Effect of ionized serum calcium on outcomes in acute kidney injury needing renal replacement therapy: Secondary analysis of the Acute Renal Failure Trial Network study. *Renal Failure* 2013 35:1310-1318. ([PMCID: PMC4082331](#))
66. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O'Connor T, **Palevsky PM**, Reilly RF, Seliger AL, Warren SR, Watnick S, Peduzzi P, Guarino P, for the VA NEPHRON-D Investigators. Combined angiotensin inhibition for treatment of diabetic nephropathy. *New England Journal of Medicine* 2013; 369:1892-1903 ([PMID 24206457](#)).
67. Mor MK, Sevick MA, Shields AM, Green JA, **Palevsky PM**, Arnold RM, Fine MJ, Weisbord SD. Sexual function, activity, and satisfaction among women receiving maintenance hemodialysis. *Clinical Journal of the American Society of Nephrology* 2014; 9: 128-134. ([PMCID: PMC3878703](#)).
68. Murugan R, Wen X, Shah N, Lee M, Kong L, Pike F, Keener C, Unruh M, Finkel K, Vijayan A, **Palevsky PM**, Paganini E, Carter M, Elder M, Kellum JA. Plasma inflammatory and apoptosis markers are associated with dialysis dependence and death among critically ill patients receiving renal replacement therapy *Nephrology Dialysis Transplantation* 2014; 29: 1854-1864. ([PMCID: PMC4173817](#))
69. Weisbord SD, Mor MK, Sevick MA, Shields AM, Rollman BL, **Palevsky PM**, Arnold RM, Green JA, Fine MJ. Associations of depressive symptoms and pain with dialysis adherence, health resource utilization, and mortality in patients receiving chronic hemodialysis. *Clinical Journal of the American Society of Nephrology* 2014; 9: 1594-1602. ([PMCID: PMC4152801](#))
70. Belayev L, Mor M, Sevick MA, Shields AM, Rollman B, **Palevsky PM**, Arnold RM, Fine MJ, Weisbord SD. Longitudinal associations of depressive symptoms and pain with quality of life in

patients receiving chronic hemodialysis. *Hemodialysis International* 2015; 19:216-224 ([PMCID: PMC25403142](#)).

71. Murugan R, Wen X, Keener C, Pike F, **Palevsky PM**, Unruh M, Finkel K, Vijayan A, Elder M, Chen Y-F, Kellum JA. Associations between intensity of renal replacement therapy, inflammatory mediators, and outcomes. *Clinical Journal of the American Society of Nephrology* 2015; 10:926-933. ([PMCID: PMC4455205](#)).

72. Pike F, Murugan R, Keener C, **Palevsky PM**, Vijayan A, Unruh M, Finkel K, Wen X, Kellum, J. Biomarker enhanced risk prediction for adverse outcomes in critically ill patients receiving renal replacement therapy. *Clinical Journal of the American Society of Nephrology* 2015; 10:1332-1339. ([PMCID: PMC4527029](#)).

73. Hoste EAJ, Bagshaw SM, Bellomo R, Cely CM, Cruz DM, Edipidis K, Forni LG, Gomersall CD, Govil D, Honoré PM, Joannes-Boyau O, Joannidis M, Korhonen A-M, Lavrentieva A, Mehta R, **Palevsky P**, Roessler E, Ronco C, Uchino S, Vazquez JA, Andrade EV, Webb S, Colman R, Kellum JA, for The AKI-EPI Study Group. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. *Intensive Care Medicine* 2015. 41: 1411-1423. ([PMID: 26162677](#)).

74. Leehey DJ, Zhang JH, Emanuele NV, Whaley-Connell A, **Palevsky PM**, Reilly RF, Guarino P, Fried LF for the VA NEPHRON-D Study Group. Blood pressure and renal outcomes in diabetic kidney disease: The VA NEPHRON-D Trial. *Clinical Journal of the American Society of Nephrology* 2015; 10:2159-2169 ([PMCID: PMC4670761](#)).

75. Liang KV, Sileanu FE, Clermont G, Murugan R, Pike F, **Palevsky PM**, Kellum JA. Modality of renal replacement therapy and recovery of kidney function after acute kidney injury in patients surviving to hospital discharge. *Clinical Journal of the American Society of Nephrology* 2016; 11: 30-38 ([PMCID: PMC4702218](#)).

76. Kellum JA, Chawla LS, Keener C, Singbartl K, **Palevsky PM**, Pike FL, Yealy DM, Huang DT, Angus DC for the ProCESS and ProGRess Investigators. The effects of alternative resuscitation strategies in acute kidney injury patients with septic shock. *American Journal of Respiratory and Critical Care Medicine* 2016; 193:281-287 ([PMCID: PMC4803059](#)).

77. McCausland FR, Asafu-Adjei J, Betensky RA, **Palevsky PM**, Waikar SS. Comparison of urine output among patients treated with more intensive vs. less-intensive renal replacement therapy: Results from the ATN study. *Clinical Journal of the American Society of Nephrology* 2016; 11: 1335-1342. ([PMCID: PMC4974887](#)).

78. **Palevsky PM**, Zhang JH, Sigler SL, Emanuele N, Fried LF for the VA NEPHRON-D Study. Incidence, severity and outcomes of acute kidney injury associated with dual renin-angiotensin system blockade. *Clinical Journal of the American Society of Nephrology* 2016; 11: 1944-1953 ([PMCID: PMC5108193](#)).

79. Pena-Polanco JE, Mor MK, Tohme FA, Fine MJ, **Palevsky PM**, Weisbord SD. Acceptance of anti-depressant treatment by patients on hemodialysis and their renal providers. *Clinical Journal of the American Society of Nephrology* 2017; 12:298-303 ([PMCID: PMC5293340](#)).

80. Balakumar V, Murugan R, Sileanu FE, **Palevsky PM**, Clermont G, Kellum JA. Both positive and negative fluid balance may be associated with reduced long-term survival in the critically ill. *Critical Care Medicine* 2017; 45:e749-e757 ([PMCID: PMC5511076](#)).
81. Tohme F, Mor MK, Pena-Polanco J, Green JA, Fine MJ, **Palevsky PM**, Weisbord SD. Predictors and outcomes of non-adherence in patients receiving maintenance hemodialysis. *International Urology and Nephrology* 2017; 49:1471-1479 ([PMCID: PMC5522640](#)).
82. Weisbord SD, Gallagher M, Jneid H, Garcia S, Cass A, Thwin SS, Conner TA, Chertow GA, Bhatt DL, Shunk K, Parikh CR, McFalls EO, Brophy M, Ferguson R, Wu H, Androsenko M, Myles J, Kaufman J, **Palevsky PM** for the PRESERVE Trial Group. Outcomes after angiography with sodium bicarbonate and acetylcysteine. *New England Journal of Medicine* 2018; 378: 603-614 ([PMID 29130810](#)).
83. Vijayan A, Delos Santos RB, Li T, Goss CW, **Palevsky PM**. Frequency of intermittent hemodialysis and its impact on renal recovery in patients with acute kidney injury: results from the Acute Renal Failure Trial Network Study. *Kidney International Reports* 2018; 3:456-463. ([PMCID: PMC5932307](#))
84. Leaf DE, Siew E, Eisenga M, Singh K, McCausland FR, Srivastava A, Ikizler TA, Ware LB, Ginde AA, Kellum JA, **Palevsky PM**, Wolf M, Waikar SS. Fibroblast growth factor 23 associates with death in critically ill patients. *Clinical Journal of the American Society of Nephrology* 2018; 13: 531-541. ([PMCID: PMC5969465](#))
85. Timilsina S, Brittan K, O'Dell JR, Brophy M, Davis-Karim A, Henrie AM, Neogi T, Newcomb J, **Palevsky PM**, Pillinger MH, Pittman D, Taylor TH, Wu H, Mikuls TR. Design and rationale for the Veterans Affairs “Cooperative Study Program 594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat” trial. *Contemporary Clinical Trials* 2018; 68:102-108 ([PMID:29597007](#))
86. Wang Y, Gallagher M, Li Q, Lo S, Cass A, Finfer S, Myburgh J, Bouman C, Faulhaber-Walter R, Kallum JA, **Palevsky PM**, Ronco C, Saudan P, Tolwani A, Bellomo R. Renal replacement therapy intensity in acute kidney injury and recovery to dialysis independence: A systematic review and individual patient meta-analysis. *Nephrology Dialysis and Transplantation* 2018; 33:1017-1024. ([PMID: 29186517](#))
87. Biswas A, Parikh CR, Feldman HI, Garg AX, Lathan S, Lin H, **Palevsky PM**, Ugwuowo U, Wilson FP. Identification of Patients Expected to Benefit from Electronic Alerts for Acute Kidney Injury. *Clinical Journal of the American Society of Nephrology* 2018; 13:842-849. ([PMCID: PMC5986973](#))
88. Yu L-R, Sun J, Daniels JR, Cao Z, Schnackenberg L, Chaudhury D, **Palevsky PM**, Ma JZ, Beger RD, Portilla D. Aptamer-based proteomics identifies mortality-associated serum biomarkers in dialysis-dependent acute kidney injury patients. *Kidney International Reports* 2018; 3: 1202-1213. ([PMCID: PMC6127416](#))
89. Murugan R, Balakumar V, Kenti SJ, Priyanka P, Chang C-CH, Clermont G, Bellomo R, **Palevsky PM**, Kellum JA. Net ultrafiltration intensity and mortality in critically ill patients with fluid overload. *Critical Care* 2018 22:223. ([PMCID: PMC6151928](#))

90. Dellinger RP, Bagshaw SM, Antonelli M, Foster DM, Klein DJ, Marshall JC, **Palevsky PM**, Weisberg LS, Schorr CA, Trzeciak S, Walker PM, for the EUPHRATES trial investigators. Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: the EUPHRATES randomized clinical trial. *Journal of the American Medical Association* 2018; 320:1455-1463. ([PMCID: 6233793](#))
91. Garcia S, Bhatt DL, Gallagher M, Jneid H, Kaufman J, **Palevsky PM**, Wu H, Weisbord SD for the PRESERVE Trial Group. Strategies to reduce acute kidney injury and improve clinical outcomes following percutaneous coronary intervention: A subgroup analysis of the Prevention of Serious Events Following Angiography (PRESERVE) Trial. *JACC: Cardiovascular Interventions*. 2018; 11:2254-2261 ([PMID: 30466822](#)).
92. Griffin BR, Jovanovich A, You Z, **Palevsky PM**, Faubel S, Jalal D. Effects of baseline thrombocytopenia and platelet decrease following RRT initiation in patients with severe AKI. *Critical Care Medicine* 2019; 47:e325-e331. ([PMID: 30585829](#)).
93. Srinavasta A, Palsson A, Leaf DE, Higuera A, Chen ME, Palacios P, Baron R, Sabbisetti V, Hoofnagle AN, Vaingankar SM, **Palevsky PM**, Waikar SS. Uric acid and acute kidney injury in the critically ill. *Kidney Medicine* 2019; 1:21-30. ([doi:10.1016/j.xkme.2019.01.003](#))
94. Leaf DE, Rajapurkar M, Lele SS, Mukhopadhyay B, Boerger EAS, Mc Causland FR, Eisenga MF, Singh K, Babitt JL, Kellum JA, **Palevsky PM**, Christov M, Waikar SS. Iron, hepcidin, and death in human AKI. *Journal of the American Society of Nephrology* 2019; 30: 493-504. ([PMCID: PMC6405140](#))
95. Liang KV, Zhang JH, **Palevsky PM**. Urea reduction ratio may be a simpler approach for measurement of adequacy of intermittent hemodialysis in acute kidney injury. *BMC Nephrology* 2019; 20:82. ([PMCID: 6404330](#))
96. Mutter M, Martin M, Yamamoto Y, Biswas A, Etropolski B, Feldman H, Garg A, Gourlie N, Latham S, Lin H, **Palevsky PM**, Parikh C, Moreira E, Ugwuowo U, Wilson FP. Electronic alerts for acute kidney injury amelioration (ELAIA-1): a completely electronic, multicenter, randomized controlled trial: design and rationale. *BMJ Open* 2019; 9:e025117. ([PMCID: 6549649](#))
97. Murugan R, Kerti SJ, Chang CH, Gallagher M, Clermont G, **Palevsky PM**, Kellum JA, Bellomo R. Association of net ultrafiltration rate with mortality among critically ill adults with acute kidney injury receiving continuous venovenous hemodiafiltration: A secondary analysis of the Randomized Evaluation of Normal Versus Augmented Level (RENAL) of Renal Replacement Therapy Trial. *JAMA Network Open* 2019; 2:e195418. ([PMCID: PMC6563576](#))
98. STARRT-AKI Investigators [**Palevsky P**]. Standard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury: Study protocol for a multi-national, multi-center, randomized controlled trial. *Canadian Journal of Kidney Health and Disease* 2019; 6: 1-11. ([PMICD: PMC6558541](#))
99. STARRT-AKI Investigators [**Palevsky P**]. Statistical analysis plan for the Standard versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial. *Critical Care and Resuscitation* 2019; 21: 162-170 ([PMID 31462203](#))

100. Parikh CR, Liu C, Mor MK, **Palevsky PM**, Kaufman JS, Thiessen Philbrook H, Weisbord SD. Kidney biomarkers of injury and repair as predictors of contrast-associated AKI: A substudy of the PRESERVE Trial. *American Journal of Kidney Diseases* 2020; 75: 187-194. ([PMICD: PMC7012712](#))
101. Murugan R, Ostermann M, Peng Z, Kitamura K, Fujitani S, Romagnoli S, Di Lullo L, Srisawat N, Todi S, Ramakrishnan N, Hoste E, Puttarajappa CM, Bagshaw SM, Weisbord S, Palevsky PM, Kellum JA, Bellomo R, Ronco, C. Net ultrafiltration prescription and practice among critically ill patients receiving renal replacement therapy: A multinational survey of critical care practitioners. *Critical Care Medicine* 2020; 48: e87-e97. ([PMID: 31939807](#))
102. Weisbord SD, **Palevsky PM**, Kaufman JS, Wu H, Androsenko M, Ferguson RE, Parikh CR, Bhatt DL, Gallagher M for the PRESERVE Trial investigators. Contrast-associated acute kidney injury and serious adverse outcomes following angiography. *Journal of the American College of Cardiology* 2020; 75:1311-1320. ([PMID: 32192658](#))
103. Webster L, Larive B, Gassman J, Bullen A, Weisbord SD, **Palevsky PM**, Fried L, Raphael K, Isakova T, Ix JH: A simple equation to estimate urinary flow rate using urine creatinine. *American Journal of Nephrology* 2020; 51:395-400. ([PMICD: PMC7228836](#))
104. Fischer M, Kourany W, Sovern K, Forrester K, Griffin C, Lightner N, Loftus S, Murphy K, Roth G, **Palevsky PM**, Crowley S. Development, implementation and user experience of the Veterans Health Administration (VHA) Dialysis Dashboard. *BMC Nephrology* 2020; 21:136. ([PMICD: PMC7160999](#))
105. Sharma S, Kelly Y, **Palevsky PM**, Waikar S. Intensity of renal replacement therapy and duration of mechanical ventilation: Secondary analysis of the Acute Renal Failure Trial Network Study. *Chest* 2020; 158:1473-1481. ([PMICD: PMC8176776](#))
106. Peerapornratana A, Priyanka P, Wang S, Singbartl K, **Palevsky PM**, Chawla LS, Yealy DM Angus DC, Kellum JA for the ProCESS and ProGRess-AKI Investigators. Sepsis-associated acute kidney disease. *Kidney International Reports* 2020; 5:839-850. ([PMICD: PMC7270721](#))
107. Tandukar S, Kim C, Kalra K, Verma S, **Palevsky PM**, Puttarajappa C. Severe hyponatremia and continuous renal replacement therapy: Safety and effectiveness of low sodium dialysate. *Kidney Medicine* 2020; 2:437-449. ([PMICD: PMC7406832](#))
108. Fiorentino M, Xu Z, Smith A, Singbartl K, **Palevsky PM**, Chawla LS, Huang DT, Yealy DM, Angus DC, Kellum JA for the ProCESS and ProGRess-AKI Investigators. Serial measurement of cell-cycle arrest biomarkers [TIMP-2]•[IGFBP7] and risk for progression to death, dialysis or severe acute kidney injury in patients with septic shock. *American Journal of Respiratory and Critical Care Medicine* 2020; 202:1262-1270 ([PMICD: PMC7605192](#)).
109. STARRT-AKI Investigators; Canadian Critical Care Trials Group, the Australian and New Zealand Intensive Care Society Clinical Trials Group, the United Kingdom Critical Care Research Group, the Canadian Nephrology Trials Network, and the Irish Critical Care Trials Group, Bagshaw SM, Wald R, Adhikari NKJ, Bellomo R, da Costa BR, Dreyfuss D, Du B, Gallagher MP, Gaudry S, Hoste EA, Lamontagne F, Joannidis M, Landoni G, Liu KD, McAuley DF, McGuinness SP, Neyra JA, Nichol AD, Ostermann M, **Palevsky PM**, Pettilä V, Quenot JP, Qiu H, Rochweg

B, Schneider AG, Smith OM, Thomé F, Thorpe KE, Vaara S, Weir M, Wang AY, Young P, Zarbock A. Timing of initiation of renal-replacement therapy initiation in acute kidney injury. *New England Journal of Medicine* 2020; 383:240-251. ([PMID: 32668114](#))

110. Liu C, Mor MK, **Palevsky PM**, Kaufman JS, Philbrook HT, Weisbord SD, Parikh CR. Post-angiography increases in serum creatinine and biomarkers of injury and repair. *Clinical Journal of the American Society of Nephrology* 2020; 15:1240-1250. ([PMICD: PMC7480551](#))

111. Poggio ED, McClelland RL, Blank K, Hansen S, Bansal S, Bomback A, Canetta P, Khairallah P, Kiryluk K, Lecker S, McMahon G, **Palevsky P**, Parikh S, Rosas S, Tuttle K, Vazquez M, Vijayan A, Rovin BH, for the Kidney Precision Medicine Project. Systematic review and meta-analysis of native kidney biopsy complications. *Clinical Journal of the American Society of Nephrology* 2020; 15:1595-1602 ([PMICD: PMC764627](#))

112. Wilson FP, Martin M, Yamamoto Y, Partridge C, Moreira E, Arora T, Biswas A, Feldman H, Garg AX, Greenberg JH, Hinchcliff M, Latham S, Li F, Lin H, Mansour SG, Moledina DG, **Palevsky PM**, Parikh CR, Simonov M, Testani J, Ugwuowo U. Electronic health record alerts for acute kidney injury: A multi-center randomized clinical trial. *British Medical Journal* 2021; 372:m4786 ([PMICD: PMC8034420](#)).

113. Kulvichit W, Wen X, Srisawat N, Pisitkun T, Smith A, **Palevsky PM**, Kellum JA. Urinary ezrin and moesin as novel markers for recovery from acute kidney injury. *Nephrology Dialysis and Transplantation*; 2021; 36:938-941. ([PMICD: PMC8075373](#))

114. de Boer IH, Alpers CE, El-Achka, TM, Azeloglu E, Balis UGJ, Barasch JM, Barisoni L, Blank K, Bomback AS, Brown K, Dagher PC, Dighe AL, Eadon MT, Gaut JP, Hachohen N, He Y, Hodgins JB, Jain S, Kellum JA, Kiryluk K, Knight R, Laszik ZG, Lienczewski C, Mariani LH, McClelland RL, Menez S, Moledina D, Mooney SD, O'Toole J, **Palevsky PM**, Parikh CR, Poggio E, Rosas S, Rosengart MR, Sarwal M, Schaub JA, Sedor JR, Sharma K, Steck B, Toto R, Troyanskaya O, Tuttle K, Vazquez M, Waikar SS, Williams K, Wilson FP, Zhang K, Iyengar SR, Kretzler M, Himmelfarb J, for the Kidney Precision Medicine Project. Rationale and design of the Kidney Precision Medicine Project. *Kidney International*. 2021; 99: 498-510. ([PMICD: PMC8330551](#))

115. Le S, Allen A, Calvert J, **Palevsky PM**, Braden G, Patel S, Pellegrini E, Green-Saxena A, Hoffman J, Das R. Convolutional neural network model for ICU acute kidney injury prediction. *Kidney International Reports*; 2021; 6:1289-1298 ([PMICD: PMC8116759](#))

116. Bullen AL, Cashion W, Webster L, **Palevsky PM**, Weisbord SD, Ix JH. Estimated Urinary Flow Rate and Contrast-Associated AKI Risk: the PRESERVE Trial. *Kidney Medicine* 2021; 3:461-463. ([PMICD: PMC8178467](#)).

117. Kelly YP, Sharma S, Mothi SS, McCausland FR, Mendu ML, McMahon GM, **Palevsky PM**, Waikar SS. Hypocalcemia is associated with hypotension during CRRT: A secondary analysis of the Acute Renal Failure Trial Network study. *Journal of Critical Care* 2021; 65: 261-267. ([PMID: 34274834](#))

118. Murugan R, Kerti SJ, Chang C-CH, Gallagher M, Neto AS, Clermont G, Ronco C, **Palevsky PM**, Kellum JA, Bellomo R. Association between net ultrafiltration rate and renal recovery among

critically ill adults with acute kidney injury receiving continuous renal replacement therapy: An observational cohort study. *Blood Purification* 2022; 51:397-409. ([PMICD: PMC8776893](#))

119. Daniels JR, Ma JZ, Cao Z, Beger RD, Sun J, Schnackenberg L, Pence L, Choudhury D, **Palevsky PM**, Portilla D, Yu L-R. Discovery of novel proteomic biomarkers for the prediction of kidney recovery from dialysis-dependent AKI patients. *Kidney* 360 2021; 2:1716-1727 ([PMICD: PMC8670726](#))

120. Sun J, Cao Z, Schnackenberg L, Pence L, Yu L-R, Choudhury D, **Palevsky PM**, Portilla D, Beger RD. Serum metabolite profiles predict outcomes in critically ill patients receiving renal replacement therapy. *Journal of Chromatography B*. 2021; 1187:123024. ([PMID: 34815179](#))

121. Switzer GE, Puttarajappa CM, Kane-Gill SL, Fried LF, Abebe KZ, Kellum JA, Jhamb M, Bruce JG, Kuniyil V, Conway PT, Knight R, Murphy J, **Palevsky PM**. Patient-reported experiences after acute kidney injury across multiple health-related quality-of-life domains. *Kidney* 360 2021; 3: 426-434. ([PMICD: PMC9034810](#))

122. Ferkowicz MJ, Winfree S, Sabo AR, Kamocka MM, Khochare S, Barwinska D, Eadon MT, Cheng Y-H, Phillips CL, Sutton TA, Kelly KJ, Dagher PC, El-Achkar TM, Dunn KW, for the Kidney Precision Medicine Project [**Palevsky PM**]. Large-scale, three-dimensional tissue cytometry of the human kidney: a complete and accessible pipeline. *Laboratory Investigation* 2021; 101:661-676. ([PMICD: PMC8363780](#))

123. O'Dell J, Brophy MT, Pillinger MH, Neogi T, **Palevsky PM**, Wu H, Davis-Karin A, Newcomb JA, Ferguson R, Pittman D, Cannon GW, Taylor T, Terkeltaub R, Cannella AC, England BR, Helget LN, Mikuls TR. Comparative effectiveness of allopurinol and febuxostat in gout management. *NEJM Evidence* 2022; 1: 10.1056/evidoa2100028 ([PMICD: PMC9012032](#))

124. Molinari L, del Rio-Pertuz G, Smith A, Landsittel, DP, Singbartl K, **Palevsky PM**, Chawla LS, Huang DT, Yealy DM, Angus DC, Kellum JA, for the ProCESS and ProGRess-AKI Investigators. Utility of biomarkers for sepsis-associated acute kidney injury staging. *JAMA Netw Open* 2022; 5:e2212709. ([PMICD: PMC9118077](#))

125. Soomro QH, Anand ST, Weisbord SD, Gallagher MP, Ferguson RE, **Palevsky PM**, Bhatt DL, Parikh CR, Kaufman JS for the PRESERVE Trial Investigators. The relationship between intravenous fluid administration and kidney outcomes after angiography. *Clinical Journal of the American Society of Nephrology* 2022; 17:1446-1456. ([PMICD: PMC9528263](#))

126. Chang H-H, Chiang J-H, Wang C-S, Chiu P-F, Abdel-Kader K, Chen H, Siew ED, Yabes J, Murugan R, Clermont F, **Palevsky PM**, Jhamb M. Predicting mortality using machine learning algorithms in patients who require renal replacement therapy in the critical care unit. *Journal of Clinical Medicine* 2022; 11:5289. ([PMICD: PMC9500742](#))

127. Wald R, Kirkham B, DaCosta BR, Ghamarian E, Adhikari NKJ, Beaubien-Souligny W, Bellomo R, Gallagher MP, Goldstein S, Hoste EAJ, Liu KD, Neyra Lozano J, Ostermann M, **Palevsky PM**, Schneider A, Vaara ST, Bagshaw SM. Fluid balance and renal replacement therapy initiation strategy: A secondary analysis of the STARRT-AKI Trial. *Critical Care* 2022; 26:360 ([PMICD: PMC9694606](#)).



128. Murugan R, Boudreaux-Kelly MY, Kellum JA, **Palevsky PM**, Weisbord S. Kidney cell cycle arrest and cardiac biomarkers and acute kidney injury following angiography: The PRESERVE Study. *Kidney Medicine* 2023; 5: 100592. ([PMICD: PMC9976574](#))
129. Weisbord SD, Mor MK, Hochheiser H, Kim N, Ho PM, Bhatt DL, Fine MJ, **Palevsky PM**. Utilization and outcomes of clinically indicated invasive cardiac care in Veterans with acute coronary syndrome and chronic kidney disease. *Journal of the American Society of Nephrology* 2023; 34:694-705. ([PMID: 36735537](#))
130. Stottlemeyer BA, Abebe KZ, **Palevsky PM**, Fried L, Schulman IH, Parikh CR, Poggio E, Siew ED, Gutierrez OM, Horwitz E, Weir MR, Wilson FP, Kane-Gill SL. Expert consensus on the nephrotoxic potential of 195 medications in the non-intensive care setting: A modified Delphi method. *Drug Safety* 2023; 46:677-687. ([PMICD: PMC10208182](#))
131. Bhatraju PK, Stanaway IB, Palmer MR, Menon R, Schaub JA, Menez S, Srivastava A, Wilson FP, Kiryluk K, **Palevsky PM**, Naik AS, Sakr SS, Jarvik GP, Parikh CR, Ware LB, Ikizler TA, Siew EP, Chinchilli VM, Coca SG, Garg AX, Go AS, Kaufman JS, Kimmel PL, Himmelfarb J, Wurfel MM. Genome-wide association study for acute kidney injury. *Kidney* 2023; 4: 870-880 ([PMICD: PMC10371295](#))
132. Kwong YD, Liu K, Hsu C, Cooper B, **Palevsky P**, Kellum J, Johansen K, Miaskowski C. Subgroups of patients with distinct health utility profiles following acute kidney injury. *Kidney* 2023; 4:881-889. ([PMICD: PMC10371285](#)).
133. Murugan R, Chang C-CH, Raza M, Nikravangolsefid N, Huang DT, **Palevsky PM**, Kashani K. Restrictive versus liberal rate of extracorporeal volume removal evaluation in acute kidney injury (RELIEVE-AKI): a pilot clinical trial protocol. *BMJ Open* 2023; 13:e075960. ([PMICD: PMC10335418](#))
134. Lake BB, Menon R, Winfree S, Hu Q, Ferreira RM, Kalhor K, Barwinska D, Otto EA, Ferkowicz M, Diep D, Plongthongkum N, Knoten A, Urata S, Naik AS, Eddy S, Zhang B, Wu Y, Salamon D, Williams JC, Wang X, Balderrama KS, Hoover P, Murray E, Vijayan A, Chen F, Waikar SS, Rosas S, Wilson FP, **Palevsky PM**, Kiryluk K, Sedor JR, Toto RD, Parikh C, Kim EH, Macosko EZ, Kharchenko PV, Gaut JP, Hodgin JB, Eadon MT, Dagher PC, El-Achkar TM, Zhang K, Kretzler M, Jain S, for the KPMP consortium. An atlas of healthy and injured cell states and niches in the human kidney. *Nature* 2023; 619: 585-594. ([PMICD: PMC10356613](#))
135. Wald R, Gaudry S, da Costa BR, Adhikari NKJ, Bellomo R, Du B, Gallagher MP, Hoste EA, Lamontagne F, Joannidis M, Liu KD, McAuley DF, McGuinness SP, Nichol AD, Ostermann M, **Palevsky PM**, Qiu H, Pettila V, Schneider AG, Smith OM, Vaara ST, Weir M, Dreyfuss D, Bagshaw SM, on behalf of the STARRT-AKI Investigators. Initiation of continuous renal replacement therapy versus intermittent hemodialysis in critically ill patients with severe acute kidney injury: a secondary analysis of STARRT-AKI Trial. *Intensive Care Medicine* 2023; 29: 1305-1316. ([PMID: 37815560](#))
136. Helget LN, O'Dell JR, Newcomb JA, Androsenko M, Brophy MT, Davis-Karim A, England BR, Ferguson R, Pillinger MH, Neogi T, **Palevsky PM**, Wu H, Kramer B, Mikuls TR. Determinants of achieving serum urate goal with treat-to-target urate-lowering therapy in gout. *Arthritis & Rheumatology* 2023; e-pub Oct 16 (doi: 10.1002/art.42731) ([PMID: 37842953](#)).

137. Adingwupu OM, Barbosa ER, **Palevsky PM**, Vassalotti JA, Levey AS, Inker LA. Cystatin C as a GFR estimation marker in acute and chronic illness. A systematic review. *Kidney Medicine* 2023; 5:100727. ([PMICD: PMC10623366](#))
138. Murugan R, Boureaux-Kelly MY, Kellu JA, **Palevsky PM** Weisbord S. Contrast-associated acute kidney injury and cardiovascular events: a secondary analysis of PRESERVE Cohort. *Clinical Kidney Journal* (In Press).
139. Murugan R, Kashani K, **Palevsky PM**. Precision net ultrafiltration dosing in continuous kidney replacement therapy: a practical approach. *Intensive Care Medicine Experimental* 2023; 11:83 ([PMID: 38015332](#))
140. Wen Y, Su E, Xu L, Menez SP, Moledina D, Obeid W, Palevsky PM, Mansour SG, Devarajan P, Cantley L<sup>3</sup>, Cahan P, Parikh CR, for the Kidney Precision Medicine Project (KPMP) and Translational Investigation of Biomarker Endpoint of Acute Kidney Injury (TRIBE-AKI) Consortia. Analysis of the human kidney transcriptome and plasma proteome identifies novel biomarkers of proximal tubule maladaptation to injury. *Science Translational Medicine* (In Press).
141. List JM, Palevsky P, Tamang S, Crowley S, Au D, Yarbrough WC, Navathe AS, Kreisler C, Parikh RB, Wang-Rodriguez J, Klutts JS, Conlin P, Pogach L, Meerwijk E, Moy E. Eliminating algorithmic racial bias in clinical decision support algorithms: Use cases from the Veterans Health Administration. *Health Equity* 2023; 7:809-816.

### ***PREPRINTS***

1. Menon R, Otto EA, Barisoni L, Ferreira RM, Limonte CP, Godfrey B, Eichinger F., Nair V, Naik AS, Subramanian L, D'Agati V, Henderson JA, Herlitz L, Kiryluk K, Moledina DG, Moeckel GW, **Palevsky PM**, Parikh CR, Randhawa P, Rosas SE, Rosenberg AZ, Stillman I, Toto R, Torrealba J, Vasquez MA, Waikar S, Alpers CE, Nelson RG, Eadon MT, Kretzler M, Hodgin JB. Defining the molecular correlate of arteriolar hyalinosis in kidney disease progression by integration of single cell transcriptomic analysis and pathology scoring. *medRxiv* 2023 Jun 14; 2023.06.14.23291150. ([PMICD: PMC10312894](#)).

### ***INVITED REVIEWS, EDITORIALS AND BOOK CHAPTERS:***

1. Fernandez PC, Weisberg LS, **Palevsky PM**. Physiologic basis for the use of sequential nephron blockade in patients with resistant edema. In: Puschett JB, Greenberg A (eds.). *Diuretics II: Chemistry, Pharmacology, and Clinical Applications*. Elsevier, New York, 1987.
2. **Palevsky PM**, Cox M. Approach to the patient with polyuria or nocturia. In: Kelley WN (ed.). *Textbook of Internal Medicine*. J.B. Lippincott, Philadelphia, PA, 1989.
3. **Palevsky PM**, Singer I. Disorders of potassium metabolism. In: Wolfson AB (ed.). *Endocrine and Metabolic Emergencies*. Churchill Livingstone, New York, 1990.
4. **Palevsky P**, Szerlip HM, Cox M. Steroid Hormones: Mechanisms of cell signaling. In: Goldfarb S, Ziyadeh FN, Stein JH (eds.) *Contemporary Issues in Nephrology: New Insights into the Renal Actions of Hormones and Autocoids*. Churchill Livingstone, NY, 1991.
5. **Palevsky PM**, Singer I. Hyponatremia. In: Kassirer JP (ed.). *Current Therapy in Internal Medicine*, 3rd Ed. B.C. Decker, Philadelphia, PA, 1991.

6. **Palevsky PM**, Singer I. Hyponatremia. In: Glasscock RJ (ed.). Current Therapy in Nephrology and Hypertension, 3rd Ed. B.C. Decker, Philadelphia, PA, 1992.
7. **Palevsky PM**. Water and tonicity homeostasis. In: Carlson RM, Geheb MA (eds.) The Principles and Practice of Medical Intensive Care. W.B. Saunders, Philadelphia, 1993.
8. Szerlip H, **Palevsky PM**, Cox M. Disorders of volume and tonicity in the surgical patient. In: Goldman DR, Brown FH, Guarnieri DM (eds.). Perioperative Medicine, 2nd Ed. McGraw-Hill, New York, 1994.
9. Szerlip H, **Palevsky PM**, Cox M. Sodium and water. In: Noe DA, Rock RC (eds.). Laboratory Medicine: The Selection and Interpretation of Clinical Laboratory Studies. Williams and Wilkins, Baltimore, 1994.
10. Mann RA, Meyers CM, **Palevsky PM**, Singh AB, Spar B, Weiss LS. Glomerulonephritis. In: Gonick HC (ed.). Current Nephrology, Vol 17. Mosby-Year Book, Chicago, 1994.
11. **Palevsky PM**, Cox M. Disorders of sodium and water metabolism. In: Mandal AK, Jennette JC (eds.). Diagnosis and Management of Renal Disease and Hypertension, 2nd Ed. Carolina Academic Press, Durham, NC, 1994.
12. **Palevsky PM**, Cox M. Diabetes insipidus. In: Rakel RE (ed.). Conn's Current Therapy - 1996, W.B. Saunders, Philadelphia, 1996.
13. **Palevsky PM**. Continuous renal replacement therapy component selection: Replacement fluid and dialysis solutions. Seminars in Dialysis 1996; 9:107-111.
14. Irwin RS, Parrillo JE, Albert R, Collop N, Fein AM, Grossman R, Hancock EW, Heffner JE, Kamholz SL, Levine S, Osborne M, **Palevsky PM**, Schwarz M, Szerlip H, Weiner-Kronish JP. Assessment in Critical Care and Pulmonology – Self-Education and Evaluation of Knowledge: Critical Care Medicine, Volume VI. American College of Chest Physicians, Northbrook, Illinois, 1996
15. **Palevsky PM**, Cox M. Disorders of the posterior pituitary. In: Kelley WN (ed.). Textbook of Internal Medicine, 3rd Ed. Lippincott-Raven, Philadelphia, 1997.
16. Fried L, **Palevsky PM**. Hyponatremia and hyponatremia. Medical Clinics of North America 1997; 81:585-609. ([PMID: 9167647](#))
17. **Palevsky PM**, Singer I. Hyponatremia. In: Kassirer JP, Greene HL (eds.). Current Therapy in Internal Medicine, 4th Ed. Mosby-Year Book, Inc., Philadelphia, PA, 1997.
18. **Palevsky PM**. Hyponatremia. In: Greenberg A, ed. Primer on Kidney Diseases, 2nd Edition. Academic Press, San Diego, 1998.
19. Greenberg A, **Palevsky PM** (eds.): Seminars in Nephrology: Electrolyte Disorders. W.B. Saunders, Philadelphia, 1998.
20. **Palevsky PM**. Hyponatremia. Seminars in Nephrology 1998; 18:20-30. ([PMID: 9459286](#))
21. **Palevsky PM**. Supportive management strategies in chronic or end stage renal failure patients with critical illness. In: Ronco C, Bellomo R (eds.). Critical Care Nephrology. Kluwer Academic Publishers, Dordrecht, The Netherlands, 1998.

22. Johnson JP, **Palevsky PM**. The kidney and liver transplantation. In: Ronco C, Bellomo R (eds.). *Critical Care Nephrology*. Kluwer Academic Publishers, Dordrecht, The Netherlands, 1998.
23. Irwin RS, Parrillo JE, Albert RK, Alberts WM, Collop N, Fein A, Grossman R, Hollenberg SM, Kamholz SL, Levine S, **Palevsky PM**, Sarosi G, Schwarz M, Szerlip H, Weiner-Kronish JP. Assessment in Critical Care and Pulmonology – Self-Education and Evaluation of Knowledge: *Critical Care Medicine, Volume VIII*. American College of Chest Physicians, Northbrook, Illinois, 1998.
24. Aslam N, **Palevsky PM**. Real-time ultrasound for placement of dialysis catheters: A new standard of care. *Seminars in Dialysis* 1999; 12:1-4.
25. Rasool A, **Palevsky PM**. Treatment of edematous disorders with diuretics. *American Journal of Medical Sciences* 2000; 319:25-37. ([PMID: 10653442](#))
26. Irwin RS, Parrillo JE, Alberts WM, Collop N, Fein A, Grossman R, Hodder R, Hollenberg SM, Hubmayr RD, Levine S, **Palevsky PM**, Rosen M, Sarosi G, Schwarz M, Weiner-Kronish JP. Assessment in Critical Care and Pulmonology – Self-Education and Evaluation of Knowledge: *Critical Care Medicine, Volume X*. American College of Chest Physicians, Northbrook, Illinois, 2000
27. Fried L, **Palevsky PM**. Acute renal failure and rhabdomyolysis. In: Lanken PN, Manaker S, Hanson CW (eds.). *The Intensive Care Unit Manual*. W.B.Saunders, Philadelphia, 2001.
28. **Palevsky PM**. Hyponatremia. In: Greenberg A, ed. *Primer on Kidney Diseases*, 3rd Edition. Academic Press, San Diego, 2001.
29. Greenberg A, **Palevsky PM**. Disturbances in fluid, electrolyte, and acid-base balance: Part 1 - Patients with chronic renal failure. In: Massry SG, Glassock RJ (eds.). *The Textbook of Nephrology*, 4th Ed. Lippincott Williams and Wilkins, Philadelphia, 2001.
30. Aslam N, **Palevsky PM**. Insertion of temporary dialysis catheters with the aid of real-time ultrasound. *Saudi Journal of Kidney Disease and Transplantation* 2001; 12:375-381. ([PMID: 18209384](#))
31. **Palevsky PM**, Matzke GR. Acid-base disorders. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. *Pharmacotherapy: A Pathophysiologic Approach*, 5<sup>th</sup> Edition. McGraw Hill, New York, 2002.
32. **Palevsky PM**, Bunchman T, Tetta C. The Acute Dialysis Quality Initiative – Part V: Operational characteristics of CRRT. *Advances in Renal Replacement Therapy* 2002; 9:268-272. ([PMID: 12382230](#))
33. Bellomo R, Kellum JA, Mehta R, **Palevsky PM**, Ronco C. The Acute Dialysis Quality Initiative II: The Vicenza Conference. *Advances in Renal Replacement Therapy* 2002; 9:290-293. ([PMID: 12382233](#))
34. Kellum JA, **Palevsky P**, Mehta R, Bellomo R, Ronco C. Acute Dialysis Quality Initiative: methodology. *Current Opinion in Critical Care* 2002; 8:500-501. ([PMID: 12454531](#))

35. Bellomo R, Kellum JA, Mehta R, **Palevsky P**, Ronco C. Acute Dialysis Quality Initiative II: the Vicenza conference. *Current Opinion in Critical Care* 2002; 8:505-508. ([PMID: 12454533](#))
36. **Palevsky PM**, Metnitz PGH, Piccinni P, Vinsonneau C. Selection of endpoints for clinical trails of acute renal failure in critically ill patients. *Current Opinion in Critical Care* 2002; 8:515-518. ([PMID: 12454535](#))
37. Irwin RS, Parrillo JE, Collop N, Fein A, Greene K, Grossman R, Hodder R, Hollenberg SM, Levine SM, MacIntyre NR, **Palevsky PM**, Pratter MR, Rosen M, Sarosi G, Schwarz M, Sessler CN. Assessment in Critical Care and Pulmonology – Self-Education and Evaluation of Knowledge: Critical Care Medicine, Volume XII. American College of Chest Physicians, Northbrook, Illinois, 2002.
38. **Palevsky PM**. Acute renal failure. *NephSAP* 2003; 2: 41-85.
39. **Palevsky PM**. Perioperative management of patients with chronic kidney disease or ESRD. *Best Practice and Research Clinical Anaesthesiology* 2004; 18:129-144. ([PMID: 14760878](#))
40. **Palevsky PM**. CRRT: Selection of patients and starting criteria. *Contributions to Nephrology* 2004; 144:214-221. ([PMID: 15264410](#))
41. **Palevsky PM**. Acute renal failure. *NephSAP* 2004; 3: 245-284.
42. Irwin RS, Parrillo JE, Braman SS, Collop N, Greene KE, Grossman RF, Hall JB, Hollenberg SM, Levine SM, MacIntyre NR, **Palevsky PM**, Rosen MJ, Sarosi GA, Schwarz MI, Sessler CN. Assessment in Critical Care and Pulmonology – Self-Education and Evaluation of Knowledge: Critical Care Medicine, Volume XIV American College of Chest Physicians, Northbrook, Illinois, 2004.
43. **Palevsky PM**. Continuous renal replacement therapy. In: Nissenson AR, Fine R (eds.). *Clinical Dialysis*, 4<sup>th</sup> Ed. McGraw Hill, New York, 2005.
44. Weisbord SD, **Palevsky PM**. Radiocontrast-induced acute renal failure. *Journal of Intensive Care Medicine* 2005; 20:63-75. ([PMID: 15855219](#))
45. **Palevsky PM**. Renal replacement therapy I: Indications and timing. *Critical Care Clinics*, 2005; 21:347-356. ([PMID: 15781167](#))
46. Venkataraman R, **Palevsky P**, Kellum J. Adequacy of dialysis in acute renal failure. *Seminars in Nephrology* 2005; 25:120-124. ([PMID: 15791564](#))
47. **Palevsky PM**. Hyponatremia. In: Greenberg A (ed.). *Primer on Kidney Diseases*, 4<sup>th</sup> Ed. National Kidney Foundation, Elsevier Science, Philadelphia, 2005.
48. Matzke GR, **Palevsky PM**. Acid-base disorders. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. *Pharmacotherapy: A Pathophysiologic Approach*, 6<sup>th</sup> Edition. McGraw Hill, New York, 2005.
49. Greenberg A, Holley JL, Oliverio MI, **Palevsky PM**. Nephrology and hypertension. Medical Knowledge Self-Assessment Program (MKSAP) 13 Update. American College of Physicians, Philadelphia, PA, 2005.

50. **Palevsky PM**, Baldwin I, Davenport A, Goldstein S, Paganini E. Renal replacement therapy and the kidney: Minimizing the impact of renal replacement therapy on recovery of acute renal failure. *Current Opinion in Critical Care* 2005; 11: 548-554. ([PMID: 16292058](#))
51. **Palevsky PM**. Epidemiology of acute kidney injury: The tip of the iceberg. *Clinical Journal of the American Society of Nephrology* 2006; 1: 6-7. ([PMID: 17699185](#))
52. **Palevsky PM**. Dialysis modality and dosing strategy in acute renal failure. *Seminars in Dialysis* 2006; 19:165-170. ([PMID: 16551296](#))
53. **Palevsky PM**, Murray PT. Acute kidney injury and critical care nephrology. *NephSAP* 2006; 5 72-129.
54. Rice TL, **Palevsky P**. Preferred treatment options for hyperkalemia. *American Journal of Health System Pharmacy* 2006; 63:513 (letter). ([PMID: 16522882](#))
55. Weisbord SD, **Palevsky PM**. Acute renal failure in the intensive care unit. *Seminars in Respiratory and Critical Care Medicine* 2006; 27:261-272. ([PMID: 16791759](#))
56. Kellum J, **Palevsky PM**. Renal support in acute kidney injury. *Lancet* 2006; 368: 344-345. ([PMID: 16876645](#))
57. Levine SM, Parrillo JE, Baumann MH, Greene KE, Grossman RF, Hall JB, Hollenberg SM, Irwin RS, MacIntyre NR, **Palevsky PM**, Rosen MJ, Sarosi GA, Schwarz MI, Sessler CN, Wheeler AP. Assessment in Critical Care and Pulmonology – Self-Education and Evaluation of Knowledge: *Critical Care Medicine*, Volume XVI. American College of Chest Physicians, Northbrook, Illinois, 2006.
58. **Palevsky PM**. Off-pump cardiac surgery and acute kidney injury. *Critical Care Medicine* 2006 34: 3052-3053. ([PMID: 17130705](#))
59. Weisbord SD, **Palevsky PM**. Acute renal failure. In: Rakel RE, Bope ET, eds. *Conn's Current Therapy – 2007*. W.B. Saunders, Philadelphia, 2007.
60. Rondon-Berrios H, **Palevsky PM**. Treatment of acute kidney injury: An update on the management of renal replacement therapy. *Current Opinion in Nephrology and Hypertension* 2007; 16:64-70. ([PMID: 17293679](#))
61. **Palevsky PM**, Murray PT. Acute kidney injury and critical care nephrology. *NephSAP* 2007; 6:286-338.
62. **Palevsky PM**. Clinical review: timing and dose of continuous renal replacement therapy in acute kidney injury. *Critical Care* 2007; 11:232. ([PMCID: PMC2246195](#))
63. Weisbord SD, **Palevsky PM**. Acute renal failure. In: Rakel RE, Bope ET, eds. *Conn's Current Therapy – 2008*. W.B. Saunders, Philadelphia, 2008.
64. Weisbord, SD, **Palevsky, PM**. Prevention of contrast-induced nephropathy with volume expansion. *Clinical Journal of the American Society of Nephrology* 2008; 3:273-280. ([PMID: 17989201](#))

65. Kellum JA, Cerda J, Kaplan LJ, Nadim MK, **Palevsky PM**. Fluids for prevention and management of acute kidney injury. *International Journal of Artificial Organs* 2008; 31:96-110. ([PMID: 18311727](#))
66. **Palevsky PM**. Indications and timing of renal replacement therapy in acute kidney injury. *Critical Care Medicine*, 2008; 36: S224-S228. ([PMID: 18382198](#))
67. Davenport A, Bouman C, Kirpalani A, Skippen P, Tolwani A, Mehta R, **Palevsky PM**. Delivery of renal replacement therapy in acute kidney injury: What are the key issues? *Clinical Journal of the American Society of Nephrology* 2008; 3:869-875. ([PMID: 18235146](#))
68. Khalil P, Murty P, **Palevsky PM**. The patient with acute kidney injury. *Primary Care: Clinics in Office Practice*, 2008; 35: 239-264. ([PMID: 18486715](#))
69. **Palevsky PM**. Setting the agenda. *Clinical Journal of the American Society of Nephrology* 2008; 3:933-934. ([PMID: 18579670](#))
70. Levine SM, Parrillo JE, Baumann MH, Greene KE, Grossman RF, Hall JB, Hollenberg SM, Irwin RS, MacIntyre NR, **Palevsky PM**, Rosen MJ, Sarosi GA, Schwarz MI, Sessler CN, Wheeler AP. Assessment in Critical Care and Pulmonology – Self-Education and Evaluation of Knowledge: *Critical Care Medicine*, Volume XVIII. American College of Chest Physicians, Northbrook, Illinois, 2008.
71. Devlin JW, Matzke GR, **Palevsky PM**. Acid-base disorders. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. *Pharmacotherapy: A Pathophysiologic Approach*, 7<sup>th</sup> Edition. McGraw Hill, New York, 2008.
72. Weisbord SD, **Palevsky PM**. Practical strategies to prevent contrast-induced nephropathy. *US Nephrology* 2008; 3:56-59.
73. **Palevsky PM** (section editor). Part 2: Acute kidney injury. In: Molony DA, Craig J, eds. *Evidence-Based Nephrology*. BMJ Books, Wiley-Blackwell Publishing, Oxford, 2009.
74. Weisbord SD, **Palevsky PM**. Renal replacement therapy in acute kidney injury. In: Molony DA, Craig J, eds. *Evidence-Based Nephrology*. BMJ Books, Wiley-Blackwell Publishing, Oxford, 2009.
75. Ranpuria R, **Palevsky PM**. Risk factors for nosocomial renal failure. In: Ronco C, Bellomo R, Kellum J, eds. *Critical Care Nephrology*, 2<sup>nd</sup> Ed. Elsevier, Philadelphia, 2009.
76. Tolwani A, **Palevsky PM** (eds.). *Seminars in Dialysis: The Clinical Application of Continuous Renal Replacement Therapies-Current Status*. Wiley-Blackwell, Hoboken, NJ, 2009. ([PMID: 19426411](#))
77. Abi Antoun T, **Palevsky PM**. Selection of modality of renal replacement therapy. *Seminars in Dialysis* 2009; 22: 108-113. ([PMID: 19426412](#))
78. **Palevsky PM**. Intensity of continuous renal replacement therapy in acute kidney injury. *Seminars in Dialysis* 2009; 22: 151-153. ([PMID: 19426419](#))
79. Weisbord SD, **Palevsky PM**. Intravenous fluid to prevent contrast-induced AKI. *Nature Reviews Nephrology* 2009; 5: 256-257. ([PMID: 19384326](#))

80. Murray PT, **Palevsky PM**. Acute kidney injury and critical care nephrology. *NephSAP* 2009; 8:173-234.
81. **Palevsky PM**. Defining contrast-induced nephropathy. *Clinical Journal of the American Society of Nephrology* 2009; 4: 1151-1153. ([PMID: 19541810](#))
82. Abdel-Kader K, **Palevsky PM**. Acute kidney injury in the elderly. *Clinics in Geriatric Medicine* 2009; 25:331-358. ([PMCID: PMC2748997](#))
83. **Palevsky PM**. Renal support in acute kidney injury – how much is enough? *New England Journal of Medicine* 2009; 361:1699-1701. ([PMID: 19846856](#))
84. **Palevsky PM**, Weisbord SD. Critical care nephrology – it's not just acute kidney injury. *Journal of the American Society of Nephrology* 2009; 20:2281-2282. ([PMID: 19797471](#))
85. **Palevsky PM**, Kellum JA. Fluids for continuous renal replacement therapy. In: Kellum JA, Bellomo R, Ronco C, eds. *Continuous Renal Replacement Therapy*. Oxford University Press, New York, 2010.
86. Bellomo R, **Palevsky PM**, Bagshaw SM, Gibney N, McAlister FA, Honore PM, Joannes-Boyau O, Prowle J, Hasse M, Cruz DN, Ronco C. Recent trials in critical care nephrology. *Contributions to Nephrology* 2010;165:299-309 ([PMID: 20427981](#))
87. Weisbord SD, **Palevsky PM**. Strategies for the prevention of contrast-induced acute kidney injury. *Current Opinion in Nephrology and Hypertension*. 2010; 19:539-549. ([PMID: 20625289](#))
88. Levine SM, Parrillo JE, Baumann MH, Bowton DL, Ginsberg F, Grossman RF, Hall JB, MacIntyre NR, Moores LK, **Palevsky PM**, Rosen MJ, Sandrock CE, Schmidt GA, Sessler CN, Wheeler AP. Assessment in Critical Care and Pulmonology – Self-Education and Evaluation of Knowledge: Critical Care Medicine, Volume XX. American College of Chest Physicians, Northbrook, Illinois, 2010.
89. Weisbord SD, **Palevsky PM**. Kidney function after contrast media: marker or mediator? *Nature Reviews Nephrology* 2010; 6:634-636. ([PMID: 20981117](#))
90. Weisbord SD, **Palevsky PM**. Iodinated contrast media and the role of renal replacement therapy. *Advances in Chronic Kidney Disease* 2011; 18:199-206. ([PMID: 21531326](#))
91. **Palevsky PM**. Epidemiology, etiology, pathophysiology, and diagnosis of acute kidney injury. In: Lerma EV, Nissenson AR, eds. *Nephrology Secrets*. Elsevier, Philadelphia, 2012.
92. Weisbord SD, **Palevsky PM**. Contrast-induced acute kidney injury: Short and long-term implications. *Seminars in Nephrology* 2011; 31: 300-309. ([PMCID: PMC3143363](#))
93. Sharfuddin A, Weisbord SD, **Palevsky PM**, Molitoris B. Acute kidney injury. In: Brenner BM, Chertow G, Marsden PA, Skorecki K, Taal M, Yu ASL eds. *Brenner and Rector's The Kidney*, 9<sup>th</sup> Edition. Elsevier Saunders, Philadelphia, 2012.
94. **Palevsky, PM**. Chronic on acute kidney disease. *Kidney International* 2012; 81:430-431. ([PMID: 22333743](#))
95. Vijayan A, **Palevsky PM**. Dosing of renal replacement therapy in acute kidney injury. *American Journal of Kidney Diseases* 2012; 59:569-576. ([PMCID: PMC3313014](#))



96. Molitoris BA, Okusa MD, **Palevsky PM**, Kimmel PL, Star RA. Designing clinical trials in acute kidney injury. *Clinical Journal of the American Society of Nephrology* 2012; 7: 842-843. ([PMID: 22442185](#))
97. **Palevsky PM**, Molitoris BA, Okusa MD, Levin A, Waikar SS, Wald R, Chertow GM, Murray PT, Parikh CR, Shaw AD, Go AS, Faubel SG, Kellum JA, Chinchilli VM, Liu KD, Cheung AK, Weisbord SD, Chawla LS, Kaufman JS, Devarajan P, Toto RM, Hsu C-Y, Greene TH, Mehta RL, Stokes JB, Thompson AM, Thompson BT, Westenfelder CS, Tumlin JA, Warnock DG, Shah SV, Xie Y, Duggan EG, Kimmel PL, Star RA. Design of clinical trials in acute kidney injury: Report from an NIDDK workshop on trial methodology. *Clinical Journal of the American Society of Nephrology* 2012; 7: 844-850. ([PMID: 22442182](#))
98. Okusa MD, Molitoris BA, **Palevsky PM**, Chinchilli VM, Liu KD, Cheung AK, Weisbord SD, Faubel SG, Kellum JA, Wald R, Chertow GM, Levin A, Waikar SS, Murray PT, Parikh CR, Shaw AD, Go AS, Chawla LS, Kaufman JS, Devarajan P, Toto RM, Hsu C-Y, Greene TH, Mehta RL, Stokes JB, Thompson AM, Thompson BT, Westenfelder CS, Tumlin JA, Warnock DG, Shah SV, Xie Y, Duggan EG, Kimmel PL, Star RA. Design of clinical trials in acute kidney injury: A report from an NIDDK workshop. Primary prevention trials. *Clinical Journal of the American Society of Nephrology* 2012; 7: 851-855. ([PMID: 22442188](#))
99. Molitoris BA, Okusa MD, **Palevsky PM**, Chawla LS, Kaufman JS, Devarajan P, Toto RM, Hsu C-Y, Greene TH, Faubel SG, Kellum JA, Wald R, Chertow GM, Levin A, Waikar SS, Murray PT, Parikh CR, Shaw AD, Go AS, Chinchilli VM, Liu KD, Cheung AK, Weisbord SD, Mehta RL, Stokes JB, Thompson AM, Thompson BT, Westenfelder CS, Tumlin JA, Warnock DG, Shah SV, Xie Y, Duggan EG, Kimmel PL, Star RA. Design of clinical trials in acute kidney injury: A report from an NIDDK workshop. Trials of patients with sepsis and in selected hospital settings. *Clinical Journal of the American Society of Nephrology* 2012; 7: 856-860. ([PMID: 22442184](#))
100. Weisbord SD, **Palevsky PM**. Prevention of contrast-induced acute kidney injury. *Journal of Clinical Outcomes Management* 2012; 19: 178-191.
101. **Palevsky PM**. Renal replacement therapy, indications. In: Vincent J-L, Hall JB, eds. *Encyclopedia of Intensive Care Medicine*. Springer-Verlag, Berlin, 2012.
102. **Palevsky PM**. Renal replacement therapy, intensity. In: Vincent J-L, Hall JB, eds. *Encyclopedia of Intensive Care Medicine*. Springer-Verlag, Berlin, 2012.
103. **Palevsky PM**. Renal replacement therapy, timing. In: Vincent J-L, Hall JB, eds. *Encyclopedia of Intensive Care Medicine*. Springer-Verlag, Berlin, 2012.
104. Sessler CN, Parrillo JE, Baumann MH, Bowton DL, Ginsberg FL, Grossman RF, Hall JB, Levine SM, MacIntyre NR, Moores LK, Niven AS, **Palevsky PM**, Sandrock CE, Schmidt GA, Wheeler AP. Assessment in Critical Care and Pulmonology – Self-Education and Evaluation of Knowledge: *Critical Care Medicine*, Volume XXII. American College of Chest Physicians, Northbrook, Illinois, 2012.
105. Hotchkiss JR, **Palevsky PM**. Care of the critically ill patient with advanced CKD or ESRD. *Current Opinion in Critical Care*. 2012; 18:599-606. ([PMID: 23079618](#))

106. **Palevsky PM.** Renal replacement therapy in acute kidney injury. *Advances in Chronic Kidney Disease* 2013; 20: 76-84. ([PMCID: PMC3531877](#))
107. Weisbord SD, **Palevsky PM.** Contrast-induced acute kidney injury. In: Coffman TM, Falk RJ, Molitoris BA, Neilson EG, Schrier RW, eds. *Schrier's Diseases of the Kidney*, 9th Edition. Lippincott Williams & Wilkins, Philadelphia, 2013.
108. **Palevsky PM,** Liu KD, Brophy PD, Chawla LS, Parikh CR, Thakar CV, Tolwani AJ, Waikar SS, Weisbord, SD. KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Acute Kidney Injury. *American Journal of Kidney Diseases* 2013; 61 :649-672. ([PMID: 23499048](#))
109. Bonventre JV, Basile D, Liu KD, McKay D, Molitoris BA, Nath KA, Nickolas TL, Okusa MD, **Palevsky PM,** Schnellmann R, Rys-Sikora K, Kimmel PL, Star RA of behalf of the Kidney Research National Dialogue (KRND). Acute kidney injury: A path forward. *Clinical Journal of the American Society of Nephrology* 2013; 8: 1606-1608. ([PMCID: PMC3805072](#))
110. Belayev LY, **Palevsky PM.** The link between AKI and CKD. *Current Opinion in Nephrology and Hypertension* 2014; 23: 149-154. ([PMCID: PMC3974345](#))
111. **Palevsky PM.** Acute kidney injury. In: Parrillo JE, Dellinger RP, eds. *Critical Care Medicine: Diagnosis and Management in the Adult*, 4<sup>th</sup> Edition. Elsevier Saunders, Philadelphia, 2014.
112. **Palevsky PM.** Renal angina: Right concept...wrong name? *Clinical Journal of the American Society of Nephrology* 2014; 9: 633-634. ([PMCID: PMC3974345](#))
113. Sessler CN, Schmidt GA, Baumann MH, Bowton DL, Ginsberg FL, Hall JB, Karam G, Levine SM, MacIntyre NR, Moores LK, Niven AS, **Palevsky PM,** Parrillo JE, Sandrock CE, Wheeler AP. *Assessment in Critical Care and Pulmonology – Self-Education and Evaluation of Knowledge: Critical Care Medicine, Volume XXIV.* American College of Chest Physicians, Northbrook, Illinois, 2014.
114. Tolwani AJ, **Palevsky PM.** Clinical pearls: Renal replacement therapy for acute kidney injury in the post-operative period. In: Thakar CV, Parikh CR, eds. *Perioperative Kidney Injury: Principles of Risk Assessment, Diagnosis and Treatment.* Springer, New York 2015.
115. Karambelkar A, Kasekar R, **Palevsky PM.** Perioperative pharmacologic management of patients with end-stage renal disease. *Seminars in Dialysis* 2015; 28:392-396. ([PMID: 25876523](#))
116. Tolwani AJ, **Palevsky PM.** Dialysis. In: Papadakos P, Gestring M, eds. *Encyclopedia of Trauma Care.* Springer-Verlag, Berlin Heidelberg, 2015.
117. Weisbord SD, **Palevsky PM.** Contrast-associated acute kidney injury. *Critical Care Clinics* 2015; 31:725-735. ([PMID: 26410140](#))
118. **Palevsky PM.** High-volume hemofiltration in post-cardiac surgery shock: A heroic therapy? *American Journal of Respiratory and Critical Care Medicine* 2015; 192:1143-1144 ([PMID: 26568234](#))
119. Sharfuddin A, Weisbord SD, **Palevsky PM,** Molitoris B. Acute kidney injury. In: Skorecki K, Chertow G, Marsden PA, Taal M, Yu ASL, eds. *Brenner and Rector's The Kidney*, 10<sup>th</sup> Edition. Elsevier Saunders, Philadelphia, 2016.

120. **Palevsky PM**, Kellum JA. Fluids for continuous renal replacement therapy. In: Kellum JA, Bellomo R, Ronco C, eds. Continuous Renal Replacement Therapy, 2<sup>nd</sup> Edition. Oxford University Press, New York, 2016.
121. Weisbord SD, **Palevsky PM**. Prevention strategies for contrast-induced nephropathy (Letter). *Annals of Internal Medicine* 2016; 164:511 ([PMID: 27043990](#))
122. Weisbord SD, **Palevsky PM**. Design of clinical trials in acute kidney injury: Lessons from the past and future directions. *Seminars in Nephrology* 2016; 36:42-52. ([PMID: 27085734](#))
123. **Palevsky PM**. Monitoring renal function. In: Webb A, Angus D, Finfer S, Gattinoni L, Singer M, eds. *Oxford Textbook of Critical care*, 2<sup>nd</sup> Edition. Oxford University Press, Oxford, 2016.
124. Weisbord SD, **Palevsky PM**. Prevention of contrast-associated acute kidney injury: What should we do? *American Journal of Kidney Diseases* 2016; 68:518-521 ([PMID: 27233380](#))
125. Bhattarai M, Rajapakase R, **Palevsky PM**. Continuous renal replacement therapy (CRRT) overview. In: Magee C, Tucker K, Singh A, eds. *Core Concepts in Dialysis and Continuous Therapies*. Springer Science, New York, 2016.
126. Fried LF, **Palevsky PM**. Declining prevalence of CKD in the United States: A cause for optimism. *Annals of Internal Medicine* 2016 165:521-522 ([PMID: 27479750](#)).
127. Liu KD, **Palevsky PM**. Renal replacement therapy in acute kidney injury: Start early or wait? *Clinical Journal of the American Society of Nephrology* 2016; 11: 1867-1871. ([PMCID: PMC5053792](#)).
128. Chawla LS, Bellomo R, Bihorac A, Goldstein SL, Siew E, Bagshaw SM, Bittleman D, Cruz D, Endre Z, Fitzgerald RL, Forni L, Kane-Gill S, Hoste E, Koyner J, Liu K, Macedo E, Mehta R, Murray P, Nadim M, Ostermann M, **Palevsky PM**, Pannu N, Rosner M, Wald R, Zarbock A, Ronco C, Kellum JA on behalf of the Acute Disease Quality Initiative Workgroup 16. Acute kidney disease and renal recovery: Guideline report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. *Nature Reviews Nephrology* 2017; 13:241-257 ([PMID: 28239173](#)).
129. Chandra D, **Palevsky P**, Sciruba F. EnRAGEed Kidneys in COPD? *American Journal of Respiratory and Critical Care Medicine* 2017; 195:1411-1412 ([PMID: 28569576](#)).
130. Weisbord SD, **Palevsky PM**. The pathogenesis, outcomes and prevention of contrast-associated acute kidney injury. In: McQueen C, Schnellmann RG, Cummings B, eds. *Comprehensive Toxicology*, 3<sup>rd</sup> Edition. Elsevier, Oxford, 2017.
131. **Palevsky PM**. Electronic alerts for acute kidney injury. *American Journal of Kidney Diseases* 2018; 71:1-2. ([PMID: 29273153](#))
132. **Palevsky PM**, Liu KD. What endpoints should not be used for clinical studies of acute kidney injury? *Intensive Care Medicine* 2018; 44:363-365 ([PMCID: PMC5696123](#)).
133. **Palevsky PM**. Acute renal replacement therapy during hospitalization: is training adequate. *Seminars in Dialysis* 2018; 31:135-139. ([PMID: 29333659](#))

134. Zuk A, **Palevsky PM**, Fried L, Harrell FE, Jr., Khan S, McKay D, Devey L, Chawla L, de Caestecker M, Kaufman J, Thompson TB, Agarwal A, Greene T, Okusa MD, Bonventre JV, Dember LM, Liu KD, Humphreys BD, Gossett D, Xie Y, Norton JM, Kimmel PL, Star RA. Overcoming translational barriers in acute kidney injury: A report from an NIDDK workshop. *Clinical Journal of the American Society of Nephrology* 2018; 13:1113-1123 ([PMCID: PMC6032575](#)).
135. Cerda J, Tolwani A, **Palevsky, PM**. Challenges of performing renal replacement therapy in the intensive care unit: The nephrologist perspective. *Clinical Nephrology* 2018; 90:11-17 ([PMID: 29633701](#)).
136. Hoste EAJ, Kellum JA, Selby NM, Zarbock A, **Palevsky PM**, Bagshaw SM, Goldstein SL, Cerda J, Chawla LS. Global epidemiology and outcomes of acute kidney injury. *Nature Reviews Nephrology* 2018; 14:607-625. ([PMID: 30135570](#))
137. **Palevsky PM**. Endpoints for clinical trials of acute kidney injury. *Nephron* 2018; 140:111-115. ([PMID 30205392](#))
138. **Palevsky PM**. Intravenous fluids: Finding the right balance. *Clinical Journal of the American Society of Nephrology* 2018; 13: 1912-1914. ([PMICD: PMC6302336](#)).
139. Liang KV, **Palevsky PM**. Definition and classification of acute kidney injury. In: Waikar SS, Murray P, Singh A, eds. *Core Concepts in Acute Kidney Injury*. Springer Science, New York 2018.
140. Tandukar S, **Palevsky PM**. Continuous renal replacement therapy – who, when, why and how. *Chest* 2019; 155:626-638. ([PMICD: PMC6435902](#))
141. Tolwani AJ, Connor, Jr. MJ, **Palevsky PM**. Renal replacement therapy for acute kidney injury. In: Himmelfarb J, Ikizler TA, eds. *Chronic Kidney Disease, Dialysis and Transplantation: A Companion to Brenner and Rector's The Kidney*, Fourth ed. Elsevier, Philadelphia 2019.
142. **Palevsky PM**. Acute kidney injury: Epidemiology, etiology, pathophysiology and diagnosis. In: Lerma EV, Sparks MA, Topf JM, eds. *Nephrology Secrets*, Fourth Ed. Elsevier, Philadelphia 2019.
143. Kashani K, Rosner MH, Haase M, Lewington AJP, O'Donoghue DJ, Wilson FP, Nadim MK, Silver SA, Zarbock A, Ostermann M, Mehta RL, Kane-Gill SL, Ding X, Pickkers P, Bihorac A, Siew ED, Barreto EF, Macedo E, Kellum JA, **Palevsky PM**, Tolwani AJ, Ronco C, Juncos LA, Rewa OG, Bagshaw SM, Mottes TA, Koyner JL, Liu KD, Forni LG, Heung M, Wu VC.. Quality improvement goals for acute kidney injury. *Clinical Journal of the American Society of Nephrology*, 2019; 14:941-953. ([PMCID: PMC6556737](#))
144. Fischer MJ, **Palevsky PM**. Performance measurement and the Kidney Quality Improvement Registry. *Clinical Journal of the American Society of Nephrology*, 2019; 14:1261-1263. ([PMICD: PMC6682816](#)).
145. Briggs JP, **Palevsky PM**. Clinical trial data sharing: The time is now. *Journal of the American Society of Nephrology* 2019; 30:1556-1558 ([PMICD: PMC6727268](#)).

146. The Management of Chronic Kidney Disease Work Group [**Palevsky PM**]. VA/DoD Clinical practice guideline for the management of chronic kidney disease. United States Departments of Veterans Affairs and Defense, 2019 (<https://www.healthquality.va.gov/guidelines/CD/ckd/VADoDCKDCPGFinal5082142020.pdf>)
147. Weisbord SD, **Palevsky PM**. Prevention and management of acute kidney injury. In: Yu ASL, Chertow G, Luyckx V, Marsden PA, Skorecki K, Taal M, eds. Brenner and Rector's The Kidney, 11<sup>th</sup> Edition. Elsevier Saunders, Philadelphia, 2020.
148. **Palevsky PM**. Measuring up. Journal of the American Society of Nephrology 2020; 31:454-455. ([PMICD: PMC7062214](#))
149. Levey AS, Eckardt KU, Dorman NM, Christiansen SL, Hoorn EJ, Ingelfinger JR, Inker LA, Levin A, Mehrotra R, **Palevsky PM**, Perazella MA, Tong A, Allison SJ, Bockenhauer D, Briggs JP, Bromberg JS, Davenport A, Feldman HI, Fouque D, Gansevoort RT, Gill JS, Greene EL, Hemmelgarn BR, Kretzler M, Lambie M, Lane PH, Laycock J, Leventhal SE, Mittelman M, Morrissey P, Ostermann M, Rees L, Ronco P, Schaefer F, St Clair Russell J, Vinck C, Walsh SB, Weiner DE, Cheung M, Jadoul M, Winkelmayer WC. Nomenclature for kidney function and disease: Report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney International 2020; 97:1117-1129. ([PMID: 32409237](#))
150. Hatamizadeh P, Tolwani A, **Palevsky PM**. Revisiting filtration fraction as an index of the risk of hemofilter clotting in continuous venovenous hemofiltration. Clinical Journal of the American Society of Nephrology; 2020: 15:1660-1662. ([PMID: 32404338](#)).
151. Gaudry S, **Palevsky PM**, Dreyfuss D. Interpreting trials on renal replacement therapy initiation: beware of methodologic issues. Critical Care 2020; 24:240. ([PMICD: PMC7236264](#))
152. Macedo E, Bihorac A, Siew ED, **Palevsky PM**, Kellum JA, Ronco C, Mehta RL, Rosner MH, Haase M, Kashani KB, Barreto EF. Quality of care after AKI development in the hospital: Consensus from the 22nd Acute Disease Quality Initiative (ADQI) Conference. European Journal of Internal Medicine. 2020; 80:45-53 ([PMID: 32616340](#))
153. Silberzweig J, Ikizler TA, Kramer H, **Palevsky PM**, Vassalotti J, Klinger AS. Rationing scarce resources: The potential impact of COVID-19 on patients with chronic kidney disease. Journal of the American Society of Nephrology 2020; 31:1926-1928. ([PMICD: PMC7461675](#))
154. Siew ED, Liu KD, Bonn J, Chinchilli V, Dember LM, Girard TD, Greene T, Hernandez AF, Ikizler TA, James MT, Kampschroer K, Kopp J, Levy M, **Palevsky PM**, Pannu N, Parikh CR, Rocco MV, Silver SA, Thissen-Philbrook H, Wald R, Xie Y, Kimmel PL, Star RA. Improving care for patients after hospitalization with acute kidney injury: Report of a National Institutes of Health, National Institute of Diabetes, Digestive and Kidney Diseases multidisciplinary workshop. Journal of the American Society of Nephrology 2020; 31:2237-2241. ([PMICD: PMC7609013](#))
155. Murugan R, Bellomo R, **Palevsky PM**, Kellum JA. Ultrafiltration in critically ill patients treated with kidney replacement therapy. Nature Reviews Nephrology 2021; 17:262-276. ([PMID: 33177700](#))
156. **Palevsky PM**. COVID-19 and acute kidney injury: Where do we stand? Journal of the American Society of Nephrology 2021; 32:1029-1032. ([PMICD: PMC8259685](#))

157. D'Agata EMC, Apata IW, Booth S, Boyce JM, Deaver K, Gualandi N, Neu A, Nguyen N, Novosad S, **Palevsky PM**, Rodgers D and the Nephrologists Transforming Dialysis Safety Committee. Suggestions for the prevention of *Clostridioides difficile* spread within outpatient hemodialysis facilities. *Kidney International* 2021; 99: 1045-1053. ([PMID: 33667504](#))
158. Murray R, Zimmerman T, Agarwal A, **Palevsky PM**, Quaggin S, Rosas SE, Kramer H. Kidney-related research in the United States: A position statement from the National Kidney Foundation and the American Society of Nephrology. *American Journal of Kidney Diseases* 2021; 78:161-167 ([PMID: 33984405](#))
159. Verma S, **Palevsky PM**. Prescribing continuous kidney replacement therapy in acute kidney injury: A narrative review. *Kidney Medicine* 2021; 3: 827-836 ([PMICD: PMC8515066](#))
160. Bataineh A, **Palevsky PM**. Vascular access for kidney replacement therapy. In: Koyner JL, Topf JM, Lerma EV, eds. *Handbook of Critical Care Nephrology*. Wolters Kluwer, Philadelphia, 2021.
161. Chen H, **Palevsky PM**. Dosing of kidney replacement therapy. In: Koyner JL, Topf JM, Lerma EV, eds. *Handbook of Critical Care Nephrology*. Wolters Kluwer, Philadelphia, 2021.
162. Quaggin SE, **Palevsky PM**. Removing race from kidney disease diagnosis. *Journal of the American Society of Nephrology* 2021; 32: 2987-2989. ([PMICD: PMC8638407](#))
163. National Kidney Foundation Research Roundtable Work Group [Palevsky, P] on behalf of the National Kidney Foundation. Research priorities for kidney-related research – An agenda to advance kidney care: A position from the National Kidney Foundation. *American Journal of Kidney Diseases* 2022; 79: 141-152. ([PMID: 34627932](#))
164. Quaggin SE, **Palevsky PM**. Removing race from kidney disease diagnosis. *American Journal of Kidney Disease* 2022; 79: 153-155. ([PMID: 34767856](#))
165. Gaudry S, **Palevsky PM**, Dreyfuss D. Extracorporeal kidney replacement therapy for acute kidney injury. *New England Journal of Medicine* 2022; 386: 964-975. ([PMID: 35263520](#))
166. Liu KD, **Palevsky PM**. Introduction to critical care nephrology and acute kidney injury. *Clinical Journal of the American Society of Nephrology* 2022; 17:570-570. ([PMICD: PMC8993467](#))
167. **Palevsky PM**, Wald R. Nephrologists rather than intensivists should manage kidney replacement therapy in the ICU: Pro. *Kidney* 2023; 4:7-9. ([PMID: 36700897](#)).
168. **Palevsky PM**. Timing and intensity of kidney replacement therapy in acute kidney injury: Walk don't run. *NephSAP* 2022; 21(1):1-5. ([doi: 10.1681/nsap.2022.21.1.e](#))
169. Prasad A, **Palevsky PM**, Bansal S, Chertow GN, Kaufman J, Kashani K, Kim ESH, Sridharan L, Amin AP, Bangalore S, Briguori C, Charytan DM, Eng M, Jneid H, Brown JR, Mehran R, Sarnak MJ, Solomon R, Thakar CV, Fowler K, Weisbord S. Management of patients with kidney disease in need of cardiovascular catheterization: A scientific workshop co-sponsored by the National Kidney Foundation and the Society of Cardiovascular Angiography and Interventions. *Journal of the Society for Cardiovascular Angiography and Interventions* 2022; 1:100445. ([doi: 10.1016/j.jscai.2022.100445](#))

170. Kramer HJ, Jaar BG, Choi MJ, **Palevsky PM**, Vassalotti JA, Rocco MV, on behalf of the National Kidney Foundation Kidney Disease Quality Outcomes Initiative. An endorsement of the removal of race from GFR estimation equations: A position statement from the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. *American Journal of Kidney Diseases* 2022; 80:691-696. ([PMID: 36058427](#))
171. **Palevsky PM** (section ed). Acute Kidney Injury. In: Craig JC, Molony DA, Strippoli GFM (eds). *Evidence-Based Nephrology*, 2<sup>nd</sup> Edition. John Wiley & Sons, Hoboken, NJ; 2023
172. **Palevsky PM**. Debate: Intermittent hemodialysis versus continuous kidney replacement therapy in the critically ill patient: Moderator commentary. *Clinical Journal of the American Society of Nephrology* 2023; 18:644-646. ([PMID: 36758153](#))
173. Shukla AM, Cavanugh KL, Jia H, Hale-Gallardo J, Wadhwa A, Fischer MJ, Ruele S, **Palevsky PM**, Fried LF, Crowley ST. Needs and considerations for standardization of kidney disease education in patients with advanced CKD. *Clinical Journal of the American Society of Nephrology* 2023; 18: 1234-1243 ([PMICD: PMC10564354](#)).
174. Pierre CC, Marzinke MA, Ahmed SB, Collister D, Colón-Franco JM, Hoenig MP, Lorey T, **Palevsky PM**, Palmer OP, Rosas SE, Vassalotti J, Whitley CT, Green DN. AACC/NKF guidance document on improving equity in chronic kidney disease care. *Journal of Applied Laboratory Medicine* 2023; 8: 789-816. ([PMID: 37379065](#))

**MULTIMEDIA/ELECTRONIC PUBLICATIONS:**

1. **Palevsky PM**. Early Referral of the Patient with Chronic Renal Insufficiency. KePRO, Harrisburg, PA, 1998 (video).
2. **Palevsky PM**. Renal support for the patient with liver failure. *Hypertension, Dialysis and Clinical Nephrology*, Medtext, Inc., Hinsdale, IL, 1999. (Online Slide/Audio Symposium <http://www.hdcn.com/symp/99asn/palev/palevsky.htm>).
3. **Palevsky PM**. Continuous renal replacement therapy. *Hypertension, Dialysis and Clinical Nephrology*, Medtext, Inc., Hinsdale, IL, 2001. (Online Slide/Audio Symposium [www.hdcn.com/symp/01asnb/pal/pall.htm](http://www.hdcn.com/symp/01asnb/pal/pall.htm)).
4. **Palevsky PM**. Acute renal failure – Pathogenesis, diagnosis and therapy. Part 1 of 2. *Hypertension, Dialysis and Clinical Nephrology*, Medtext, Inc., Hinsdale, IL, 2005. (Online Slide/Audio Symposium <http://www.hdcn.com/symp/05asnb/pal1/pall1.htm>).
5. **Palevsky PM**. Acute renal failure – Pathogenesis, diagnosis and therapy. Part 2 of 2. *Hypertension, Dialysis and Clinical Nephrology*, Medtext, Inc., Hinsdale, IL, 2005. (Online Slide/Audio Symposium <http://www.hdcn.com/symp/05asnb/pal2/pal2.htm>).
6. **Palevsky PM**. Acute renal replacement therapy. *Hypertension, Dialysis and Clinical Nephrology*, Medtext, Inc., Hinsdale, IL, 2009. (Online Slide/Audio Symposium [http://www.hdcn.com/symp/08asnb/139/08asnb\\_pal.htm](http://www.hdcn.com/symp/08asnb/139/08asnb_pal.htm)).
7. **Palevsky PM**. Continuous arteriovenous hemodialysis: Technical considerations. UpToDate, UpToDate, Inc., Waltham, MA, 1999-2018 ([www.UpToDate.com](http://www.UpToDate.com)).

8. **Palevsky PM.** Continuous venovenous hemodialysis: Technical considerations. UpToDate, UpToDate, Inc., Waltham, MA, 1999-2018 ([www.UpToDate.com](http://www.UpToDate.com)).
9. **Palevsky PM.** Continuous venovenous hemodiafiltration: Technical considerations. UpToDate, UpToDate, Inc., Waltham, MA, 2006-2018 ([www.UpToDate.com](http://www.UpToDate.com)).
10. **Palevsky PM.** Kidney replacement therapy (dialysis) in acute kidney injury in adults: Indications, timing, and dialysis dose. UpToDate, UpToDate, Inc., Waltham, MA, 2007-2023 ([www.UpToDate.com](http://www.UpToDate.com)).
11. **Palevsky PM.** Definition and staging criteria of acute kidney injury in adults. UpToDate, UpToDate, Inc., Waltham, MA, 2012-2023 ([www.UpToDate.com](http://www.UpToDate.com)).
12. Mandel J, **Palevsky PM.** Treatment of severe hypovolemia or hypovolemic shock in adults. UpToDate, UpToDate, Inc., Waltham, MA, 2012-2023 ([www.UpToDate.com](http://www.UpToDate.com)).
13. **Palevsky PM, Weisbord SD.** Acute kidney injury: Contrast nephrotoxicity. In: Himmelfarb J, Linas S, Tuttle KR, eds. Decision Support in Medicine: Nephrology and Hypertension. Decision Support in Medicine, LLC., Wilmington, DE, 2013 ([www.DecisionSupportinMedicine.com](http://www.DecisionSupportinMedicine.com)).
14. **Palevsky PM.** Acute kidney injury: complications associated with acute kidney injury. In: Himmelfarb J, Linas S, Tuttle KR, eds. Decision Support in Medicine: Nephrology and Hypertension. Decision Support in Medicine, LLC., Wilmington, DE, 2013 ([www.DecisionSupportinMedicine.com](http://www.DecisionSupportinMedicine.com)).
15. **Palevsky PM, Abi Antoun T.** Diabetes insipidus. In: Kellum JA, Fortenberry JD, Fuchs BD, Shaw A. eds. Decision Support in Medicine: Critical Care Medicine. Decision Support in Medicine, LLC., Wilmington, DE, 2013 ([www.DecisionSupportinMedicine.com](http://www.DecisionSupportinMedicine.com)).
16. **Palevsky PM, Yenchek R.** Disorders of water Balance. In: Kellum JA, Fortenberry JD, Fuchs BD, Shaw A. eds. Decision Support in Medicine: Critical Care Medicine. Decision Support in Medicine, LLC., Wilmington, DE, 2013 ([www.DecisionSupportinMedicine.com](http://www.DecisionSupportinMedicine.com)).
17. **Palevsky PM, Abi Antoun T.** Dysnatremia: Hypernatremia. In: Kellum JA, Fortenberry JD, Fuchs BD, Shaw A. eds. Decision Support in Medicine: Critical Care Medicine. Decision Support in Medicine, LLC., Wilmington, DE, 2013 ([www.DecisionSupportinMedicine.com](http://www.DecisionSupportinMedicine.com)).
18. **Palevsky PM, Abi Antoun T.** Dysnatremia: Hyponatremia. In: Kellum JA, Fortenberry JD, Fuchs BD, Shaw A. eds. Decision Support in Medicine: Critical Care Medicine. Decision Support in Medicine, LLC., Wilmington, DE, 2013 ([www.DecisionSupportinMedicine.com](http://www.DecisionSupportinMedicine.com)).
19. **Palevsky PM, Weisbord SD.** Contrast-induced acute kidney injury (CIAKI). In: Kellum JA, Fortenberry JD, Fuchs BD, Shaw A. eds. Decision Support in Medicine: Critical Care Medicine. Decision Support in Medicine, LLC., Wilmington, DE, 2013 ([www.DecisionSupportinMedicine.com](http://www.DecisionSupportinMedicine.com)).
20. **Palevsky PM, Radhakrishnan J, Townsend, RR.** COVID-19: Issues related to acute kidney injury, glomerular disease and hypertension. UpToDate, UpToDate, Inc., Waltham, MA, 2020-2023 ([www.UpToDate.com](http://www.UpToDate.com)).
21. **Palevsky PM, Radhakrishnan J.** COVID-19: Issues related to end-stage kidney disease. UpToDate, UpToDate, Inc., Waltham, MA, 2020-2023 ([www.UpToDate.com](http://www.UpToDate.com)).



**PUBLISHED ABSTRACTS:**

1. **Palevsky PM**, Cox M. cAMP-mediated protein dephosphorylation in toad urinary bladder. *Kidney International* 1987; 31: 177. Elsevier
2. **Palevsky PM**, McEntee C, Cantwell R, Cox M, Hudson AP. Molecular characterization of the mitochondrial genome of the giant-toad (*Bufo marinus*). *Federation Proceedings* 1987; 46:1000. Presented, Annual Meeting of FASEB, April 1987.
3. Cox M, Blazer-Yost B, **Palevsky P**, Szerlip H. The aldosterone-induced glycoprotein, GP70, is a component of the renal epithelial apical membrane Na<sup>+</sup> channel. *Mineral and Electrolyte Metabolism* 1989; 15:367. Presented, Annual Meeting of the North American Society of Renal Biochemistry and Metabolism, June 1989.
4. Blazer-Yost B, **Palevsky P**, Szerlip H, Cox M. The aldosterone-induced glycoprotein, GP70, is a component of the renal epithelial apical membrane sodium channel. Presented, *Forefronts in Nephrology: Organization of Membrane Polarity in Epithelial Cells*, July 1989.
5. **Palevsky P**, Blazer-Yost B, Cox M, Szerlip H. Aldosterone induces a subunit of the epithelial Na<sup>+</sup> channel. *Kidney International* 1990; 37:233. Presented, Annual Meeting of the American Society of Nephrology, December 1989.
6. **Palevsky PM**, Prasad SJ, Greenberg A. Comparison of urea and creatinine clearance during CVVH and CVVHD. *ASAIO Abstracts* 1991; 20:90. Presented, Annual Meeting of the American Society for Artificial Internal Organs, April 1991.
7. **Palevsky P**, Piraino B, Perlmutter J, Greenberg A. Slow continuous ultrafiltration and dialysis (SCUD) for the treatment of acute renal failure. *Journal of the American Society of Nephrology* 1991; 2:343. Presented, Annual Meeting of the American Society of Nephrology, November 1991.
8. Relton S, Greenberg A, **Palevsky PM**. Dialysate and blood flow dependence of diffusive solute clearance during CVVHD. *ASAIO Abstracts* 1992; 21:80. Presented, Annual Meeting of the American Society for Artificial Internal Organs, May 1992.
9. **Palevsky PM**, Relton S, Greenberg A. Slow continuous ultrafiltration and dialysis (SCUD): Experience in 22 ICU patients. *ASAIO Abstracts* 1992; 21:80. Presented, Annual Meeting of the American Society for Artificial Internal Organs, May 1992.
10. **Palevsky PM**, McCauley J, Venkataramanan R, Johnson JP. FK506 inhibits aldosterone-stimulated sodium transport in A6 cells. *Journal of the American Society of Nephrology* 1992; 3:846. Presented, Annual Meeting of the American Society of Nephrology, November 1992.
11. **Palevsky PM**, Sands JJ, Wynne L, Bussard R, Lockett R, Stevenson J, Washington MS. Vascular access failure rates in ESRD Network 4. *Journal of the American Society of Nephrology* 1992; 3:385. Presented, Forum of ESRD Networks, November 1992.
12. Bisordi JE, **Palevsky PM**, Stevenson J, Washington M. Focused Review Experience in Network 4. *Nephrology News & Issues* 1995; 9:(6)42. Presented, Forum of ESRD Networks, November 1992.

13. Rokaw MD, **Palevsky PM**, Johnson JP. Aldosterone (aldo) stimulates protein lipidation and G-protein synthesis in A6 cells. *Journal of the American Society of Nephrology* 1993; 4:446. Presented, Annual Meeting of the American Society of Nephrology, November 1993.
14. Rokaw MD, Johnson JP, **Palevsky PM**. FK506, rapamycin & cyclosporin A: effects on aldosterone-stimulated sodium current. *Journal of the American Society of Nephrology* 1993; 4:447. Presented, Annual Meeting of the American Society of Nephrology, November, 1993.
15. Rokaw MD, **Palevsky PM**, Johnson JP. Aldosterone (A) stimulates protein acylation and G-protein (GP) synthesis in A6 cells. Presented, American Physiological Society Conference: Signal Transduction and Gene Regulation, November 1993.
16. **Palevsky PM**, Greenberg A, Burr R, Moreland L, Tokiwa Y. Failure of low-molecular weight dextrans to prevent clotting during continuous renal replacement therapy. *ASAIO Abstracts* 1994; 23:92. Presented, Annual Meeting of the American Society for Artificial Internal Organs, April 1994.
17. **Palevsky PM**, Rokaw MD, Johnson JP. Inhibition of sodium transport in A6 cells by cyclosporin A, FK506 and rapamycin. *Clinical Research* 1994; 42:316A. Presented, American Federation for Clinical Research Meeting, April 1994.
18. Johnson JP, Rokaw MD, **Palevsky PM**, Cunningham S, Benos DJ. Transcriptional, translational and post-translational regulation of a Na<sup>+</sup> channel associated G-protein by aldosterone (aldo). *Clinical Research* 1994; 42:319A. Presented, American Federation for Clinical Research Meeting, April 1994.
19. Martin TG, **Palevsky PM**, Matzke GR, Joy M, Hodgman MJ. Massive theophylline OD requiring prolonged extracorporeal elimination. Presented, North American Congress of Clinical Toxicology - 94.
20. Bhagrath R, Greenberg A, **Palevsky PM**. Hypernatremia in hospital. *Journal of the American Society of Nephrology* 1994; 5:365. Presented, Annual Meeting of the American Society of Nephrology, October 1994.
21. Matzke GR, Alexander AC, Frye R, Reynolds R, **Palevsky P**, Johnston J, Whitman C, Dixon RB, Rault R. The effect of hemodialysis on the disposition of nalmefene and nalmefene glucuronide. *Journal of the American Society of Nephrology* 1994; 5:499. Presented, Annual Meeting of the American Society of Nephrology, October 1994.
22. Joy MS, Matzke GR, **Palevsky PM**, Johnston JR, Greenberg A. Dialysate and blood flow dependence of vancomycin clearance during continuous veno-venous hemodiafiltration (CVVHD). *Pharmacotherapy* 1995; 15:380. Presented, Annual Meeting of the American College of Clinical Pharmacy, August 1995.
23. Rokaw MD, West ME, **Palevsky PM**, Hegley R, Watlington C, Johnson JP. FK506 and rapamycin but not cyclosporin inhibit aldosterone-stimulated Na<sup>+</sup>/K<sup>+</sup>-ATPase activity. *Journal of the American Society of Nephrology* 1995; 6:744. Presented, Annual Meeting of the American Society of Nephrology, November 1995.

24. **Palevsky P**, Matzke G, Joy M. Continuous hemodialysis and continuous hemodiafiltration in the treatment of massive theophylline overdose. *Blood Purification* 1995; 13:392-393. Presented, International Conference on Continuous Renal Replacement Therapy, San Diego, CA, November 1995.
25. Matzke GR, Joy M, **Palevsky P**, Frye R, Johnston JR, Greenberg A. Continuous venovenous hemodialysis clearance of vancomycin is highly membrane dependent. *Blood Purification* 1995; 13:401. Presented, International Conference on Continuous Renal Replacement Therapy, San Diego, CA, November 1995.
26. Frye RF, Matzke GR, Alexander CM, **Palevsky P**, Rault R, Branch R. Effect of renal insufficiency on CYP activity. Presented, Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics, March 1996.
27. Frye RF, Matzke GR, **Palevsky P**, Rault R. Impaired 6-hydrochlorzoxazone elimination in patients with renal insufficiency: Implication for pharmacokinetic studies. Presented, Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics, March 1996.
28. Matzke GR, Frye RF, Joy M, **Palevsky P**. Continuous venovenous hemodialysis (CVVHD) clearance of ceftriaxone. *ASAIO Journal* 1996; 42:90, 1996. Presented, Annual Meeting of the American Society for Artificial Organs, May 1996.
29. Brady JJ, Kellum JA, Johnson JP, **Palevsky P**, D.J. Kramer, M.R. Pinsky: Differential effects of diffusive versus convective therapy on TNF- $\alpha$  levels in humans with systemic inflammatory response syndrome. *Chest* 1996; 110:153S. Presented, Annual Meeting of the American College of Chest Physicians, October 1996.
30. Matzke GR, Joy MS, Frye RF, **Palevsky P**. Clearance of ceftazidime (TAZ) by continuous venovenous hemofiltration (CVVH) and hemodialysis (CVVHD). *Journal of the American Society of Nephrology* 1996; 7:1521. Presented, Annual Meeting of the American Society of Nephrology, November 1996.
31. Matzke GR, Frye RF, Joy MS, **Palevsky P**. Determinants of ceftriaxone clearance by CVVHD and CVVH. *Journal of the American Society of Nephrology* 1996; 7:1521. Presented, Annual Meeting of the American Society of Nephrology, November 1996.
32. Acker CG, Johnson JP, **Palevsky PM**, Greenberg A. Hyperkalemia in hospital. *Journal of the American Society of Nephrology* 1996; 7:1346. Presented, Annual Meeting of the American Society of Nephrology, November 1996.
33. **Palevsky PM**, Washington MS, Rohay J, Stevenson J, Dyer N, Lockett R. Barriers to the delivery of adequate hemodialysis. *Journal of the American Society of Nephrology* 1999; 10: 335A. Presented, Annual Meeting of the American Society of Nephrology, November 1999.
34. Matzke GR, Frye RF, Nolan TD, Baritot DA, **Palevsky PM**. Vancomycin removal by low and high flux hemodialysis with polymethylmethacrylate dialyzers. *Journal of the American Society of Nephrology* 1999; 10:193A. Presented, Annual Meeting of the American Society of Nephrology, November 1999.

35. Matzke GR, Nolan TD, Frye RF, Baritot DA, **Palevsky PM**. In-vitro model for tobramycin disposition during hemodialysis with low and high flux biocompatible membranes. Journal of the American Society of Nephrology 1999; 10:193A. Presented, Annual Meeting of the American Society of Nephrology, November 1999.
36. Matzke GR, Frye RF, Nolan TD, Baritot DA, **Palevsky PM**. Cefazolin and ceftazidime clearance during hemodialysis with low and high flux polymethylmethacrylate dialyzers. Journal of the American Society of Nephrology 1999; 10:193A. Presented, Annual Meeting of the American Society of Nephrology, November 1999.
37. Matzke GR, **Palevsky PM**, Frye RF. In-vitro model for tobramycin disposition during hemodialysis with conventional and high-flux biocompatible membranes. Journal of the American Society of Nephrology 2000; 11:286A. Presented, Annual Meeting of the American Society of Nephrology, October 2000.
38. **Palevsky PM**, Frye RF, Matzke GR. Effect of dialyzer reprocessing on the clearance of low and intermediate molecular weight solutes. Journal of the American Society of Nephrology 2001; 12:273A. Presented, Annual Meeting of the American Society of Nephrology, October 2001.
39. Weisbord SD, Bruns SJ, Saul MI, **Palevsky PM**. Are intravenous fluids used to limit the risk of contrast nephropathy? Journal of the American Society of Nephrology 2002; 13:447A. Presented, Annual Meeting of the American Society of Nephrology, November 2002.
40. Weisbord SD, Bruns SJ, Saul MI, Chang CH, **Palevsky PM**. The high costs of acute renal failure following the administration of intravenous contrast media in hospitalized patients. Journal of the American Society of Nephrology 2002; 13:447A. Presented, Annual Meeting of the American Society of Nephrology, November 2002.
41. **Palevsky PM**, O'Connor TZ, Zhang JH, Star R, VA/NIH Acute Renal Failure Trial Network. VA/NIH Acute Renal Failure Trial Network: Study Design. Journal of the American Society of Nephrology 2003; 14:512A. Presented, Annual Meeting of the American Society of Nephrology, November 2003.
42. **Palevsky PM**, Zgibor JC, Stevenson JA, Rohay JM, Perry SB, Dyer NJ, Freed B. Influenza immunization in ESRD patients: Comparison between Medicare billing and facility data. Journal of the American Society of Nephrology 2003; 14:719A. Presented, Annual Meeting of the American Society of Nephrology, November 2003.
43. Weisbord SD, Kip KE, Saul MI, **Palevsky PM**. Defining clinically significant radiocontrast nephropathy. Journal of the American Society of Nephrology 2003; 14:280A. Presented, Annual Meeting of the American Society of Nephrology, November 2003.
44. Pesacreta M, Overberger P, **Palevsky PM**, and the VA/NIH Acute Renal Failure Trial Network. Management of renal replacement therapy in acute renal failure: A survey of practitioner prescribing practices. Journal of the American Society of Nephrology 2004; 15:350A. Presented, Annual Meeting of the American Society of Nephrology October, 2004.
45. **Palevsky PM**, O'Connor T, Zhang J and the VA/NIH Acute Renal Failure Trial Network Study Group. Management of renal replacement therapy in acute renal failure: An observational study. Journal of the American Society of Nephrology 2005; 16: 910A.

46. Weisbord SD, Bernardini J, Mor MK, Hartwig KC, Nicoletta PJ, **Palevsky PM**, Piraino B. Does Coronary Angiography Lead to Loss of Residual Renal Function in Peritoneal Dialysis Patients? *Journal of the American Society of Nephrology* 2005; 16: 458A. Presented, Annual Meeting of the American Society of Nephrology, November 2005.
47. Zhang JH, **Palevsky PM**, O'Connor T. The role of an observational cohort in the VA/NIH Acute Renal Failure Trial Network (ATN) Study to address potential concerns arising from the ARDS Network controversy. *Clinical Trials* 2006. Presented, Annual Meeting of the Society for Clinical Trials, May 2006.
48. Zhang JH, **Palevsky PM**, O'Connor T. The challenge of recruiting acute renal failure patients in the ICU: Experience in the VA/NIH Acute Renal Failure Trial Network (ATN) Study. *Clinical Trials* 2006. Presented, Annual Meeting of the Society for Clinical Trials, May 2006.
49. Crowley S, Schein R, Dev D, Finkel K, Vijayan A, Paganini E, Chertow G, Zhang J, O'Connor T, **Palevsky P** for the VA/NIH Acute Renal Failure Trial Network. Lessons for successful study enrollment from the VA/NIH ATN Study. *Journal of the American Society of Nephrology* 2006; 17:770A. Presented, Annual Meeting of the American Society of Nephrology, November 2006.
50. Crowley S, Schein R, Dev D, Finkel K, Vijayan A, Paganini E, Chertow G, Zhang J, O'Connor T, **Palevsky P**, for the VA/NIH Acute Renal Failure Trial Network. Dialysis Catheter Complications in the VA/NIH ATN Study. *Journal of the American Society of Nephrology* 2007; 18:463A. Presented, Annual Meeting of the American Society of Nephrology, November 2007.
51. **Palevsky PM**, Zhang J, O'Connor TO, for the VA/NIH Acute Renal Failure Trial Network. Intensive versus non-intensive renal replacement therapy (RRT) in critically ill patients with acute kidney injury (AKI). *American Journal of Respiratory and Critical Care Medicine* 2008; 177: A767. Presented, ATS 2008 Toronto, May 2008.
52. **Palevsky PM**, Overberger P, Franchini R, O'Connor TZ, Zhang JH for the VA/NIH Acute Renal Failure Trial Network. One-year outcomes in critically ill patients with acute kidney injury treated with intensive versus less intensive renal replacement therapy. *Journal of the American Society of Nephrology* 2008; 19:93A. Presented, Annual Meeting of the American Society of Nephrology, November 2008.
53. **Palevsky PM**, Franchini R, O'Connor TZ, Zhang JH for the VA/NIH Acute Renal Failure Trial Network. Recovery of kidney function in critically ill patients with acute kidney injury treated with intensive versus less intensive renal replacement therapy. *Journal of the American Society of Nephrology* 2008; 19:790A. Presented, Annual Meeting of the American Society of Nephrology, November 2008.
54. Demirjian S, Paganini EP, Zhang JH, O'Connor TZ, Vitale J, **Palevsky PM** for the VA/NIH Acute Renal Failure Trial Network. Severity of illness does not modify the effect of intensity of renal replacement therapy on outcome in critically ill patients with AKI: Results from the VA/NIH Acute Renal Failure Trial Network (ATN) study. *Journal of the American Society of Nephrology* 2008; 19:791A. Presented, Annual Meeting of the American Society of Nephrology, November 2008.

55. Demirjian S, Paganini EP, Zhang JH, O'Connor TZ, Vitale J, **Palevsky PM** for the VA/NIH Acute Renal Failure Trial Network. Predictive scoring systems perform poorly in critically ill patients with AKI requiring renal replacement: Data from the VA/NIH Acute Renal Failure Trial Network. *Journal of the American Society of Nephrology* 2008; 19:794A. Presented, Annual Meeting of the American Society of Nephrology, November 2008.
56. Crowley ST, Zhang JH, O'Connor TZ, Franchini R, **Palevsky PM** for the VA/NIH Acute Renal Failure Trial Network. Management of renal replacement therapy in critically ill patients with acute kidney injury: An observational study. *Journal of the American Society of Nephrology* 2008; 19:798A. Presented, Annual Meeting of the American Society of Nephrology, November 2008.
57. Zhang JH, O'Connor TZ, **Palevsky PM** for the VA/NIH Acute Renal Failure Trial Network. Evaluation of treatment separation in the VA/NIH Acute Renal Failure Trial Network (ATN) Study. *Clinical Trials* 2009. Presented, Annual Meeting of the Society for Clinical Trials, May 2009.
58. Zhang JH, O'Connor TZ, Swanson KM, **Palevsky PM** for the VA/NIH Acute Renal Failure Trial Network. Evaluation of trial safety in an ICU trial: experience from the VA/NIH Acute Renal Failure Trial Network (ATN) Study. *Clinical Trials* 2009. Presented, Annual Meeting of the Society for Clinical Trials, May 2009.
59. Snodgrass AJ, Swanson KM, O'Connor TZ, Vitale JN, **Palevsky PM** for the VA/NIH Acute Renal Failure Trial Network. Concomitant medication collection use and analysis in clinical research. *Clinical Trials* 2009. Presented, Annual Meeting of the Society for Clinical Trials, May 2009.
60. Johansen KL, Smith MW, Unruh ML, Siroka A M, O'Connor TZ, **Palevsky PM**, for the VA/NIH Acute Renal Failure Trial Network. Predictors of health utility among 60-day survivors of AKI in the VA/NIH Acute Renal Failure Trial Network Study. *Journal of the American Society of Nephrology* 2009; 20: 21A. Presented, Annual Meeting of the American Society of Nephrology, October 2009.
61. Green JA, Mor MK, Shields AM, Porter P, **Palevsky PM**, Fine MJ, Arnold RM, Weisbord SD. Health literacy in hemodialysis patients. *Journal of the American Society of Nephrology* 2009; 20: 449A. Presented, Annual Meeting of the American Society of Nephrology, October 2009.
62. Smith MW, Johansen KL, Unruh ML, Siroka A M, O'Connor TZ, **Palevsky PM**, for the VA/NIH Acute Renal Failure Trial Network. Intensity of renal dialysis does not affect health utility among 60-day survivors of AKI. *Journal of the American Society of Nephrology* 2009; 20: 459A. Presented, Annual Meeting of the American Society of Nephrology, October 2009.
63. Srisawat N, Wen XY, Lee M, Kong L, Unruh ML, Finkel KW, Vijayan A, Paganini EP, Ramkumar M, **Palevsky PM**, Kellum JA. Urinary Biomarkers Predict Renal Recovery in Critically Ill Patients with Renal Support: Result from BioMaRK Study. *Journal of the American Society of Nephrology* 2010; 21: 241A. Presented, Annual Meeting of the American Society of Nephrology, November 2010.

64. Smith MW, Johansen KL, Unruh ML, Siroka AM, O'Connor TZ, **Palevsky PM** for the VA/NIH Acute Renal Failure Trial Network. Health Utility at 60 Days Predicts 12-Month Mortality among AKI Survivors. *Journal of the American Society of Nephrology* 2010; 21: 387A. Presented, Annual Meeting of the American Society of Nephrology, November 2010.
65. Wen X, Murugan R, Kong L, Shah N, Lee MJ, Carter M, Elder M, **Palevsky PM**, Unruh M, Kellum JA for the BioMaRK Investigators. Higher concentrations of inflammatory and apoptotic biomarkers are associated with mortality and non-recovery of kidney function. *Journal of the American Society of Nephrology* 2011; 22: 83A. Presented, Annual Meeting of the American Society of Nephrology, November 2011.
66. Chandra D, Stamm JA, **Palevsky PM**, Gladwin MT, Sciruba FC. The relationship between pulmonary emphysema and kidney function in smokers. *Journal of the American Society of Nephrology* 2011; 22: 177A. Presented, Annual Meeting of the American Society of Nephrology, November 2011.
67. Wen X, Murugan R, Kong L, Shah N, Lee MJ, Carter M, Elder M, **Palevsky PM**, Unruh M, Kellum JA for the BioMaRK Investigators. Differential effects of renal replacement therapy on plasma inflammatory and apoptotic biomarkers in acute kidney injury. *Journal of the American Society of Nephrology* 2011; 22: 206A. Presented, Annual Meeting of the American Society of Nephrology, November 2011.
68. Green J, Mor MK, Shields A-M, Sevick MA, Arnold RA, **Palevsky PM**, Fine MJ, Weisbord SD. Health literacy and outcomes in hemodialysis patients. *Journal of the American Society of Nephrology* 2011; 22: 260A. Presented, Annual Meeting of the American Society of Nephrology, November 2011.
69. Zhang JH, **Palevsky PM**, Chertow GM, Zhou B. Piecewise analysis of mortality hazard and survival probability in patients with acute kidney injury (AKI). *Journal of the American Society of Nephrology* 2011; 22: 609A. Presented, Annual Meeting of the American Society of Nephrology, November 2011.
70. Soni, R, **Palevsky PM**. The smartphone in nephrology: Preliminary survey on current trends and perceived needs. *American Journal of Kidney Diseases* 2013 61:B91. Presented, National Kidney Foundation 2013 Spring Clinical Meetings, April 2013.
71. Liang KV, Murugan R, Sileanu FE, **Palevsky PM**, Kellum JA. Does choice of renal replacement therapy modality impact renal recovery and clinical outcomes in acute kidney injury in the intensive care unit? *Journal of the American Society of Nephrology* 2013; 24: 42A. Presented, Annual Meeting of the American Society of Nephrology, November 2013.
72. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O'Connor T, **Palevsky PM**, Reilly RF, Seliger AL, Warren SR, Watnick S, Peduzzi P, Guarino P, for the VA NEPHRON-D Investigators. Combined angiotensin inhibition for treatment of diabetic nephropathy. *Journal of the American Society of Nephrology* 2013; 24: 1B. Presented, Annual Meeting of the American Society of Nephrology, November 2013.
73. Seliger SL, Zhang JH, **Palevsky PM**, Emanuele N, Fried LF. Risk and severity of hyperkalemia with combined angiotensin antagonism in diabetic nephropathy in the VA

NEPHRON-D Study. Journal of the American Society of Nephrology 2013; 24: 5B. Presented, Annual Meeting of the American Society of Nephrology, November 2013.

74. **Palevsky PM**, Zhang JH, Seliger SL, Emanuele N, Fried LF. Acute kidney injury (AKI) associated with combined angiotensin antagonism in patients with diabetic nephropathy – a secondary analysis of the VA NEPHRON-D Study. Journal of the American Society of Nephrology 2013; 24: 7B. Presented, Annual Meeting of the American Society of Nephrology, November 2013.

75. Delos Santos RB, Li T, **Palevsky PM**, Vijayan A. Hemodialysis in acute kidney injury: Results from the VA/NIH ATN Trial. Journal of the American Society of Nephrology 2014; 25: 9A. Presented, Annual Meeting of the American Society of Nephrology, November 2014.

76. McCausland FR, Asafuadjei JK, Betensky RA, **Palevsky PM**, Waikar SS. Renal replacement intensity and urine volume in critically ill patients – Results from the ATN study. Journal of the American Society of Nephrology 2014; 25: 633A. Presented, Annual Meeting of the American Society of Nephrology, November 2014.

77. Wang AY, Lo S, Gallagher M, Cass A, Li Q, Finfer S, Myburgh J, Bouman C, Faulhaber-Walter R, Kellum JA, **Palevsky PM**, Ronco C, Saudan P, Tolwani A, Bellomo R. Renal replacement therapy intensity for acute kidney injury and recovery to dialysis independence. Nephrology 2015; 20 (Supp 3):86. Presented, 51<sup>st</sup> Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology, September 2015.

78. Leehey DJ, Zhang JH, Emanuele N, Whaley-Connell A, **Palevsky PM**, Reilly RF, Guarino P, Fried. Blood pressure and renal outcomes in diabetic kidney disease: Results from the VA NEPHRON-D Trial. Journal of the American Society of Nephrology 2015; 26: 11A. Presented, Annual Meeting of the American Society of Nephrology, November 2015.

79. Wang AY, Lo SN, Gallagher MP, Li Q, Cass A, Myburgh JA, Faulhaber-Walter R, Kellum JA, **Palevsky PM**, Ronco C, Saudan P, Tolwani AJ, Bellomo R. Renal replacement therapy intensity for acute kidney injury and recovery to dialysis independence. Journal of the American Society of Nephrology 2015; 26:86A. Presented, Annual Meeting of the American Society of Nephrology, November 2015.

80. Rajapakase RP, Keener CM, **Palevsky PM**, Kellum JA, Foldes E. Validation of the Acute Renal Failure Trial Network (ATN) study risk model for predicting mortality in critically ill adults with acute kidney injury. Journal of the American Society of Nephrology 2015; 26: 102A–103A. Presented, Annual Meeting of the American Society of Nephrology, November 2015.

81. Liang KV, Zhang JH, **Palevsky PM**. Measurement of adequacy of intermittent hemodialysis in acute kidney injury: Is there a simpler approach? Journal of the American Society of Nephrology 2015; 26: 117A. Presented, Annual Meeting of the American Society of Nephrology, November 2015.

82. Pankratz VS, Argyropoulos C, Abdel-Kader K, Liang KV, **Palevsky PM**, Unruh ML. SOFA scores as predictors of mortality and dialysis dependence in acute kidney injury. Journal of the American Society of Nephrology 2015; 26: 470A. Presented, Annual Meeting of the American Society of Nephrology, November 2015.



83. Jun M, Wang Y, **Palevsky PM**, Cass A, Faulhaber-Walter R, Kellum JA, Gallagher MP. Timing of renal replacement therapy and risk of death: A pooled observational analysis of 5 randomized trials. *Journal of the American Society of Nephrology* 2016; 27: 563A. Presented, Annual Meeting of the American Society of Nephrology, November 2016.
84. Wilson FP, Biswas A, Parikh CR, Feldman HI, Garg AX, **Palevsky PM**, Latham SR. Development and validation of a model to improve targeting of electronic alerts for hospitalized patients with acute kidney injury. *Journal of the American Society of Nephrology* 2016; 27: 2B Presented, Late-Breaking Clinical Trials, Annual Meeting of the American Society of Nephrology, November 2016.
85. Balakumar V, Murugan RM, **Palevsky PM**, Kellum JA. Intensity of ultrafiltration and mortality in critically ill patients with AKI and fluid overload. *Journal of the American Society of Nephrology* 2017; 28: 100A. Presented, Annual Meeting of the American Society of Nephrology, November 2017.
86. Fried LF, Huang Y, Zhang JH, **Palevsky PM**, Johnson GR, Seliger SL, McCullough PA, Conner TA, Brophy M, Emanuele N. ESRD and mortality after VA NEPHRON-D. *Journal of the American Society of Nephrology* 2017; 28: 284A. Presented, Annual Meeting of the American Society of Nephrology, November 2017.
87. Griffin B, You Z, **Palevsky PM**, Faubel S, Jalal DI. Thrombocytopenia predicts mortality in patients with AKI requiring renal replacement therapy (RRT). *Journal of the American Society of Nephrology* 2017; 28: 412A. Presented, Annual Meeting of the American Society of Nephrology, November 2017.
88. Casey ET, Crowley ST, Birdsong J, **Palevsky PM**. detection of chlorite in dialysis water, an unrecognized safety issue. *Journal of the American Society of Nephrology* 2017; 28: 653A. Presented, Annual Meeting of the American Society of Nephrology, November 2017.
89. Liang KY, Emler DR, Bastacky S, **Palevsky PM**, Kellum JA. AKI biomarker expression in glomeruli of lupus nephritis biopsies. *Journal of the American Society of Nephrology* 2017; 28: 706A. Presented, Annual Meeting of the American Society of Nephrology, November 2017.
90. Bhatt D, Weisbord S, Androsenko M, Brophy MT, Cass A, Chertow G, Conner TA, Ferguson R, Gallagher M, Kaufman J, McFalls E, Myles J, **Palevsky PM**, Parikh C, Y Shunk K, Thwin SS, Wu H. Sodium bicarbonate and N-acetylcysteine for the prevention of serious adverse outcomes following angiography (PRESERVE). Presented, Annual Meeting of the American Heart Association, November 2017.
91. Parikh C, **Palevsky PM**, Kaufman JS, Philbrook HT, Weisbord SD. Kidney injury biomarkers and contrast-associated AKI: A sub-study of the PRESERVE trial. *Journal of the American Society of Nephrology* 2018; 29 (Abstract Suppl):B8 Presented, Annual Meeting of the American Society of Nephrology, November 2018.
92. Ambruso SL, Griffin B, You Z, Kendrick JB, **Palevsky PM**, Janovich AJ, Faubel S. Effects of obesity on mortality in critically ill patients with AKI. *Journal of the American Society of Nephrology* 2018; 29 (Abstract Suppl):431. Presented, Annual Meeting of the American Society of Nephrology, November 2018.

93. Wilson PF, Biswas A, Martin M, Yamamoto Y, Moreira E, Parikh Cr, Feldman HI, Garg AX, **Palevsky PM**, Ugwuowo UC. Provider-level exposure to AKI alerts in an ongoing randomized trial. *Journal of the American Society of Nephrology* 2018; 29 (Abstract Suppl):879. Presented, Annual Meeting of the American Society of Nephrology, November 2018.
94. Ambruso SL, Faubel S, Griffin B, Janovich AJ, Kendrick JB, You Z, **Palevsky PM**. Association of Body Mass Index with Outcomes in a Critically Ill Population on Renal Replacement Therapy. *Journal of the American Society of Nephrology* 2018; 29 (Abstract Suppl):431. Presented, Annual Meeting of the American Society of Nephrology, November 2018.
95. Yatim KM, Desilva RN, **Palevsky PM**. Assessing hemodialysis adequacy for inpatients with AKI before and after an educational intervention. *American Journal of Kidney Diseases* 2019; 73:748-749. Presented, National Kidney Foundation 2019 Spring Clinical Meetings, May 2019.
96. Liu C, Weisbord SD, Kaufman JS, Philbrook HT, Mor MK, **Palevsky PM**, Parikh CR. Contrast-associated AKLI is not reflective of intrinsic injury. *Journal of the American Society of Nephrology* 2019; 30 (Abstract Suppl): 83. Presented, Annual Meeting of the American Society of Nephrology, November 2019.
97. Webster L, Gassman JJ, Bullen A, Weisbord SD, **Palevsky PM**, Fried LF, Raphael KL, Isakova T, Ix JH. A simple equation to estimate urinary flow rate using urine creatinine. *Journal of the American Society of Nephrology* 2019; 30 (Abstract Suppl): 608. Presented, Annual Meeting of the American Society of Nephrology, November 2019.
98. Calvert J, Allen AO, Le SH, **Palevsky PM**, Braden GL, Patel S, Pellegrini E, Green-Saxena A, Hoffman J, Das R. Development and validation of a convolutional neural network model for intensive care unit AKI prediction. *Journal of the American Society of Nephrology* 2020; 31 (Abstract Suppl): 16. Presented, Annual Meeting of the American Society of Nephrology, October 2020.
99. Chang HH, Chiang JH, Wang CS, Chiu PF, Abdel-Kader A, Chen HW, Siew E, Yabes J, Murugan R, Clermont G, **Palevsky PM**, Jhamb M. Predicting mortality using machine learning algorithms in patients who require renal replacement therapy in the critical care unit. *Journal of the American Society of Nephrology* 2020; 31 (Abstract Suppl): 63. Presented, Annual Meeting of the American Society of Nephrology, October 2020.
100. O'Dell J, Neogi T, Pillinger M, **Palevsky P**, Newcomb J, Brophy M, Wu H, Davis-Karim A, Ferguson R, Pittman D, Taylor T, Terkeltaub R, Cannella A, England B, Helget L, Mikuls T. Urate lowering therapy in the treatment of gout: A multicenter, randomized, double-blind comparison of allopurinol and febuxostat using a treat-to-target strategy. *Arthritis & Rheumatology* 2021; 73 (S9): 3968-3970. Presented, American College of Rheumatology Convergence 2021, November 2021
101. Soomro QH, Anand S, Weisbord SD, Gallagher M, Ferguson Ryan, **Palevsky PM**, Kaufman J. The relationship between intravenous fluid administration and renal outcomes after angiography. *Journal of the American Society of Nephrology* 2021; 32 (Abstract Suppl): 1. Presented, American Society of Nephrology Kidney Week 2021, November 2021

102. Stottlemeyer BA, Abebe KZ, Fried L, **Palevsky PM**, Kane-Gill SL. Expert consensus on the nephrotoxic potential of 195 medications in the non-intensive care setting: a modified-Delphi method. Presented, American College of Clinical Pharmacy Virtual Poster Symposium, May 2022.
103. Schaub JA, Menon R, Bhatraju PK, Melo Ferreira R, Lake B, Otto EA, Sealfon RS, Troyanskaya O, Hodgins JB, Barisoni L, Eadon MT, Zhang K, Castro AMV, Wilson FP, Murugan R, Rosengart MR, **Palevsky PM**, Jain S, Himmelfarb J, Kretzler M. Proximal tubular epithelial cell states in KPMP protocol kidney biopsies are linked to short term AKI patient outcomes. *Journal of the American Society of Nephrology* 2022; 33 (Abstract Suppl): 23. Presented, Annual Meeting of the American Society of Nephrology, November 2022.
104. Wen Y, Su E, Xu L, Menez S, Moledina DG, **Palevsky PM**, Cantley LG, Cahan P, Parikh CR, for the Kidney Precision Medicine Project (KPMP) and Translational Research in Biomarker Endpoints of Acute Kidney Injury (TRIBE-AKI) consortia. Integration of human kidney transcriptome and plasma proteome identifies novel biomarkers of proximal tubular maladaptation to injury. *Journal of the American Society of Nephrology* 2022; 33 (Abstract Suppl): 358. Presented, Annual Meeting of the American Society of Nephrology, November 2022.
105. Chowdhury R, **Palevsky PM**. MALA: Surviving extreme metformin toxicity. *Journal of the American Society of Nephrology* 2022; 33 (Abstract Suppl): 743. Presented, Annual Meeting of the American Society of Nephrology, November 2022.
106. Helget LN, Davis-Karim A, O'Dell JR, Mikuls TR, Newcomb JA, Androsenko M, Brophy MT, England BR, Ferguson R, Pillinger MH, Neogi T, Wu H, **Palevsky PM**. Efficacy and safety of urate lowering therapy (ULT) in CKD patients with gout. *Journal of the American Society of Nephrology* 2022; 33 (Abstract Suppl): 850. Presented, Annual Meeting of the American Society of Nephrology, November 2022.
107. Helget LN, O'Dell JR, Newcomb JA, Androsenko M, Brophy MT, Davis-Karim A, England BR, Ferguson R, Pillinger MH, Neogi T, **Palevsky PM**, Wu H, Mikuls TR. Race and disease severity predict reduced response to treat-to-target urate lowering therapy in gout: Post-hoc analysis of a multicenter, randomized, double-blind, non-inferiority trial. *Arthritis & Rheumatology* 2022; 74 (S9): 3129-3131. Presented, American College of Rheumatology Convergence 2022, November 2022.
108. Helget LN, O'Dell JR, Newcomb JA, Androsenko M, Brophy MT, Davis-Karim A, England BR, Ferguson R, Pillinger MH, Neogi T, **Palevsky PM**, Wu H, Mikuls TR. Health-related quality of life improvements resulting from a treat-to-target strategy in the management of gout: Post-hoc analysis of a multicenter, randomized, double-blind, non-inferiority trial. *Arthritis & Rheumatology* 2022; 74 (S9): 3556-3558. Presented, American College of Rheumatology Convergence 2022, November 2022.
109. Helget LN, Davis-Karim A, O'Dell JR, Mikuls TR, Newcomb JA, Androsenko M, Brophy MT, England BR, Ferguson R, Pillinger MH, Neogi T, Wu H, **Palevsky PM**. Efficacy and safety of allopurinol and febuxostat in patients with gout and chronic kidney disease: A subgroup analysis of the STOP Gout Study. *Arthritis & Rheumatology* 2022; 74 (S9): 3618-3620. Presented, American College of Rheumatology Convergence 2022, November 2022.

110. Kwong YD, Liu K, Hsu C, Cooper B, **Palevsky P**, Kellum J, Johansen K, Miaskowski C. Distinct subgroups of patients identified based on health utility in early acute kidney injury using latent class analysis. *American Journal of Kidney Diseases* 2023; 81 (Suppl 1): S4. Presented, National Kidney Foundation 2023 Spring Clinical Meetings, April 2023.
111. Adingwupu OM, Barbosa ER, **Palevsky PM**, Vassalotti JA, Levey AS, Inker LA. Cystatin C as a GFR estimation marker in acute and chronic illness: a systematic review. *Journal of the American Society of Nephrology* 2023; 34 (Abstract Suppl): 370. Presented, Annual Meeting of the American Society of Nephrology, November 2023.
112. Chen X, Sealfon RS, Mao W, Pan Z, Lake B, Menon R, Ferreira RM, Naglah A, **Palevsky PM**, Torrealba J, Parikh CR, Rosas SE, Kiryluk K, Schaub JA, Barisoni L, Sarder P, Hodgins JB, Eadon MT, Jain S, Kretzler M, Troyanskaya O, KPMP. A network-based view of AKI and CKD at subtype and spatial niche resolution. *Journal of the American Society of Nephrology* 2023; 34 (Abstract Suppl): 405. Presented, Annual Meeting of the American Society of Nephrology, November 2023.
113. Barry A, Helget L, Androsenko M, Wu H, Kramer B, Newcomb J, Brophy M, Davis-Karim A, England B, Ferguson R, Pillinger M, Neogi T, **Palevsky P**, O'Dell J, Mikuls TR. Gout flares during the initiation and escalation of treat-to-target urate lowering therapy: a post-hoc analysis of a randomized multicenter comparative effectiveness trial. *Arthritis & Rheumatology* 2023; 75 (S9):469-470. Presented, American College of Rheumatology Convergence 2023, November 2023.
114. Qu J, Helget L, Androsenko M, Wu H, Kramer B, Newcomb J, Brophy M, Davis-Karim A, England B, Ferguson R, Pillinger M, Neogi T, **Palevsky P**, O'Dell J, Mikuls TR. Treat-to-target urate lowering therapy reduces gout flare burden: post-hoc analysis of a multicenter, randomized, double-blind, non-inferiority trial. *Arthritis & Rheumatology* 2023; 75 (S9). 1630-1632. Presented, American College of Rheumatology Convergence 2023, November 2023.

#### ***OTHER PUBLICATIONS:***

1. **Palevsky PM**. Biden administration should prioritize kidney health in first 100 days. *Nephrology News & Issues*. January 2021 (<https://www.healio.com/news/nephrology/20210112/biden-administration-should-prioritize-kidney-health-in-first-100-days>).
2. **Palevsky PM**, Quaggin SE. Putting fellows first. *Kidney News*. July 2021; 13 (7): 9.
3. **Palevsky PM**, Quaggin SE. How to take race out of the equation for kidney disease diagnosis. *The Hill*. September 30, 2021 (<https://thehill.com/opinion/healthcare/574657-how-to-take-race-out-of-the-equation-for-kidney-disease-diagnosis/>)
4. **Palevsky PM**. Staffing and supply chain shortages are causing deadly disruptions to dialysis. *The Hill*. May 24, 2022 (<https://thehill.com/opinion/healthcare/3499481-staffing-and-supply-chain-shortages-are-causing-deadly-disruptions-to-dialysis/>)

---

## PROFESSIONAL ACTIVITIES

### **TEACHING:**

#### **University of Pittsburgh:**

1989-present	Body Fluid Homeostasis Block: <i>Renal Organ System Course</i> (Course Co-Director, 1997)
1989-1993	Physical Diagnosis
1992-1993	Patient/Doctor Relationship Block: <i>Behavioral Medicine</i>
1998-2002	Renal and Electrolyte Pathophysiology and Therapeutics (School of Pharmacy: Pharm 5217)
2005-2006	Methods & Logic in Medicine

#### **Doctoral Candidates and Post-Doctoral Trainees Mentored:**

Sudhakar Relton, MD	1991-1992
Ernesto Banalagay, MD	1992-1993
Yumi Tokiwa, MD	1994-1995
Ravinder Bhagrath, MD	1994-1995
Michael Rokaw, MD	1994-1996
Linda Fried, MD	1995-1996
Christopher Acker, MD	1996-1997
Melanie Joy, PharmD	1996-1998
G. V. Ramesh Prasad, MD	1997-1998
Altaf Rasool, MD	1997-1998
Nabeel Aslam, MD	1998-2000
Thomas Nolin, PharmD, PhD	1999-2003
Steven Weisbord, MD	2001-2004
Matthew Pesacreta, MD	2003-2004
Kevin Sperling, MD	2006-2007
Suneel Udani, MD	2006-2007
Patricia Khalil, MD	2007-2008
Preethy Murty, MD	2007-2008
Khaled Abdel-Kader, MD	2008-2009
Tania Abi Antoun, MD	2008-2009
Robert Yenchek, MD	2010-2011
Ritu Soni, MD	2012-2013
Linda Belayev, MD	2013-2014
Riyaj Kasekar, MD	2013-2014
Ameet Karambelkar, MD	2013-2014
Ridhmi Rajapakse, MD	2014-2015
Emily Joyce, MD	2015-2017
Srijan Tandukar, MD	2017-2018
Karim Yatim, MD	2017-2019
Ayham Bataineh, MD	2018-2019
Huiwen Chen, MD	2018-2019
Siddharth Verma, MD	2019-2020

Raad Chowdhury, MD 2021-2022  
Sophia Knoell 2022-2023

**Faculty Members Mentored**

Linda Fried, MD, MPH  
Steven Weisbord, MD, MS  
Raghavan Murugan, MD, MS  
Kelly Liang, MD  
Emily Joyce, MD

**Visiting Professorships:**

2001 University of Florida College of Medicine, Gainesville, Florida

2004 Johns Hopkins University School of Medicine, Baltimore, Maryland

2005 Winthrop University Hospital, Mineola, New York  
Center for Drug Evaluation and Research, US Food and Drug Administration,  
Rockville, Maryland  
Indiana University Medical School, Indianapolis, Indiana  
University of California, San Francisco, California  
Stanford University Medical Center, Palo Alto, California

2006 University of Arkansas for Medical Sciences, Little Rock, Arkansas  
Washington University at St. Louis, St. Louis, Missouri  
Baystate Medical Center, Springfield, Massachusetts  
First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China  
VA Medical Center, Washington, District of Columbia

2007 University of Pennsylvania, Philadelphia, Pennsylvania  
Johns Hopkins University, Baltimore, Maryland  
Columbia University College of Physicians and Surgeons, New York, New York  
Yale University School of Medicine, New Haven, Connecticut

2009 Feinberg School of Medicine, Northwestern University, Chicago, Illinois  
Rhode Island Hospital, Alpert Medical School, Brown University, Providence,  
Rhode Island  
University of California, San Francisco, California  
Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts  
University of Nebraska, Omaha, Nebraska

2010 University of Louisville, Louisville, Kentucky  
University of Toronto, Toronto, Ontario, Canada  
University of Iowa, Iowa City, Iowa  
New York University, New York, New York

2011 Drexel University, Philadelphia, Pennsylvania

2012 Temple University, Philadelphia, Pennsylvania  
State University of New York at Stony Brook, Stony Brook, New York

- 2013 Institute of Nephrology, National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine  
Case Western Reserve University/University Hospital, Cleveland, Ohio  
Hofstra North Shore-LIJ School of Medicine, Manhasset, New York
- 2014 Oregon Health Sciences University, Portland, Oregon
- 2015 Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts  
Mayo Clinic, Jacksonville, Florida  
University of Washington, Seattle, Washington
- 2016 Ohio State University, Columbus, Ohio  
Vanderbilt University, Nashville, Tennessee  
University of Virginia, Charlottesville, Virginia  
University of Maryland, Baltimore, Maryland  
University of Pennsylvania, Philadelphia, Pennsylvania  
Cooper Medical School of Rowan University, Camden, New Jersey
- 2017 University of Alabama at Birmingham, Birmingham, Alabama  
Texas Health Presbyterian Dallas, Dallas, Texas
- 2018 University of Massachusetts, Worcester, Massachusetts  
University of Wisconsin, Madison, Wisconsin
- 2019 Baylor University Medical Center, Dallas, Texas
- 2020 Mayo Clinic, Rochester, Minnesota  
New York Medical College/Westchester Medical Center, Valhalla, New York  
(*Virtual visit due to COVID-19 Pandemic*)
- 2021 Robert Wood Johnson Medical School, Rutgers University, New Brunswick, New Jersey (*Virtual visit due to COVID-19 Pandemic*)  
Tower Health Reading Hospital, Reading, Pennsylvania (*Virtual visit due to COVID-19 Pandemic*)  
University of Maryland School of Medicine (*Virtual visit due to COVID-19 Pandemic*)
- 2022 Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania  
St. Louis University School of Medicine, St. Louis, Missouri (*Virtual visit due to COVID-19 Pandemic*)  
Northwestern University Feinberg School of Medicine, Chicago, Illinois
- 2023 University of Virginia School of Medicine, Charlottesville, Virginia  
Cedars Sinai Medical Center, Los Angeles, California

**Invited Lectures at Regional, National and International Meetings:**

- 1994 *ICU Nephrology: Dialytic Techniques*  
27th Annual Meeting of the American Society of Nephrology, Orlando, Florida

- 1995 *Continuous Renal Replacement Therapy*  
Wyoming Valley Medical Center, Wilkes Barre, Pennsylvania
- 1997 *Advances in Hemodialysis: Dialysate Urea Monitoring*  
Renal Round Table, Seven Springs, Pennsylvania
- DOQI Hemodialysis Adequacy Practice Guidelines*  
ESRD Network 4, Philadelphia, Pennsylvania
- 1998 *Hemodialysis Adequacy*  
DOQI Implementation Workshop  
National Kidney Foundation of Western Pennsylvania, Pittsburgh, Pennsylvania
- Hypokalemia*  
Kidney Disease in Primary Care  
National Kidney Foundation of Ohio/Ohio State University Medical Center,  
Columbus, Ohio
- Continuous Renal Replacement Therapy*  
New Jersey Chapter, Society of Critical Care Medicine  
Eatontown, New Jersey
- Renal Management in End Stage Liver Disease*  
*Continuous Renal Replacement Therapy: Vascular Access*  
*Continuous Renal Replacement Therapy: Dialysate & Replacement Solutions*  
Intensive Care Nephrology: Intensive Review and Case Discussions  
American Society of Nephrology, Philadelphia, Pennsylvania
- 1999 *Dysnatremias: Hypernatremia*  
*Renal Support for the Patient with End-Stage Liver Disease*  
*Renal Replacement Therapies in the ICU: Continuous Renal Replacement Therapy*  
Intensive Care Nephrology: Comprehensive Review and Case Discussions  
American Society of Nephrology, Miami Beach, Florida
- 2000 *Renal-Support for the Patient with End-Stage Liver Disease*  
Kidney Foundation of Central Pennsylvania/Penn State College of Medicine,  
Hershey, Pennsylvania
- Electrolyte Disturbances in the ICU: Dysnatremias*  
*The Kidney in Liver Failure*  
Intensive Care Nephrology: What the Nephrologist Needs to Know  
American Society of Nephrology, Toronto, Ontario, Canada
- The Nephrologist's Role in the Intensive Care Unit*  
American Society of Nephrology Annual Meeting, Toronto, Ontario, Canada
- Critical Care Medicine Cram Course*  
American College of Chest Physicians, San Francisco, California



- 2001 *Renal Replacement Therapy in ARF: What We Know We Don't Know*  
*Acute Dialysis Quality Initiative: Continuous Renal Replacement Therapy*  
NephroAsia 2001, Singapore
- Continuous Renal Replacement Therapy*  
*Practical Issues in Hemodialysis*  
American Society of Nephrology Board Review Course, Chicago, Illinois
- Continuous Renal Replacement Therapy*  
Intensive Care Nephrology: Unmasking the Secrets of the ICU  
American Society of Nephrology, San Francisco, California
- Critical Care Medicine Cram Course*  
American College of Chest Physicians, Philadelphia, Pennsylvania
- 2002 *Renal Support in Acute Renal Failure*  
James B Hudson Nephrology Update  
Medical College of Georgia, Augusta, Georgia
- Renal Support in Acute Renal Failure*  
Nephrology 2002  
Harvard Medical School, Boston, Massachusetts
- Continuous Renal Replacement Therapy*  
*Practical Issues in Hemodialysis*  
American Society of Nephrology Board Review Course  
San Francisco, California
- Water, Water Everywhere... An overview of water treatment for hemodialysis*  
Renal Roundtable, Seven Springs, Pennsylvania
- Continuous Renal Replacement Therapy*  
Critical Care Nephrology: Everything We Need To Know  
American Society of Nephrology, Philadelphia, Pennsylvania
- Literature Review: Dialysis – Dialysis in Acute Renal Failure*  
American Society of Nephrology Annual Meeting, Philadelphia, Pennsylvania
- 2003 *Contemporary Management of the Patient with ARF in the ICU*  
*Renal Replacement Therapy for ARF: the VA/NIH ARF Trial Network*  
CRRT 2003, San Diego, California
- Renal Support in Acute Renal Failure*  
Nephrology 2003  
Harvard Medical School, Boston, Massachusetts
- The VA/NIH ARF Trial Network*  
Renal Roundtable, Seven Springs, Pennsylvania

- 2004 *Renal Support in Acute Renal Failure*  
Nephrology 2004  
Harvard Medical School, Boston, Massachusetts
- Use of Different Dialysis Modalities in Acute Kidney Failure*  
National Kidney Foundation Clinical Meeting 2004, Chicago, Illinois
- Dialytic Treatment in Acute Renal Failure: Some Answers, Some Questions*  
Renal Care Group Medical Conference, Dallas, Texas
- Dose and Timing of Dialysis in Acute Renal Failure: Too Little, Too Late?*  
American Thoracic Society International Conference, Orlando, Florida
- Renal Replacement Therapy in the ICU: Consensus and Recommendations from ADQI – CRRT: Selection of Patients and Starting Criteria*  
3<sup>rd</sup> International Course on Critical Care Nephrology, Vicenza, Italy
- Acute Renal Failure: What we know we don't know.*  
Medical Grand Rounds, Mercy Hospital, Pittsburgh, Pennsylvania
- Acute Renal Failure: Pathogenesis, Diagnosis and Therapy*  
American Society of Nephrology Board Review Course San Francisco, California
- Fistula First*  
Renal Roundtable/Horizons in Dialysis, Seven Springs, Pennsylvania
- Transition to Renal Replacement Therapy*  
Chronic Kidney Disease Symposium for Primary Care Providers  
National Kidney Foundation of Western Pennsylvania, Pittsburgh, Pennsylvania
- 2005 *The Dose of Dialysis in Acute Renal Failure: The VA/NIH Acute Renal Failure Trial Network Study*  
Society for Critical Care Medicine Annual Meeting, Phoenix, Arizona
- Renal Support in Acute Renal Failure*  
Nephrology 2005  
Harvard Medical School, Boston, Massachusetts
- Acute Renal Failure: Pathogenesis, Diagnosis and Therapy*  
American Society of Nephrology Board Review Course  
San Francisco, California
- Prevention of Radiocontrast Nephropathy*  
*Design of the Acute Renal Failure Trial Network (ATN) Study*  
*Renal Replacement Therapy for ARF – What Do We Know?*  
X Encontro Paulista de Nefrologia, Campos do Jordão, SP, Brazil
- Prevention and Economics of Contrast Nephropathy*  
Renal Regulation and Nephrotoxicity of Therapeutic Agents: Updates, Controversies, and Debates, American Society of Nephrology, Philadelphia, Pennsylvania

*Renal Replacement Therapy in ARF: Timing and Dose of Therapy*  
*Renal Replacement Therapy in ARF: Choosing a Modality – Does it Matter?*  
ICU Nephrology and Acute Renal Failure: What the Nephrologist Must Know,  
American Society of Nephrology, Philadelphia, Pennsylvania

*Preventive Strategies for CIN*

*Contrast Nephrology: Can ARF be Prevented?*

*Literature Review - The Year in Nephrology: ICU Nephrology*

American Society of Nephrology Annual Meeting, Philadelphia, Pennsylvania

2006

*Perils and Pitfalls of Clinical Trials: Lessons Learned from the ATN Study*

Mid-Atlantic Nephrology Young-Investigators Forum, Baltimore, Maryland

*Making the Transition from Training to Practice - Academics*

RPA 2006 Spring Fellows Workshop, Baltimore Maryland

*Renal Support in Acute Kidney Injury*

Nephrology 2006

Harvard Medical School, Boston, Massachusetts

*Prevention and Treatment of Acute Kidney Injury*

2006 Nephrology & Hypertension Symposium

Hamot Medical Center, Erie, Pennsylvania

*Acute Renal Failure: Pathogenesis, Diagnosis and Therapy*

American Society of Nephrology Board Review Course San Francisco, California

*Transitioning to Renal Replacement Therapy*

Second Annual Chronic Kidney Disease Symposium

Memorial Medical Center/Conemaugh Health System, Johnstown, Pennsylvania

*Renal Replacement Therapy in ARF: Timing and Dose of Therapy*

*Renal Replacement Therapy in ARF: Choosing a Modality – Does it Matter?*

Critical Care Nephrology: 2006 Update

American Society of Nephrology, San Diego, California

*Prevention of Radiocontrast Nephropathy*

Radiocontrast Nephropathy: An Update

American Society of Nephrology, San Diego, California

*Renal Support in Acute Kidney Injury*

Guangdong Blood Purification Forum

Guangdong Society of Nephrology, Guangzhou, China

*Prescribing Renal Replacement Therapy in Acute Kidney Injury: What are the data?*

National Capital Nephrology Forum

Bethesda, Maryland

2007

*Complications of Continuous Renal Replacement Therapy  
Modalities of Renal Replacement Therapy: IHD vs SLED vs CRRT*  
I Simposio de Cuidado Crítico Nefrológico de Centroamérica y el Caribe  
San José, Costa Rica

*Modality of Renal Support in Acute Kidney Injury*  
Society for Critical Care Medicine Annual Meeting, Orlando, Florida

*Management of Acute Kidney Injury*  
Nephrology Survival Skill for Physician Assistants and Nurse Practitioners  
Renal Physicians Association, Baltimore, Maryland

*Timing and Dose of Renal Replacement Therapy in Acute Kidney Injury  
An Overview of the VA/NIH Acute Renal Failure Trial Network Study*  
National Kidney Foundation 2007 Clinical Meeting, Orlando, Florida

*Renal Support in Acute Kidney Injury*  
Nephrology 2007  
Harvard Medical School, Boston, Massachusetts

*Timing of Renal Replacement Therapy in Acute Kidney Injury*  
World Congress of Nephrology, Rio de Janeiro, Brazil

*Design and Conduct of Clinical Trials in AKI: The Acute Renal Failure Trial  
Network Study*

*Acute Kidney Injury Post Radiocontrast*  
Acute Kidney Injury: Emerging Concepts (World Congress of Nephrology Satellite  
Symposium), Salvador, Brazil

*What is the Impact of Intensity of Renal Replacement on Outcome?*  
9<sup>th</sup> International Consensus Conference in Intensive Care Medicine: Management  
and Prevention of Acute Renal Failure in an ICU Patient  
Montreal, Quebec, Canada

*Indications, Timing and Dose of Dialysis  
Disorders of Sodium and Potassium*  
Critical Care Nephrology for the Intensivist  
ATS 2007, American Thoracic Society, San Francisco, California

*The VA/NIH Acute Renal Failure Trial Network (ATN) Study*  
Midwest CRRT Symposium  
Indianapolis, Indiana

*Renal Replacement Therapy in Acute Kidney Injury: What Are the Data?*  
Dialysis Clinics, Inc. Medical Directors Meeting  
Sandestin Beach, Florida

*Contrast-Induced Nephropathy*  
*Renal Replacement Therapy in Acute Kidney Injury: When, What and How Much?*  
*Technical Issues for the Delivery of Renal Replacement Therapy in the ICU*  
Critical Care Nephrology: 2007 Update  
American Society of Nephrology, San Francisco, California

2008 *Pathophysiology of Acute Kidney Injury*  
*Indications, Timing and Dose of RRT*  
Acute Kidney Injury in Critical Illness  
Society for Critical Care Medicine Annual Meeting, Honolulu, Hawaii

*Acid Base and Electrolyte Problems in the Critically Ill (workshop)*  
*Timing of Initiation for RRT: Principles and Practice (workshop)*  
*Intensity of Dialysis: Does it Matter?*  
*Advances in Renal Support: Literature Review*  
13<sup>th</sup> Annual Conference on Continuous Renal Replacement Therapies  
San Diego, California

*Acute Kidney Injury in the ICU: Deciding the Timing and Modality of Renal Replacement Therapy*  
28<sup>th</sup> Annual Dialysis Conference, Orlando, FL

*Making the Transition from Training to Practice - Academics*  
RPA 2008 Spring Fellows Workshop, Austin, Texas

*Renal Support in Acute Kidney Injury*  
Nephrology 2008  
Harvard Medical School, Boston, Massachusetts

*Urinary Markers for Acute Kidney Injury*  
National Kidney Foundation 2008 Spring Clinical Meetings, Dallas, Texas

*ESRD Conditions for Coverage*  
ESRD Network 4 Annual Meeting, Hershey, Pennsylvania

*Fistula First: A CMS Breakthrough Initiative*  
ESRD Network 4 Surgeon Workshop, Hershey, Pennsylvania

*Dose of Dialysis and the ATN Study*  
American Thoracic Society International Conference, Toronto, Ontario, Canada

*Research Progress in Acute Kidney Injury: Dialysis Trials*  
Acute Kidney Injury Network, Bethesda, Maryland

*Medicare Conditions for Coverage: Quality Assessment and Performance Improvement*  
6<sup>th</sup> Annual NCAP Forum, Washington, DC

*Acute Kidney Injury: Prevention and Non-Dialytic Treatment*  
*Acute Renal Replacement Therapy*  
*Case Discussions: Acute Kidney Injury and ICU Nephrology*  
American Society of Nephrology Board Review Course and Update  
San Francisco, California

*Managing Renal Replacement Therapy in Acute Kidney Injury*  
2008 Nephrology Update  
National Kidney Foundation of Georgia & The Georgia-South Carolina Society of  
Nephrology, Hilton Head Island, South Carolina

*Results of Recent Studies*  
*Switching to Intermittent Hemodialysis*  
*What Can Go Wrong and How to Prevent It*  
CRRTeams, Pittsburgh, Pennsylvania

*Critical Care Board Review Cram Course: Questions 36-40*  
*Renal Replacement Therapy in the ICU: What's New/What's Optimal; Review of  
the ATN Trial*  
American College of Chest Physicians Chest 2008, Philadelphia, Pennsylvania

*Management of Renal Replacement Therapy in the ICU*  
Critical Care Nephrology: 2008 Update  
American Society of Nephrology, Philadelphia, Pennsylvania

*Intensity of Renal Support in Acute Kidney Injury: Results from the VA/NIH Acute  
Renal Failure Trial Network (ATN) Study*  
American Society of Nephrology Renal Week 2008, Philadelphia, Pennsylvania

2009 *The VA/NIH Acute Renal Failure Trial Network Study*  
Society for Critical Care Medicine Annual Meeting, Nashville, Tennessee

*Acute Kidney Injury and Therapies*  
Nephrology Educators' Forum, Lake Louise, Alberta, Canada

*Renal Support in AKI: When, What and How Much?*  
Greater Hartford Nephrology Conference, Hartford, Connecticut

*Solute Control and Dose*  
*Patient Selection and Outcomes*  
*The Acute Renal Failure Trial Network Study: What Have We learned?*  
*Acid Base and Electrolyte Problems in the Critically Ill (workshop)*  
*Timing of Initiation for RRT: Principles and Practice (workshop)*  
14<sup>th</sup> Annual Conference on Continuous Renal Replacement Therapies  
San Diego, California

*Making the Transition from Training to Practice – Academics*  
RPA 2009 Spring Fellows Workshop, Baltimore, Maryland

*Literature Review 2008 - Acute Kidney Injury*  
*What's New in Acute Kidney Injury – Dose of Dialysis for Acute Kidney Injury: Lessons Learned from the ATN Study and Other Trials*  
*Dialysis and Acute Kidney Injury: Who, What, When and How?*  
*Hospital Acquired Hyponatremia*  
National Kidney Foundation 2009 Spring Clinical Meetings, Nashville, Tennessee  
*Renal Support in Acute Kidney Injury*  
Nephrology 2009  
Harvard Medical School, Boston, Massachusetts  
*Intensity of Renal Replacement Therapy in Acute Kidney Injury*  
World Congress of Nephrology, Milan, Italy  
*Causes and Management of Acute Renal Failure*  
Massachusetts General Hospital Nephrology Update – 2009  
Cambridge, Massachusetts  
*Evidence-Based Treatment of Acute Kidney Injury*  
*Pathogenesis and Prevention of Contrast-Induced Nephropathy*  
*Ethical Dilemmas in Nephrology (workshop)*  
36<sup>th</sup> Annual Renal Disease and Electrolyte Course  
The Given Institute of the University of Colorado, Aspen, Colorado  
*Renal Replacement Therapy in Acute Kidney Injury: When, What and How Much?*  
University of Texas Southwestern Medical Center/Dallas Nephrology Associates  
Dallas, Texas  
*Acute Kidney Injury: Prevention and Non-Dialytic Treatment*  
*Acute Renal Replacement Therapy*  
*Case Discussions: Case Discussions: Acute Kidney Injury, Hepatorenal Syndrome, Cardiorenal Syndrome, and ICU Nephrology*  
American Society of Nephrology Board Review Course and Update  
San Francisco, California  
*Management of Acute Kidney Injury*  
Aultman Hospital, Canton, Ohio  
*Modality of Renal Replacement Therapy in AKI: What Should We Use?*  
*Timing and Dose of Renal replacement Therapy in AKI*  
Critical Care Nephrology: 2009 Update  
American Society of Nephrology, San Diego, California  
*Intensity of Renal Replacement Therapy in Acute Kidney Injury: Mission Accomplished?*  
American Society of Nephrology Renal Week 2009, San Diego, California

*Critical Care Board Review Cram Course: Questions 36-40*  
*Renal Replacement Therapy in the ICU: What's New/What's Optimal*  
American College of Chest Physicians Chest 2009, San Diego, California

*Renal Support: Options and Evidence*  
*What Can Go Wrong and How to Prevent It*  
CRRTeams 2009, Pittsburgh, Pennsylvania

2010

*Dose Trials: Lessons Learned and Applied*  
*Starting and Stopping RRT: Principles and Practice (workshop)*  
15<sup>th</sup> Annual Conference on Continuous Renal Replacement Therapies  
San Diego, California

*Renal Support in Acute Kidney Injury*  
Nephrology 2010  
Harvard Medical School, Boston, Massachusetts

*Contrast: Long and Short-Term Outcomes*  
ASN-ASP Workshop on Acute Kidney Injury in Older Adults  
Bethesda, Maryland

*Outcomes and Recovery after Acute Kidney Injury*  
*Why the RENAL and the ATN Studies are Different*  
*Strategies for Prevention of Contrast Nephropathy*  
Annual Scientific Meeting of the College of Intensive Care Medicine of Australia  
and New Zealand, Sydney, Australia

*Dialysis Adequacy: How To Prescribe an Adequate Dose: Shoot low*  
*Trials in AKI: The ATN Trial*  
19<sup>th</sup> International Vicenza Course on Critical Care Nephrology  
Vicenza, Italy

*Acute Kidney Injury: Prevention and Non-Dialytic Treatment*  
*Case Discussions: Acute Kidney Injury, Hepatorenal Syndrome, Cardiorenal*  
*Syndrome, and ICU Nephrology*

*Drug Intoxications*  
American Society of Nephrology Board Review Course and Update  
San Francisco, California

*Debate: Does Increased Dialysis Dose Improve Renal Outcomes in AKI – No*  
International Society of Blood Purification: ISBP 2010  
Los Angeles, California

*Renal Support: Options and Evidence*  
*What Can Go Wrong and How to Prevent It*  
CRRTeams 2010, Pittsburgh, Pennsylvania



*Renal Replacement Therapy in AKI: Do We Know When to Start?*

*Renal Replacement Therapy in AKI: Selecting a Modality*

*Renal Replacement Therapy in AKI: How Much is Enough?*

Critical Care Nephrology: 2010 Update

American Society of Nephrology, Denver, Colorado

*Design and Execution of Multicenter AKI Trials: Lessons Learned from the ATN Study*

*Challenges and Success in AKI trials—Past and Future Trials*

*Golden Window of Fluid Administration in Acute Kidney Injury: What Type, When, and How Much*

American Society of Nephrology Renal Week 2010, Denver, Colorado

*State of the Art Lecture: Challenges and Successes in AKI Trials*

AKI Clinical Trial Design Workshop

National Institute of Diabetes and Digestive and Kidney Diseases

Natcher Conference Center, National Institutes of Health, Bethesda, Maryland

2011

*Managing Your Kidney Patient Population: How Do You Measure Up?*

Renal Physicians Association 2011 Annual Meeting, Washington, DC

*Renal Support in Acute Kidney Injury*

Nephrology 2011

Harvard Medical School, Boston, Massachusetts

*Acute Kidney Injury: Epidemiology and Clinical Manifestations*

*Meet the Professor: Acute Kidney Injury Cases*

Massachusetts General Hospital Nephrology Update – 2011

Cambridge, Massachusetts

*A Diagnostic Approach to Acute Kidney Injury*

Renal Physicians Association Advanced Practitioner Conference

Indianapolis, Indiana

*Acute Kidney Injury: Prevention and Non-Dialytic Treatment*

*Case Discussions: Acute Kidney Injury, Hepatorenal Syndrome, Cardiorenal Syndrome, and ICU Nephrology*

*Drug Intoxications*

American Society of Nephrology Board Review Course and Update

San Francisco, California

*Timing and Modality of Renal Replacement Therapy in Acute Kidney Injury*

*Dosing Renal Replacement Therapy in Acute Kidney Injury*

Critical Care Nephrology: 2011 Update

American Society of Nephrology, Philadelphia, Pennsylvania

*How Do Survivors of an Acute Kidney Injury Episode Rate Their Quality of Life*

*How to Choose among IHD, CVVH, CVVHDF, CVVHD and SLED*

American Society of Nephrology Kidney Week 2011, Philadelphia, Pennsylvania

2012

*Acute Kidney Injury*

American Society of Nephrology Highlights 2012, Dallas, Texas  
American Society of Nephrology Highlights 2012, Washington, DC

*Acute Kidney Injury: Classification and Care*

Renal Physicians Association 2011 Annual Meeting, Washington, DC

*Renal Support in Acute Kidney Injury*

Nephrology 2012

Harvard Medical School, Boston, Massachusetts

*Clinical Performance Measurement – Are You Ready?*

*Workshop: Urine Microscopy*

*KDOQI Commentary on the KDIGO AKI Guidelines: Contrast-induced AKI*

National Kidney Foundation 2012 Spring Clinical Meetings, Washington, DC

*Acute Kidney Injury: Epidemiology and Clinical Manifestations*

*Acute Kidney Injury Cases*

Massachusetts General Hospital Nephrology Update – 2012

Cambridge, Massachusetts

*Acute Kidney Injury: Prevention and Non-Dialytic Treatment*

*Case Discussions: Acute Kidney Injury and ICU Nephrology*

American Society of Nephrology Board Review Course and Update

San Francisco, California

*Is Acute Kidney Injury a Predictor of Chronic Kidney Disease?*

Florida Society of Nephrology 26<sup>th</sup> Annual Meeting, Manalapan, Florida

*Timing and Modality of Renal Replacement Therapy in Acute Kidney Injury*

*Dosing Renal Replacement Therapy in Acute Kidney Injury*

*Renal Management of Poisonings and Intoxications*

Critical Care Nephrology: 2012 Update

American Society of Nephrology, San Diego, California

2013

*Current Trials in Acute Kidney Injury: Lessons from the PRESERVE Trial*

*Meet The Expert: How I Design and Conduct Clinical Trials in AKI*

*What Fluids Should Be Used for Resuscitation to Protect the Kidney?*

*Bicarbonate*

CRRT 2013, San Diego, California

*Acute Kidney Injury*

American Society of Nephrology Highlights 2013, Philadelphia, Pennsylvania

American Society of Nephrology Highlights 2013, Rosario, Argentina

*Acute Kidney Injury Prevention: What is Your Role?*

2013 Nephrology Update: Journey through the Stages of CKD for the Primary Care Team, Erie, Pennsylvania

*Extracorporeal Therapies – Dose, Modality, Timing: What Should I Know in 2013?*  
*Workshop: Urine Microscopy*  
*Strategies to Prevent AKI During Hospitalization*  
National Kidney Foundation 2013 Spring Clinical Meetings, Orlando, FL

*Renal Support in Acute Kidney Injury*  
Nephrology 2013  
Harvard Medical School, Boston, Massachusetts

*The Relationship of Acute Kidney Injury and Chronic Kidney Disease*  
*Modality of Renal Replacement Therapy in Acute Kidney Injury*  
*Case Discussions: Acute Kidney Injury and Acute Dialysis*  
Nephrology, Dialysis, Transplantation: Up To Date.  
Ukrainian Association of Nephrologists and National Kidney Foundation of  
Ukraine, Ivano-Frankiv'sk, Ukraine

*Acute Kidney Injury: Prevention and Non-Dialytic Treatment*  
*Case Discussions: Acute Kidney Injury and ICU Nephrology*  
American Society of Nephrology Board Review Course and Update  
Chicago, IL

*Water, Water Everywhere... An overview of water treatment for hemodialysis*  
Renal Roundtable/Horizons in Nephrology, Seven Springs, Pennsylvania

*Dialysis Dosing in AKI Patients*  
2013 Nephrology Update  
Cleveland Clinic, Cleveland, Ohio

*Acute Kidney Injury Prevention: What is Your Role?*  
Lancaster General Hospital, Lancaster, Pennsylvania

*Renal Replacement Therapy in Acute Kidney Injury: Timing, Dose and Modality*  
Critical Care Nephrology: 2013 Update  
American Society of Nephrology, Atlanta, Georgia

2014 *Meet the Expert: How I Use the KDIGO AKI Guidelines to Manage Patients*  
*At Risk for AKI: What Should We Do? – Focus on Hydration*  
CRRT 2014, San Diego, California

*Renal Support in Acute Kidney Injury*  
*Contrast-Induced Nephropathy*  
Nephrology 2014  
Harvard Medical School, Boston, Massachusetts

*Special Use Water Systems: Dialysis*  
Water Safety in Healthcare  
Department of Veterans Affairs National Infectious Diseases Service  
Cincinnati, Ohio

*Acute Kidney Injury: Prevention and Non-Dialytic Treatment  
Case Discussions: Acute Kidney Injury and ICU Nephrology*  
American Society of Nephrology Board Review Course and Update  
Chicago, IL

*American Society of Nephrology Highlights 2014: Acute Kidney Injury*  
XVII Congreso de la Sociedad Latinoamericana de Nefrología e Hipertensión  
Santiago, Chile

*Selecting a Modality of Renal Replacement Therapy  
Dosing Renal Replacement Therapy*  
Critical Care Nephrology: 2014 Update  
American Society of Nephrology, Philadelphia, Pennsylvania

*Building a Research Program – Insights to a Successful Career in Research*  
NIDDK New PI Workshop  
Natcher Conference Center, National Institutes of Health, Bethesda, Maryland

2015 *Palliative Care in Patients with Kidney Disease*  
Palliative Care from Head to Toe: Integrating Palliative Care Management in  
Veterans with Advanced Chronic Disease  
VA Healthcare VISN 4, Pittsburgh, PA

*Acute Kidney Injury*  
American Society of Nephrology Highlights 2015, Chicago, Illinois  
American Society of Nephrology Highlights 2015, Houston, Texas

*Ebola and Acute Kidney Injury: Lessons Learned*  
Renal Physicians Association 2015 Annual Meeting, Baltimore, Maryland

*Renal Support in Acute Kidney Injury  
Contrast-Induced Nephropathy*  
Nephrology 2015  
Harvard Medical School, Boston, Massachusetts

*Options in Renal Replacement Therapy*  
Fellows Track Symposium, ATS 2015  
American Thoracic Society, Denver, Colorado

*Debate on Renal Angina: Right Concept...Wrong Name*  
33<sup>rd</sup> Vicenza Course on Critical Care Nephrology, Vicenza, Italy

*American Society of Nephrology Highlights 2014: Acute Kidney Injury*  
XLIII Curso Anual de Actualización de Nefrología Clínica  
Instituto Mexicano de Investigaciones Nefrológicas, Mexico City

*Acute Kidney Injury: Prevention and Non-Dialytic Treatment  
Case Discussions: Acute Kidney Injury and ICU Nephrology*  
American Society of Nephrology Board Review Course and Update  
Chicago, IL

*Selecting a Modality of Renal Replacement Therapy*  
*Dosing of Renal Replacement Therapy*  
Critical Care Nephrology: 2015 Update  
American Society of Nephrology, San Diego, California

*Dialysis and Water Safety*  
Water Management and Safety Webinar  
VHA Center for Engineering & Occupational Safety and Health

2016 *Prevention Trials in Acute Kidney Injury: Where Do We Stand?*  
2016 Roundtable: Pragmatic clinical trials in AKI and RRT  
AKI & CRRT 2016: 21<sup>st</sup> International Conference on Critical Care Nephrology San Diego, California

*Debate: Timing of RRT in Acute Kidney Injury: Start early*  
AKI & CRRT 2016: 21<sup>st</sup> International Conference on Critical Care Nephrology San Diego, California

*Acute Kidney Injury: Highlights and Trends from 2015*  
ASN Highlights 2016: India, Mumbai, India

*Contrast-Induced Nephropathy*  
*Renal Support in Acute Kidney Injury*  
Nephrology 2016  
Harvard Medical School, Boston, Massachusetts

*Acute Renal Replacement Therapy: When and What*  
*Quality of Care in Acute Kidney Injury: Don't Add Insult to Injury*  
National Kidney Foundation 2016 Spring Clinical Meetings,  
Boston, Massachusetts

*Acute Kidney Injury: Prevention and Non-Dialytic Treatment*  
*Case Discussions: Acute Kidney Injury and ICU Nephrology*  
American Society of Nephrology Board Review Course and Update  
Chicago, IL

*Renal Replacement Therapy for AKI: Challenges in 2016 and Beyond*  
Renal Roundtable/Horizons in Nephrology, Seven Springs, Pennsylvania

*Selecting a Modality of Renal Replacement Therapy*  
*Dosing of Renal Replacement Therapy*  
Critical Care Nephrology: 2016 Update  
American Society of Nephrology, Chicago, Illinois

2017 *Acute Kidney Injury Highlights: What's Trending*  
ASN Highlights 2017: Translating Kidney Week into Clinical Practice  
Mumbai, India

*Contrast-Associated Acute Kidney Injury: Addressing This Common Challenge*  
*Optimizing Renal Support in Acute Kidney Injury*  
Nephrology 2017

Harvard Medical School, Boston, Massachusetts

*Key Aspects for Renal Replacement Therapy in the Critically Ill Patient*  
*Contrast-Associated AKI: How to Identify the Risks and Prevent It*  
*Management of AKI in the Outpatient Setting*  
*Controversies in Renal Replacement Therapy for AKI: My Approach to the*  
*Prescription of RRT for AKI*

*We Don't Have to Fail at Acute Renal Failure: A Multidisciplinary Approach to*  
*Quality Improvement*

National Kidney Foundation 2017 Spring Clinical Meetings, Orlando, Florida

*Timing and Dose of Renal Replacement Therapy in Acute Kidney Injury*  
*Highlights from the American Society of Nephrology: Acute Kidney Injury*  
12° Congresso Mineiro de Nefrologia, Ouro Preto, Minas Gerais, Brazil

*Acute Kidney Injury: Prevention and Non-Dialytic Treatment*  
*Case Discussions: Acute Kidney Injury and ICU Nephrology*  
American Society of Nephrology Board Review Course and Update  
Chicago, IL

*Update on Contrast Nephropathy*

*Update on Renal Replacement Therapy in Acute Kidney Injury*

East by Southwest: First Annual Update in Nephrology, Santa Fe, New Mexico

*Water for Dialysis*

Maintenance Dialysis

American Society of Nephrology, New Orleans, Louisiana

*Dosing and Modality of Renal Replacement Therapy*

Critical Care Nephrology: 2017 Update

American Society of Nephrology, New Orleans, Louisiana

*Diuretics and Furosemide Stress Test*

*Renal Replacement Modality and Dose*

*Workshop: Continuous Renal Replacement Therapy*

Advance Practice Acute Kidney Injury, Pittsburgh, Pennsylvania

2018

*Contrast-Associated Acute Kidney Injury: Addressing This Common Challenge*  
*Optimizing Renal Support in Acute Kidney Injury*

Nephrology 2018

Harvard Medical School, Boston, Massachusetts

*Renal Replacement Therapy of AKI in the ICU: When and How?*

New York State Thoracic Society 2018 Annual Assembly

Westchester Medical Center, Valhalla, New York

*Prescription Strategies for Renal Replacement Therapy in the ICU*  
*Update in Contrast Nephropathy: Epidemiology, Prevention and Management*  
*Defining the Appropriate Triggers for RRT Initiation in Patients with AKI*  
National Kidney Foundation 2018 Spring Clinical Meetings, Austin, Texas

*The PRESERVE Trial*

*Precision Medicine and CRRT*

*Clinical Management of CRRT: Dose Delivery versus Dose Prescription*  
36<sup>th</sup> Vicenza Course on AKI & CRRT, Vicenza, Italy

*Dosing and Modality of Renal Replacement Therapy*

Critical Care Nephrology: 2018 Update  
American Society of Nephrology, San Diego, California

*CRRT in the ICU should be provided by the nephrologist*

*Hyperkalemia: Who, Why and Where?*

American Society of Nephrology Kidney Week 2018, San Diego, California

*Hepatitis C: Detection and Prevention*

Targeting Zero Infections: Hepatitis C Detection, Prevention and Treatment  
Nephrologists Transforming Dialysis Safety Webinar

2019

*Intermediate Outcomes after Dialysis-Requiring AKI: Timing of Recovery, Residual Kidney Function, and Progression*

*Improving Care for Patients after Hospitalization with AKI*

National Institute of Diabetes and Digestive and Kidney Diseases

Natcher Conference Center, National Institutes of Health, Bethesda, Maryland

*Contrast Induced Nephropathy: What is New?*

*Acute Renal Replacement Therapy and Cardiovascular Diseases: When to Start? What Modality to Use?*

University of Florida Nephrocardiology Conference 2019, Orlando, Florida

*Contrast-Associated Acute Kidney Injury: Addressing This Common Challenge*

*Optimizing Renal Support in Acute Kidney Injury*

Nephrology 2019

Harvard Medical School, Boston, Massachusetts

*Intravenous Contrast and the ICU Patient*

*Renal Replacement Therapy in the ICU: Modality, Mode and Dose*

National Kidney Foundation 2019 Spring Clinical Meetings

Boston, Massachusetts

*Outcomes After Angiography with Sodium Bicarbonate and Acetylcysteine*

Kidney Disease Clinical Trialists 2019

Maison Française, Washington, District of Columbia

*Prevention of Contrast-Associated Acute Kidney Injury  
Intravenous Fluids: Finding the Right Balance  
Timing of Renal Replacement Therapy in Acute Kidney Injury*  
Chilean Society of Nephrology  
Congress of Nephrology, Hypertension and Transplant 2019, Coquimbo, Chile

*Dosing and Modality of Renal Replacement Therapy*  
Critical Care Nephrology: 2019 Update  
American Society of Nephrology, Washington, District of Columbia

*CJASN and JASN: Top Clinical Trials*  
American Society of Nephrology, Washington, District of Columbia

2020 *Prevention and Treatment of AKI: A Comprehensive Primer  
Optimizing Renal Support in Acute Kidney Injury*  
Nephrology 2020  
Harvard Medical School, Boston, Massachusetts (Virtual due to COVID-19)  
*Dosing and Modality of Renal Replacement Therapy*  
Critical Care Nephrology: 2020 Update  
American Society of Nephrology, Kidney Week 2020 (Virtual due to COVID-19)

2021 *Cardiovascular Interventions and AKI: Does preventing AKI improve future  
outcomes?*  
4<sup>th</sup> Annual Cardio Renal Connections Conference, San Antonio, Texas (Virtual due  
to COVID-19)

*Strategies for prevention of CA-AKI: Recommendations from the NKF-SCAI  
consensus conference*

*Imaging Techniques in Critically Ill Patients with Kidney Disease  
Contrast-Based Imaging: When and How to Use*  
AKI & CRRT 2021, San Diego, California (Virtual due to COVID-19)

*Prevention and Treatment of AKI: A Comprehensive Primer  
Optimizing Renal Support in Acute Kidney Injury*  
Nephrology 2021  
Harvard Medical School, Boston, Massachusetts (Virtual due to COVID-19)

*Presidential Address*  
National Kidney Foundation 2021 Spring Clinical Meetings  
(Virtual due to COVID-19)

*Leadership and Future of Nephrology: Virtual Panel Discussion*  
6<sup>th</sup> Annual Nephrology Business Leadership University, Plano, Texas  
(Hybrid Virtual due to COVID-19)

*Imaging Techniques for Critically Ill Patients with Kidney Diseases  
Dosing and Modality of Renal Replacement Therapy*  
Critical Care Nephrology: 2021 Update  
American Society of Nephrology, Kidney Week 2021 (Virtual due to COVID-19)



*Galvanizing the Kidney Community: The Healthcare Community's Call to Action*  
American Society of Nephrology, Kidney Week 2021 (Virtual due to COVID-19)

*Timing of Kidney Replacement Therapy in AKI*  
XXXVIII Chilean Annual Congress of Nephrology  
Chilean Society of Nephrology, Santiago, Chile (Virtual due to COVID-19)

2022 *Acute Kidney Injury in Covid 19: Where do we stand?*  
Annual Dialysis Conference (Virtual due to COVID-19)

*Prevention and Treatment of AKI: A Comprehensive Primer*  
*Optimizing Renal Support in Acute Kidney Injury*  
Nephrology 2022  
Harvard Medical School, Boston, Massachusetts (Virtual due to COVID-19)

*COVID-19 and AKI: Insights on Pathophysiology and Outcomes*  
*Presidential Address*  
National Kidney Foundation 2022 Spring Clinical Meetings  
Boston, Massachusetts

*Government Agencies Prioritize Global Kidney Health: Veterans Health Administration*

American Association of Kidney Patients 4<sup>th</sup> Annual Global Summit on Kidney Innovations (Virtual due to COVID-19)

*Veterans Health Administration Kidney Medicine Program*  
American Association of Kidney Patients National Patient Meeting (Virtual due to COVID-19)

*Dosing and Modality of Renal Replacement Therapy*  
Critical Care Nephrology: 2022 Update  
American Society of Nephrology, Kidney Week 2022 (Virtual on-demand session)

*Prevention of Contrast-Associated AKI in Patients Undergoing Coronary Angiography*

*Adoption of the Race-Free eGFR Equations: Where are we now*  
American Society of Nephrology, Kidney Week 2022, Orlando, Florida

2023 *Prevention and Treatment of AKI: A Comprehensive Primer*  
*Optimizing Renal Support in Acute Kidney Injury*  
Nephrology 2022

Harvard Medical School, Boston, Massachusetts (Virtual due to COVID-19)

*Acute Kidney Injury: A High-Value Care Approach*  
American College of Physicians Internal Medicine Meeting 2023  
San Diego, California

*Choice of RRT Modality: A call for a pragmatic, patient-focused approach*  
ExtraCorporeal Organ Support, ECMO and Temporary Circulatory Support (ECOS-TCS) International Congress, Paris, France (Virtual talk)

*Moving from Race-Based to Race-Conscious Medicine to Address Health Inequities: Implementation of Race-Free eGFR Equations*

Examining the History, Consequences, and Effects of Race-Based Clinical Algorithms on Health Equity: A Workshop

National Academies of Sciences, Engineering and Medicine, Washington, DC  
(Virtual Meeting)

*VA Kidney Initiatives Related to eGFR and Albuminuria Testing in Diabetes Mellitus and Cystatin C Testing for Selected Patients*

Veterans Administration Extension for Community Healthcare Outcomes (Renal - VA ECHO) (On-line Webinar)

**Continuing Medical Education Courses Organized:**

- 1998 Intensive Care Nephrology: Intensive Review and Case Discussions  
American Society of Nephrology, Philadelphia, Pennsylvania
- 1999 Intensive Care Nephrology: Comprehensive Review and Case Discussions  
American Society of Nephrology, Miami Beach, Florida
- 2000 Intensive Care Nephrology: What the Nephrologist Needs to Know  
American Society of Nephrology, Toronto, Ontario, Canada
- 2001 Intensive Care Nephrology: Unmasking the Secrets of the ICU  
American Society of Nephrology, San Francisco, California
- 2002 Critical Care Nephrology: Everything We Need to Know  
American Society of Nephrology, Philadelphia, Pennsylvania
- 2005 ICU Nephrology and Acute Renal Failure: What the Nephrologist Must Know  
American Society of Nephrology, Philadelphia, Pennsylvania
- 2006 Critical Care Nephrology: 2006 Update  
American Society of Nephrology, San Diego, California
- 2007 Critical Care Nephrology: 2007 Update  
American Society of Nephrology, San Francisco, California
- 2008 CRRTeams  
Pittsburgh, Pennsylvania
- 2008 Critical Care Nephrology: 2008 Update  
American Society of Nephrology, Philadelphia, Pennsylvania
- 2009 Critical Care Nephrology: 2009 Update  
American Society of Nephrology, San Diego, California
- 2009 CRRTeams 2009  
Pittsburgh, Pennsylvania
- 2010 CRRTeams 2010  
Pittsburgh, Pennsylvania
- 2010 Critical Care Nephrology: 2010 Update  
American Society of Nephrology, Denver, Colorado
- 2011 Critical Care Nephrology: 2011 Update  
American Society of Nephrology, Philadelphia, Pennsylvania
- 2012 Critical Care Nephrology: 2012 Update  
American Society of Nephrology, San Diego, California

2013 Critical Care Nephrology: 2013 Update  
American Society of Nephrology, Atlanta, Georgia

2014 Critical Care Nephrology: 2014 Update  
American Society of Nephrology, Philadelphia, Pennsylvania

2017 Advanced Practices in Acute Kidney Injury  
Center for Critical Care Nephrology, Pittsburgh, Pennsylvania

**RESEARCH:**

**Research Funding:**

**Current:**

The Pittsburgh Scientific and Data Research Center for the Caring for Outpatients after Acute Kidney Injury (COPE-AKI) Consortium (Pitt-SDRC): (MPIs: Kaleab Abebe, Linda Fried, Sandra Gill, Paul M. Palevsky)

Role: Principal Investigator (MPI) 1.8 months/yr  
Grant Support: 5U01DK130010  
2021-2026 \$3,663,198

Restrictive versus Liberal rate of Extracorporeal Volume removal Evaluation in Acute Kidney Injury (RELIEVE-AKI) (PIs: Raghavan Murugan, Kianoush Kashani)

Role: Co-investigator 0.36 months/yr  
Grant Support: 1R01DK128100  
2021-2024 \$896,908

Phenotyping Renal Cases In Sepsis and surgery for Early Acute Kidney Injury (PReCISE AKI) (MPIs: Paul M. Palevsky, Matthew R. Rosengart, Raghavan Murugan)

Role: Contact Principal Investigator (MPI) 0.9 months/yr  
Grant Support: NIH/NIDDK (1UH3 DK114861)  
2019-2024 (NCE) \$957,927

VA Cooperative Study #594: Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat (Stop GOUT) (PI: James O'Dell)

Role: Co-investigator/Member Steering Committee  
Grant Support: VA Cooperative Studies Program (CSP #594)  
2015-2024 \$22.6 million

VA Cooperative Study #2026: Beta Blocker Dialyzability on Cardiovascular Outcomes (BRAVO) (PI: Areef Ishani)

Role: Co-Investigator/Member Steering and Implementation Committees  
Grant Support: VA Cooperative Studies Program (CSP #2026)  
2022-2026

VA Cooperative Study #2034: Intensity of Statin Therapy in Veterans with Chronic Kidney Disease (INTENSIVE-CKD) (PI: Steven Weisbord)

Role: Co-Investigator/Member Planning Committee  
Grant Support: VA Cooperative Studies Program (CSP #2034)  
2022-2023 (Planning Phase)

Pending:

A Trial Of Mineralocorticoid Receptor Antagonists In Chronic Kidney Disease (ATOMIC) (PI: Manjula Kurella Tamura)

Role: Co-Principal Proponent

Grant Support: VA Cooperative Studies Program

Completed (prior 10 years):

Urea for Chronic Hyponatremia: A pilot study (PI: Helbert Rondon-Berrios)

Role: Co-investigator

0.3 months

Grant Support: NIH/NIDDK (R21 DK122023)

2020-2023

\$175,000

STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI): A Multi-Centre, Randomized Controlled Trial (PIs: Sean Bagshaw, Ron Wald)

Role: Co-Investigator

Grant Support: Canadian Institutes of Health Research (389635)

2018-2021

Can\$1,556,776

VA Cooperative Study #578: Prevention of Serious Adverse Events Following Angiography (MPI: Steven D. Weisbord, Paul M. Palevsky)

Role: Principal Investigator/Study Co-Chair

Grant Support: VA Cooperative Studies Program (CSP #578)

2011-2021 (NCE)

\$23.4 million

Biomarker Effectiveness Analysis in Contrast Nephropathy (BEACON) (PI: Raghavan Murugan)

Role: Co-Investigator

Grant Support: NIH/NIDDK (R01 DK106256)

2016-2021

\$1,354,963

Validating the GRACE 2.0 Score Derived from Administrative Data to Define Appropriateness of Invasive Care for the Management of Acute Coronary Syndrome (PI: Steve Weisbord)

Role: Co-investigator

Grant Support: VA HSR&D (PPO 19-371)

2020-2021

COVID-19 and Kidney Disease in the Veteran Population (PI: Steven Weisbord)

Role: Co-Investigator

Grant Support: VA CSR&D

2020-2021

\$29,411

Phenotyping Renal Cases In Sepsis and surgery for Early Acute Kidney Injury (PReCISE AKI) (MPIs: John A. Kellum, Paul M. Palevsky, Matthew R. Rosengart)

Role: Contact Principal Investigator (MPI)

0.9 months

Grant Support: NIH/NIDDK (1UG3 DK114861)

2017-2019

\$514,671

Early Identification of Acute Kidney Injury Using Deep Recurrent Neural Nets, Presented with Probable Etiology (PI: Das Ritankar)

Role: Co Investigator

Grant Support: NIH/NIAAA (R43 AA027674-01)

2018-2019

\$349,320

Adjudication of Recovery from Acute Kidney Injury (PI: John A. Kellum)

Role: Co-investigator

Grant Support: BioPorto Diagnostics

2017-2018

\$149,729

Biomarker Collection and Analysis in the PRESERVE Trial Cohort (MPIs: Steven D. Weisbord, Paul M. Palevsky, Chirag Parikh)

Role: Principal Investigator (MPI)

Grant Support: NIH/NIDDK (R01 DK098214)

2013-2018 (NCE)

\$773,226

Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized Controlled Trial of Adults Treated for Endotoxemia and Septic Shock (EUPHRATES Trial) (PI: Phillip Dellinger)

Role: Co-Investigator/Member Steering Committee

Sponsor: Spectral Diagnostics (SDI-PMX-NA001)

2009-2017

Protocolized Goal-directed Resuscitation of Septic Shock to Prevent AKI (ProGReSS-AKI) (PI: John Kellum)

Role: Co-Investigator

Grant Support: NIH/NIDDK (R01 DK083961)

2010-2016

\$2,582,820

VA Cooperative Study #565: Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor Treatment of Diabetic Nephropathy (PI: Linda Fried)

Role: Co-Investigator/Member Steering Committee

Grant Support: VA Cooperative Studies Program (CSP #565)

2007-2015

\$20.7 million

**Grant Reviews:**

Department of Veterans Affairs

National Institute of Diabetes, Digestive & Kidney Diseases

National Kidney Foundation of Michigan

PSI Foundation of Ontario

**Editorial Positions:**

American College of Chest Physicians – Self-Education and Evaluation of Knowledge/Critical Care Medicine

1995-2014 Editorial Board Member

Seminars in Nephrology, Volume 8, Number 1

1998 Guest Editor

American Society of Nephrology – Nephrology Self-Assessment Program  
2001-2010 Associate Editor: Acute Renal Failure  
2021 Guest Editor, Acute Kidney Injury and Critical Care Nephrology

Journal of Intensive Care Medicine  
2003-present Editorial Board Member: Nephrology

UpToDate  
2005-present Section Editor: Acute Kidney Injury

Clinical Journal of the American Society of Nephrology  
2005-2010 Associate Editor: Acute Renal Failure  
2011-2016 Deputy Editor  
2017-present Editorial Board Member  
2021-2023 Guest Editor, Critical Care Nephrology series

Blood Purification  
2008-2021 Associate Editor

Seminars in Dialysis, Volume 22, Number 2  
2009 Guest Editor

Journal of the American Society of Nephrology  
2017-2020 Deputy Editor

American Journal of Kidney Diseases  
2021-present Editorial Board Member

**Journal Peer Reviews:**

American Journal of Kidney Diseases  
American Journal of Physiology  
American Journal of Respiratory and Critical Care Medicine  
Annals of Internal Medicine  
ASAIO Journal  
BMJ Quality & Safety  
Chest  
Clinical Journal of the American Society of Nephrology  
Canadian Medical Association Journal  
Critical Care  
Critical Care Medicine  
Hemodialysis International  
Intensive Care Medicine  
JAMA  
JAMA Internal Medicine  
Journal of the American Society of Nephrology  
Journal of Intensive Care Medicine  
Kidney International  
Nephrology Dialysis and Transplantation  
Nephron

New England Journal of Medicine  
Southern Journal of Medicine

***Other:***

2008-2013	Member, VA ORD Medical-Surgical Data Monitoring Committee
2010-2013	Member, NIDDK Kidney Research National Dialogue (KRND) Working Group on Acute Kidney Injury
2012-2021	Member, NIDDK Observational Study Monitoring Board for the Chronic Renal Insufficiency Cohort (CRIC) Study
2013-2021	Chair, NIDDK Hemodialysis Novel Therapies Consortium Protocol Review Committee and Data Safety Monitoring Board.
2016	Member, NIDDK Committee on Future Studies for the Chronic Kidney Disease in Children (CKiD) and Chronic Renal Insufficiency Cohort (CRIC) Studies
2018-present	Chair, NIDDK Optimal Management of HIV Positive Adults at Risk for Kidney Disease in Nigeria Protocol Review Committee and Data Safety Monitoring Board.
2019-present	Member, United States Renal Data System Contract Management Board
2020-present	Member, Pentoxifylline in Diabetic Kidney Disease (CSP #2008) Data Monitoring Committee

***CLINICAL:***

Renal Consult Services 6 weeks/year  
VA Pittsburgh Healthcare System

***SERVICE:***

***VA Pittsburgh Healthcare System***

1990-1998	Ethics Advisory Committee (Co-Chair, 1998)
1990-2015	Adverse Event and Peer Review Committee
1990-1991	Chair, Ad Hoc Committee on DNR Policy
1992-1993	Chair, Ad Hoc Committee on Informed Consent Policy
1994	Chair, Study Group on DNR Status and Transfer of Patients
1995-1998	Research and Development Committee
1997-2000	Subcommittee on Human Studies (IRB)
2002-2008	Research and Development Committee (Chair, 2003-2004)
2013-2014	Chair, Medication Reconciliation Workgroup
2014	Medical Executive Board (At-Large Medical Staff Member)
2014	Clinical Product Review Committee
2014-present	Clinical Systems Improvement Committee (Chair, 2018-2021)

***Department of Veterans Affairs***

1999-2000	DoD Workgroup on Management of Renal Failure
2008-2013	VA Medical-Surgical Data Monitoring Committee
2010-present	Kidney Health Steering Committee
2011-present	Renal Field Advisory Board
2014-2018	Water Safety Oversight Committee
2018-2019	VA/DoD Clinical Practice Guideline in CKD Workgroup

**University of Pittsburgh**

1991-1995	FAST Group Advisor
1997-1998	Committee on Student Promotions
2001-2010	FAST Group Advisor
2015-2018	FAST Group Advisor

**Food and Drug Administration**

2009-2012	Chair, Gastroenterology and Urology Devices Panel Medical Devices Advisory Committee Centers for Devices and Radiological Health
2013-present	Consultant, Gastroenterology and Urology Devices Panel Medical Devices Advisory Committee Centers for Devices and Radiological Health
2013, 2016, 2017	Ad-hoc Voting Member, Endocrinologic and Metabolic Drugs Advisory Committee, Center for Drug Evaluation and Research
2018	Ad-hoc Voting Member, Antimicrobial Drugs Advisory Committee, Center for Drug Evaluation and Research
2021	Ad-hoc Voting Member, Cardiovascular and Renal Drugs Advisory Committee, Center for Drug Evaluation and Research
2022	Ad-hoc Voting Member, Cellular, Tissue and Gene Therapies Advisory Committee, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research

**ESRD Network 4***ESRD Network 4, Inc.*

1989-2010	Medical Review Board (Co-Chair, 1997-2000; Chair, 2000-2007)
1990-1994	Member, Medical Case Review Subcommittee
1991-1994	Chair, Standards Committee
1994-1996	Member, Disaster Preparedness Subcommittee
1994-1997	Chair, Quality of Life Subcommittee
1997-2010	Member, Executive Committee/Board of Directors
1997-2001	Member, Data Subcommittee
2008-2010	President

*The Renal Network, Inc.*

2010-2013	Vice President, Board of Trustees
2010-2013	Member, Executive Committee
2010-2013	President, ESRD Network 4 Coordinating Council
2010-2013	Member, ESRD Network 4 Medical Review Board

*Quality Insights Renal Network 4*

2013-2018	Board of Directors (Vice-Chair, 2013-2016; Chair, 2017-2018)
2013-present	Medical Review Board (Chair, 2019-present)

**Professional Organizations****Acute Dialysis Quality Initiative (ADQI)**

2000-2003	Executive Council
-----------	-------------------



<u>American Heart Association – Council on the Kidney</u>	
2003-2008	Communications Committee
<u>American Medical Association – Physician Consortium for Performance Improvement</u>	
2010-2015	Co-Chair, Kidney Disease Work Group
<u>American Society of Artificial Internal Organs</u>	
1993-1994	Fellowship Committee
<u>American Society of Nephrology</u>	
1999-2002	Government Relations Committee
2001	Ad-hoc Work Group on Reform in Graduate Medical Education
2002-2005	Co-Chair, Policy and Public Affairs Committee
2004-2010	Acute Kidney Injury Advisory Group
2008-2009	Web-presence Working Group
2017-present	Nephrologists Transforming Dialysis Safety
<u>Forum of ESRD Networks</u>	
1997-2007	Member, Medical Advisory Committee (Chair, 2004-2007)
2000-2006	Member, Board of Directors
2019-present	Member, Medical Advisory Committee
<u>Kidney Care Partners</u>	
2009-2013	Performance, Excellence and Accountability in Kidney Care (PEAK) Campaign Data/Results Expert Panel
2016-2020	Kidney Care Quality Alliance (KCQA) Steering Committee Co-Chair
<u>National Kidney Foundation</u>	
1998-1999	Member, Council on Dialysis
2010-2011	Member, Program Committee Spring Clinical Meetings 2011
2011-2012	Member, Program Committee Spring Clinical Meetings 2012
2011-2013	Chair, KDOQI Workgroup on the KDIGO Clinical Practice Guidelines for Acute Kidney Injury
2013-present	Member, Scientific Advisory Board
2019-present	Member, Board of Directors
2019-2020	President-elect
2020-2022	President
2022-present	Past-President
<u>NKF serving the Alleghenies</u>	
1991-1993	Kidney Ball Committee
1992-2012	Medical Advisory Committee
1993-1997	Co-Chair, Research Committee
2018-present	Medical Advisory Committee
2019-2022	Gift of Life Honors Leadership Committee
<u>National Quality Forum</u>	
2007	Member, National Voluntary Consensus Standards for ESRD Care Steering Committee/Technical Advisory Panel Co-Chair, Anemia Workgroup

Renal Physicians Association

2000-2002	Clinical Practice Guideline Workgroup: Appropriate Patient Preparation for Renal Replacement Therapy
2001-2003	Physician Accountability Committee
2003-2009	Board of Directors
2003-present	Quality, Safety and Accountability Committee (Chair, 2008-2013)

Veritus Medicare Services

2000-2005	Intermediary Advisory Committee
-----------	---------------------------------

***Community***

Quaker Valley School District

2000-2003	Student Assessment Committee
-----------	------------------------------

Beth Samuel Jewish Center

2003-2005	2 <sup>nd</sup> Vice-President
2005-2007	1 <sup>st</sup> Vice-President
2007-2008	President